id	sid	tid	token	lemma	pos
ajlm-1628	1	1	abstract	abstract	ADJ
ajlm-1628	1	2	introduction	introduction	NOUN
ajlm-1628	1	3	methods	method	NOUN
ajlm-1628	1	4	results	result	VERB
ajlm-1628	1	5	discussion	discussion	NOUN
ajlm-1628	1	6	acknowledgements	acknowledgement	NOUN
ajlm-1628	1	7	references	reference	NOUN
ajlm-1628	1	8	about	about	ADP
ajlm-1628	1	9	the	the	DET
ajlm-1628	1	10	author(s	author(s	NOUN
ajlm-1628	1	11	)	)	PUNCT
ajlm-1628	1	12	bonifasius	bonifasius	PROPN
ajlm-1628	1	13	s.	s.	PROPN
ajlm-1628	1	14	singu	singu	PROPN
ajlm-1628	1	15	school	school	PROPN
ajlm-1628	1	16	of	of	ADP
ajlm-1628	1	17	pharmacy	pharmacy	NOUN
ajlm-1628	1	18	,	,	PUNCT
ajlm-1628	1	19	faculty	faculty	NOUN
ajlm-1628	1	20	of	of	ADP
ajlm-1628	1	21	health	health	NOUN
ajlm-1628	1	22	sciences	sciences	PROPN
ajlm-1628	1	23	,	,	PUNCT
ajlm-1628	1	24	university	university	PROPN
ajlm-1628	1	25	of	of	ADP
ajlm-1628	1	26	namibia	namibia	PROPN
ajlm-1628	1	27	,	,	PUNCT
ajlm-1628	1	28	windhoek	windhoek	PROPN
ajlm-1628	1	29	,	,	PUNCT
ajlm-1628	1	30	namibia	namibia	PROPN
ajlm-1628	1	31	helen	helen	PROPN
ajlm-1628	1	32	morrison	morrison	PROPN
ajlm-1628	1	33	school	school	PROPN
ajlm-1628	1	34	of	of	ADP
ajlm-1628	1	35	pharmacy	pharmacy	NOUN
ajlm-1628	1	36	,	,	PUNCT
ajlm-1628	1	37	faculty	faculty	NOUN
ajlm-1628	1	38	of	of	ADP
ajlm-1628	1	39	health	health	NOUN
ajlm-1628	1	40	sciences	sciences	PROPN
ajlm-1628	1	41	,	,	PUNCT
ajlm-1628	1	42	university	university	PROPN
ajlm-1628	1	43	of	of	ADP
ajlm-1628	1	44	namibia	namibia	PROPN
ajlm-1628	1	45	,	,	PUNCT
ajlm-1628	1	46	windhoek	windhoek	PROPN
ajlm-1628	1	47	,	,	PUNCT
ajlm-1628	1	48	namibia	namibia	PROPN
ajlm-1628	1	49	lydia	lydia	PROPN
ajlm-1628	1	50	irengeya	irengeya	PROPN
ajlm-1628	1	51	school	school	PROPN
ajlm-1628	1	52	of	of	ADP
ajlm-1628	1	53	pharmacy	pharmacy	NOUN
ajlm-1628	1	54	,	,	PUNCT
ajlm-1628	1	55	faculty	faculty	NOUN
ajlm-1628	1	56	of	of	ADP
ajlm-1628	1	57	health	health	NOUN
ajlm-1628	1	58	sciences	sciences	PROPN
ajlm-1628	1	59	,	,	PUNCT
ajlm-1628	1	60	university	university	PROPN
ajlm-1628	1	61	of	of	ADP
ajlm-1628	1	62	namibia	namibia	PROPN
ajlm-1628	1	63	,	,	PUNCT
ajlm-1628	1	64	windhoek	windhoek	PROPN
ajlm-1628	1	65	,	,	PUNCT
ajlm-1628	1	66	namibia	namibia	PROPN
ajlm-1628	1	67	roger	roger	PROPN
ajlm-1628	1	68	k.	k.	PROPN
ajlm-1628	1	69	verbeeck	verbeeck	PROPN
ajlm-1628	1	70	school	school	PROPN
ajlm-1628	1	71	of	of	ADP
ajlm-1628	1	72	pharmacy	pharmacy	NOUN
ajlm-1628	1	73	,	,	PUNCT
ajlm-1628	1	74	faculty	faculty	NOUN
ajlm-1628	1	75	of	of	ADP
ajlm-1628	1	76	health	health	NOUN
ajlm-1628	1	77	sciences	sciences	PROPN
ajlm-1628	1	78	,	,	PUNCT
ajlm-1628	1	79	university	university	PROPN
ajlm-1628	1	80	of	of	ADP
ajlm-1628	1	81	namibia	namibia	PROPN
ajlm-1628	1	82	,	,	PUNCT
ajlm-1628	1	83	windhoek	windhoek	PROPN
ajlm-1628	1	84	,	,	PUNCT
ajlm-1628	1	85	namibia	namibia	PROPN
ajlm-1628	1	86	citation	citation	PROPN
ajlm-1628	1	87	singu	singu	PROPN
ajlm-1628	2	1	bs	bs	PROPN
ajlm-1628	2	2	,	,	PUNCT
ajlm-1628	2	3	morrison	morrison	PROPN
ajlm-1628	2	4	h	h	PROPN
ajlm-1628	2	5	,	,	PUNCT
ajlm-1628	2	6	irengeya	irengeya	PROPN
ajlm-1628	2	7	l	l	PROPN
ajlm-1628	2	8	,	,	PUNCT
ajlm-1628	2	9	verbeeck	verbeeck	NOUN
ajlm-1628	2	10	rk	rk	NOUN
ajlm-1628	2	11	.	.	PUNCT
ajlm-1628	3	1	therapeutic	therapeutic	ADJ
ajlm-1628	3	2	drug	drug	NOUN
ajlm-1628	3	3	monitoring	monitoring	NOUN
ajlm-1628	3	4	of	of	ADP
ajlm-1628	3	5	phenytoin	phenytoin	NOUN
ajlm-1628	3	6	and	and	CCONJ
ajlm-1628	3	7	valproic	valproic	ADJ
ajlm-1628	3	8	acid	acid	NOUN
ajlm-1628	3	9	in	in	ADP
ajlm-1628	3	10	critically	critically	ADV
ajlm-1628	3	11	ill	ill	ADJ
ajlm-1628	3	12	patients	patient	NOUN
ajlm-1628	3	13	at	at	ADP
ajlm-1628	3	14	windhoek	windhoek	PROPN
ajlm-1628	3	15	central	central	PROPN
ajlm-1628	3	16	hospital	hospital	PROPN
ajlm-1628	3	17	,	,	PUNCT
ajlm-1628	3	18	namibia	namibia	PROPN
ajlm-1628	3	19	.	.	PUNCT
ajlm-1628	4	1	afr	afr	PROPN
ajlm-1628	4	2	j	j	PROPN
ajlm-1628	4	3	lab	lab	PROPN
ajlm-1628	4	4	med	med	PROPN
ajlm-1628	4	5	.	.	PUNCT
ajlm-1628	5	1	2022;11(1	2022;11(1	NUM
ajlm-1628	5	2	)	)	PUNCT
ajlm-1628	6	1	,	,	PUNCT
ajlm-1628	6	2	a1628	a1628	PROPN
ajlm-1628	6	3	.	.	PUNCT
ajlm-1628	7	1	https://doi.org/10.4102/ajlm.v11i1.1628	https://doi.org/10.4102/ajlm.v11i1.1628	X
ajlm-1628	7	2	original	original	ADJ
ajlm-1628	7	3	research	research	NOUN
ajlm-1628	7	4	therapeutic	therapeutic	ADJ
ajlm-1628	7	5	drug	drug	NOUN
ajlm-1628	7	6	monitoring	monitoring	NOUN
ajlm-1628	7	7	of	of	ADP
ajlm-1628	7	8	phenytoin	phenytoin	NOUN
ajlm-1628	7	9	and	and	CCONJ
ajlm-1628	7	10	valproic	valproic	ADJ
ajlm-1628	7	11	acid	acid	NOUN
ajlm-1628	7	12	in	in	ADP
ajlm-1628	7	13	critically	critically	ADV
ajlm-1628	7	14	ill	ill	ADJ
ajlm-1628	7	15	patients	patient	NOUN
ajlm-1628	7	16	at	at	ADP
ajlm-1628	7	17	windhoek	windhoek	PROPN
ajlm-1628	7	18	central	central	PROPN
ajlm-1628	7	19	hospital	hospital	PROPN
ajlm-1628	7	20	,	,	PUNCT
ajlm-1628	7	21	namibia	namibia	PROPN
ajlm-1628	7	22	bonifasius	bonifasius	PROPN
ajlm-1628	7	23	s.	s.	PROPN
ajlm-1628	7	24	singu	singu	PROPN
ajlm-1628	7	25	,	,	PUNCT
ajlm-1628	7	26	helen	helen	PROPN
ajlm-1628	7	27	morrison	morrison	PROPN
ajlm-1628	7	28	,	,	PUNCT
ajlm-1628	7	29	lydia	lydia	PROPN
ajlm-1628	7	30	irengeya	irengeya	PROPN
ajlm-1628	7	31	,	,	PUNCT
ajlm-1628	7	32	roger	roger	PROPN
ajlm-1628	7	33	k.	k.	PROPN
ajlm-1628	7	34	verbeeck	verbeeck	PROPN
ajlm-1628	7	35	received	receive	VERB
ajlm-1628	7	36	:	:	PUNCT
ajlm-1628	7	37	22	22	NUM
ajlm-1628	7	38	may	may	PROPN
ajlm-1628	7	39	2021	2021	NUM
ajlm-1628	7	40	;	;	PUNCT
ajlm-1628	7	41	accepted	accept	VERB
ajlm-1628	7	42	:	:	PUNCT
ajlm-1628	7	43	14	14	NUM
ajlm-1628	7	44	apr	apr	NOUN
ajlm-1628	7	45	.	.	PUNCT
ajlm-1628	7	46	2022	2022	NUM
ajlm-1628	7	47	;	;	PUNCT
ajlm-1628	7	48	published	publish	VERB
ajlm-1628	7	49	:	:	PUNCT
ajlm-1628	7	50	21	21	NUM
ajlm-1628	7	51	july	july	PROPN
ajlm-1628	7	52	2022	2022	NUM
ajlm-1628	7	53	copyright	copyright	NOUN
ajlm-1628	7	54	:	:	PUNCT
ajlm-1628	7	55	©	©	PROPN
ajlm-1628	7	56	2022	2022	NUM
ajlm-1628	7	57	.	.	PUNCT
ajlm-1628	8	1	the	the	DET
ajlm-1628	8	2	author(s	author(s	PROPN
ajlm-1628	8	3	)	)	PUNCT
ajlm-1628	8	4	.	.	PUNCT
ajlm-1628	9	1	licensee	licensee	NOUN
ajlm-1628	9	2	:	:	PUNCT
ajlm-1628	9	3	aosis	aosis	NOUN
ajlm-1628	9	4	.	.	PUNCT
ajlm-1628	10	1	this	this	PRON
ajlm-1628	10	2	is	be	AUX
ajlm-1628	10	3	an	an	DET
ajlm-1628	10	4	open	open	ADJ
ajlm-1628	10	5	access	access	NOUN
ajlm-1628	10	6	article	article	NOUN
ajlm-1628	10	7	distributed	distribute	VERB
ajlm-1628	10	8	under	under	ADP
ajlm-1628	10	9	the	the	DET
ajlm-1628	10	10	terms	term	NOUN
ajlm-1628	10	11	of	of	ADP
ajlm-1628	10	12	the	the	DET
ajlm-1628	10	13	creative	creative	ADJ
ajlm-1628	10	14	commons	common	NOUN
ajlm-1628	10	15	attribution	attribution	NOUN
ajlm-1628	10	16	license	license	NOUN
ajlm-1628	10	17	,	,	PUNCT
ajlm-1628	10	18	which	which	PRON
ajlm-1628	10	19	permits	permit	VERB
ajlm-1628	10	20	unrestricted	unrestricted	ADJ
ajlm-1628	10	21	use	use	NOUN
ajlm-1628	10	22	,	,	PUNCT
ajlm-1628	10	23	distribution	distribution	NOUN
ajlm-1628	10	24	,	,	PUNCT
ajlm-1628	10	25	and	and	CCONJ
ajlm-1628	10	26	reproduction	reproduction	NOUN
ajlm-1628	10	27	in	in	ADP
ajlm-1628	10	28	any	any	DET
ajlm-1628	10	29	medium	medium	NOUN
ajlm-1628	10	30	,	,	PUNCT
ajlm-1628	10	31	provided	provide	VERB
ajlm-1628	10	32	the	the	DET
ajlm-1628	10	33	original	original	ADJ
ajlm-1628	10	34	work	work	NOUN
ajlm-1628	10	35	is	be	AUX
ajlm-1628	10	36	properly	properly	ADV
ajlm-1628	10	37	cited	cite	VERB
ajlm-1628	10	38	.	.	PUNCT
ajlm-1628	11	1	abstract	abstract	ADJ
ajlm-1628	11	2	background	background	NOUN
ajlm-1628	11	3	:	:	PUNCT
ajlm-1628	11	4	phenytoin	phenytoin	NOUN
ajlm-1628	11	5	and	and	CCONJ
ajlm-1628	11	6	valproic	valproic	ADJ
ajlm-1628	11	7	acid	acid	NOUN
ajlm-1628	11	8	,	,	PUNCT
ajlm-1628	11	9	anticonvulsants	anticonvulsant	NOUN
ajlm-1628	11	10	,	,	PUNCT
ajlm-1628	11	11	have	have	VERB
ajlm-1628	11	12	a	a	DET
ajlm-1628	11	13	low	low	ADJ
ajlm-1628	11	14	therapeutic	therapeutic	ADJ
ajlm-1628	11	15	index	index	NOUN
ajlm-1628	11	16	and	and	CCONJ
ajlm-1628	11	17	are	be	AUX
ajlm-1628	11	18	highly	highly	ADV
ajlm-1628	11	19	plasma	plasma	NOUN
ajlm-1628	11	20	protein	protein	NOUN
ajlm-1628	11	21	bound	bind	VERB
ajlm-1628	11	22	,	,	PUNCT
ajlm-1628	11	23	mainly	mainly	ADV
ajlm-1628	11	24	to	to	ADP
ajlm-1628	11	25	albumin	albumin	NOUN
ajlm-1628	11	26	.	.	PUNCT
ajlm-1628	12	1	hypoalbuminaemia	hypoalbuminaemia	PROPN
ajlm-1628	12	2	is	be	AUX
ajlm-1628	12	3	common	common	ADJ
ajlm-1628	12	4	in	in	ADP
ajlm-1628	12	5	critically	critically	ADV
ajlm-1628	12	6	ill	ill	ADJ
ajlm-1628	12	7	patients	patient	NOUN
ajlm-1628	12	8	and	and	CCONJ
ajlm-1628	12	9	increases	increase	VERB
ajlm-1628	12	10	the	the	DET
ajlm-1628	12	11	unbound	unbound	NOUN
ajlm-1628	12	12	drug	drug	NOUN
ajlm-1628	12	13	concentration	concentration	NOUN
ajlm-1628	12	14	.	.	PUNCT
ajlm-1628	13	1	thus	thus	ADV
ajlm-1628	13	2	,	,	PUNCT
ajlm-1628	13	3	monitoring	monitor	VERB
ajlm-1628	13	4	unbound	unbound	NOUN
ajlm-1628	13	5	rather	rather	ADV
ajlm-1628	13	6	than	than	ADP
ajlm-1628	13	7	total	total	ADJ
ajlm-1628	13	8	plasma	plasma	NOUN
ajlm-1628	13	9	drug	drug	NOUN
ajlm-1628	13	10	concentrations	concentration	NOUN
ajlm-1628	13	11	is	be	AUX
ajlm-1628	13	12	recommended	recommend	VERB
ajlm-1628	13	13	to	to	PART
ajlm-1628	13	14	optimise	optimise	VERB
ajlm-1628	13	15	the	the	DET
ajlm-1628	13	16	dosing	dosing	NOUN
ajlm-1628	13	17	of	of	ADP
ajlm-1628	13	18	these	these	DET
ajlm-1628	13	19	drugs	drug	NOUN
ajlm-1628	13	20	.	.	PUNCT
ajlm-1628	14	1	objective	objective	NOUN
ajlm-1628	14	2	:	:	PUNCT
ajlm-1628	14	3	this	this	DET
ajlm-1628	14	4	retrospective	retrospective	ADJ
ajlm-1628	14	5	study	study	NOUN
ajlm-1628	14	6	determined	determine	VERB
ajlm-1628	14	7	unbound	unbound	NOUN
ajlm-1628	14	8	plasma	plasma	NOUN
ajlm-1628	14	9	concentrations	concentration	NOUN
ajlm-1628	14	10	of	of	ADP
ajlm-1628	14	11	phenytoin	phenytoin	NOUN
ajlm-1628	14	12	and	and	CCONJ
ajlm-1628	14	13	valproic	valproic	ADJ
ajlm-1628	14	14	as	as	ADP
ajlm-1628	14	15	a	a	DET
ajlm-1628	14	16	more	more	ADV
ajlm-1628	14	17	accurate	accurate	ADJ
ajlm-1628	14	18	value	value	NOUN
ajlm-1628	14	19	of	of	ADP
ajlm-1628	14	20	drug	drug	NOUN
ajlm-1628	14	21	levels	level	NOUN
ajlm-1628	14	22	than	than	ADP
ajlm-1628	14	23	total	total	ADJ
ajlm-1628	14	24	plasma	plasma	NOUN
ajlm-1628	14	25	drug	drug	NOUN
ajlm-1628	14	26	concentrations	concentration	NOUN
ajlm-1628	14	27	.	.	PUNCT
ajlm-1628	15	1	methods	method	NOUN
ajlm-1628	15	2	:	:	PUNCT
ajlm-1628	15	3	total	total	ADJ
ajlm-1628	15	4	plasma	plasma	NOUN
ajlm-1628	15	5	concentrations	concentration	NOUN
ajlm-1628	15	6	were	be	AUX
ajlm-1628	15	7	retrieved	retrieve	VERB
ajlm-1628	15	8	for	for	ADP
ajlm-1628	15	9	56	56	NUM
ajlm-1628	15	10	intensive	intensive	ADJ
ajlm-1628	15	11	care	care	NOUN
ajlm-1628	15	12	unit	unit	NOUN
ajlm-1628	15	13	patients	patient	NOUN
ajlm-1628	15	14	for	for	ADP
ajlm-1628	15	15	phenytoin	phenytoin	NOUN
ajlm-1628	15	16	and	and	CCONJ
ajlm-1628	15	17	93	93	NUM
ajlm-1628	15	18	for	for	ADP
ajlm-1628	15	19	valproic	valproic	ADJ
ajlm-1628	15	20	acid	acid	NOUN
ajlm-1628	15	21	.	.	PUNCT
ajlm-1628	16	1	total	total	ADJ
ajlm-1628	16	2	drug	drug	NOUN
ajlm-1628	16	3	concentrations	concentration	NOUN
ajlm-1628	16	4	were	be	AUX
ajlm-1628	16	5	converted	convert	VERB
ajlm-1628	16	6	to	to	ADP
ajlm-1628	16	7	unbound	unbound	NOUN
ajlm-1628	16	8	concentrations	concentration	NOUN
ajlm-1628	16	9	using	use	VERB
ajlm-1628	16	10	a	a	DET
ajlm-1628	16	11	serum	serum	NOUN
ajlm-1628	16	12	albumin	albumin	NOUN
ajlm-1628	16	13	-	-	PUNCT
ajlm-1628	16	14	based	base	VERB
ajlm-1628	16	15	normalising	normalising	ADJ
ajlm-1628	16	16	equation	equation	NOUN
ajlm-1628	16	17	.	.	PUNCT
ajlm-1628	17	1	results	result	NOUN
ajlm-1628	17	2	:	:	PUNCT
ajlm-1628	17	3	total	total	ADJ
ajlm-1628	17	4	phenytoin	phenytoin	NOUN
ajlm-1628	17	5	plasma	plasma	NOUN
ajlm-1628	17	6	concentration	concentration	NOUN
ajlm-1628	17	7	was	be	AUX
ajlm-1628	17	8	below	below	ADV
ajlm-1628	17	9	(	(	PUNCT
ajlm-1628	17	10	41.1	41.1	NUM
ajlm-1628	17	11	%	%	NOUN
ajlm-1628	17	12	of	of	ADP
ajlm-1628	17	13	patients	patient	NOUN
ajlm-1628	17	14	)	)	PUNCT
ajlm-1628	17	15	,	,	PUNCT
ajlm-1628	17	16	within	within	ADP
ajlm-1628	17	17	(	(	PUNCT
ajlm-1628	17	18	46.4	46.4	NUM
ajlm-1628	17	19	%	%	NOUN
ajlm-1628	17	20	)	)	PUNCT
ajlm-1628	17	21	or	or	CCONJ
ajlm-1628	17	22	above	above	ADV
ajlm-1628	17	23	(	(	PUNCT
ajlm-1628	17	24	12.5	12.5	NUM
ajlm-1628	17	25	%	%	NOUN
ajlm-1628	17	26	)	)	PUNCT
ajlm-1628	17	27	the	the	DET
ajlm-1628	17	28	therapeutic	therapeutic	ADJ
ajlm-1628	17	29	range	range	NOUN
ajlm-1628	17	30	(	(	PUNCT
ajlm-1628	17	31	10	10	NUM
ajlm-1628	17	32	μg	μg	NOUN
ajlm-1628	17	33	/	/	SYM
ajlm-1628	17	34	ml	ml	PROPN
ajlm-1628	17	35	–	–	PUNCT
ajlm-1628	17	36	20	20	NUM
ajlm-1628	17	37	μg	μg	NOUN
ajlm-1628	17	38	/	/	SYM
ajlm-1628	17	39	ml	ml	NOUN
ajlm-1628	17	40	)	)	PUNCT
ajlm-1628	17	41	.	.	PUNCT
ajlm-1628	18	1	however	however	ADV
ajlm-1628	18	2	,	,	PUNCT
ajlm-1628	18	3	the	the	DET
ajlm-1628	18	4	predicted	predict	VERB
ajlm-1628	18	5	unbound	unbound	NOUN
ajlm-1628	18	6	plasma	plasma	NOUN
ajlm-1628	18	7	concentration	concentration	NOUN
ajlm-1628	18	8	of	of	ADP
ajlm-1628	18	9	phenytoin	phenytoin	NOUN
ajlm-1628	18	10	was	be	AUX
ajlm-1628	18	11	above	above	ADP
ajlm-1628	18	12	the	the	DET
ajlm-1628	18	13	therapeutic	therapeutic	ADJ
ajlm-1628	18	14	range	range	NOUN
ajlm-1628	18	15	(	(	PUNCT
ajlm-1628	18	16	1	1	NUM
ajlm-1628	18	17	μg	μg	NOUN
ajlm-1628	18	18	/	/	SYM
ajlm-1628	18	19	ml	ml	PROPN
ajlm-1628	18	20	–	–	PUNCT
ajlm-1628	18	21	2	2	NUM
ajlm-1628	18	22	μg	μg	NOUN
ajlm-1628	18	23	/	/	SYM
ajlm-1628	18	24	ml	ml	NOUN
ajlm-1628	18	25	)	)	PUNCT
ajlm-1628	18	26	in	in	ADP
ajlm-1628	18	27	the	the	DET
ajlm-1628	18	28	majority	majority	NOUN
ajlm-1628	18	29	of	of	ADP
ajlm-1628	18	30	patients	patient	NOUN
ajlm-1628	18	31	(	(	PUNCT
ajlm-1628	18	32	57.1	57.1	NUM
ajlm-1628	18	33	%	%	NOUN
ajlm-1628	18	34	)	)	PUNCT
ajlm-1628	18	35	.	.	PUNCT
ajlm-1628	19	1	for	for	ADP
ajlm-1628	19	2	valproic	valproic	ADJ
ajlm-1628	19	3	acid	acid	NOUN
ajlm-1628	19	4	,	,	PUNCT
ajlm-1628	19	5	the	the	DET
ajlm-1628	19	6	total	total	ADJ
ajlm-1628	19	7	plasma	plasma	NOUN
ajlm-1628	19	8	concentration	concentration	NOUN
ajlm-1628	19	9	of	of	ADP
ajlm-1628	19	10	most	most	ADJ
ajlm-1628	19	11	patients	patient	NOUN
ajlm-1628	19	12	(	(	PUNCT
ajlm-1628	19	13	87.1	87.1	NUM
ajlm-1628	19	14	%	%	NOUN
ajlm-1628	19	15	)	)	PUNCT
ajlm-1628	19	16	was	be	AUX
ajlm-1628	19	17	below	below	ADP
ajlm-1628	19	18	the	the	DET
ajlm-1628	19	19	therapeutic	therapeutic	ADJ
ajlm-1628	19	20	range	range	NOUN
ajlm-1628	19	21	(	(	PUNCT
ajlm-1628	19	22	50	50	NUM
ajlm-1628	19	23	μg	μg	NOUN
ajlm-1628	19	24	/	/	SYM
ajlm-1628	19	25	ml	ml	PROPN
ajlm-1628	19	26	–	–	PUNCT
ajlm-1628	19	27	100	100	NUM
ajlm-1628	19	28	μg	μg	NOUN
ajlm-1628	19	29	/	/	SYM
ajlm-1628	19	30	ml	ml	NOUN
ajlm-1628	19	31	)	)	PUNCT
ajlm-1628	19	32	;	;	PUNCT
ajlm-1628	19	33	among	among	ADP
ajlm-1628	19	34	remaining	remain	VERB
ajlm-1628	19	35	patients	patient	NOUN
ajlm-1628	19	36	(	(	PUNCT
ajlm-1628	19	37	12.9	12.9	NUM
ajlm-1628	19	38	%	%	NOUN
ajlm-1628	19	39	)	)	PUNCT
ajlm-1628	19	40	,	,	PUNCT
ajlm-1628	19	41	it	it	PRON
ajlm-1628	19	42	was	be	AUX
ajlm-1628	19	43	within	within	ADP
ajlm-1628	19	44	the	the	DET
ajlm-1628	19	45	therapeutic	therapeutic	ADJ
ajlm-1628	19	46	range	range	NOUN
ajlm-1628	19	47	.	.	PUNCT
ajlm-1628	20	1	in	in	ADP
ajlm-1628	20	2	the	the	DET
ajlm-1628	20	3	majority	majority	NOUN
ajlm-1628	20	4	of	of	ADP
ajlm-1628	20	5	patients	patient	NOUN
ajlm-1628	20	6	(	(	PUNCT
ajlm-1628	20	7	91.4	91.4	NUM
ajlm-1628	20	8	%	%	NOUN
ajlm-1628	20	9	)	)	PUNCT
ajlm-1628	20	10	,	,	PUNCT
ajlm-1628	20	11	the	the	DET
ajlm-1628	20	12	predicted	predict	VERB
ajlm-1628	20	13	unbound	unbound	NOUN
ajlm-1628	20	14	plasma	plasma	NOUN
ajlm-1628	20	15	concentration	concentration	NOUN
ajlm-1628	20	16	of	of	ADP
ajlm-1628	20	17	valproic	valproic	ADJ
ajlm-1628	20	18	acid	acid	NOUN
ajlm-1628	20	19	was	be	AUX
ajlm-1628	20	20	between	between	ADP
ajlm-1628	20	21	2.5	2.5	NUM
ajlm-1628	20	22	μg	μg	NOUN
ajlm-1628	20	23	/	/	SYM
ajlm-1628	20	24	ml	ml	PROPN
ajlm-1628	20	25	and	and	CCONJ
ajlm-1628	20	26	20	20	NUM
ajlm-1628	20	27	μg	μg	NOUN
ajlm-1628	20	28	/	/	SYM
ajlm-1628	20	29	ml	ml	NOUN
ajlm-1628	20	30	.	.	PUNCT
ajlm-1628	21	1	conclusion	conclusion	NOUN
ajlm-1628	21	2	:	:	PUNCT
ajlm-1628	21	3	the	the	DET
ajlm-1628	21	4	usefulness	usefulness	NOUN
ajlm-1628	21	5	of	of	ADP
ajlm-1628	21	6	monitoring	monitor	VERB
ajlm-1628	21	7	the	the	DET
ajlm-1628	21	8	total	total	ADJ
ajlm-1628	21	9	phenytoin	phenytoin	NOUN
ajlm-1628	21	10	or	or	CCONJ
ajlm-1628	21	11	valproic	valproic	ADJ
ajlm-1628	21	12	acid	acid	NOUN
ajlm-1628	21	13	levels	level	NOUN
ajlm-1628	21	14	for	for	ADP
ajlm-1628	21	15	dose	dose	NOUN
ajlm-1628	21	16	optimisation	optimisation	NOUN
ajlm-1628	21	17	is	be	AUX
ajlm-1628	21	18	limited	limit	VERB
ajlm-1628	21	19	as	as	SCONJ
ajlm-1628	21	20	it	it	PRON
ajlm-1628	21	21	is	be	AUX
ajlm-1628	21	22	an	an	DET
ajlm-1628	21	23	inaccurate	inaccurate	ADJ
ajlm-1628	21	24	indicator	indicator	NOUN
ajlm-1628	21	25	of	of	ADP
ajlm-1628	21	26	a	a	DET
ajlm-1628	21	27	patient	patient	NOUN
ajlm-1628	21	28	’s	’s	PART
ajlm-1628	21	29	drug	drug	NOUN
ajlm-1628	21	30	therapeutic	therapeutic	ADJ
ajlm-1628	21	31	state	state	NOUN
ajlm-1628	21	32	.	.	PUNCT
ajlm-1628	22	1	thus	thus	ADV
ajlm-1628	22	2	,	,	PUNCT
ajlm-1628	22	3	the	the	DET
ajlm-1628	22	4	unbound	unbound	NOUN
ajlm-1628	22	5	plasma	plasma	NOUN
ajlm-1628	22	6	drug	drug	NOUN
ajlm-1628	22	7	concentrations	concentration	NOUN
ajlm-1628	22	8	should	should	AUX
ajlm-1628	22	9	be	be	AUX
ajlm-1628	22	10	quantified	quantify	VERB
ajlm-1628	22	11	experimentally	experimentally	ADV
ajlm-1628	22	12	or	or	CCONJ
ajlm-1628	22	13	predicted	predict	VERB
ajlm-1628	22	14	in	in	ADP
ajlm-1628	22	15	resource	resource	NOUN
ajlm-1628	22	16	-	-	PUNCT
ajlm-1628	22	17	limited	limit	VERB
ajlm-1628	22	18	settings	setting	NOUN
ajlm-1628	22	19	.	.	PUNCT
ajlm-1628	23	1	keywords	keyword	NOUN
ajlm-1628	23	2	:	:	PUNCT
ajlm-1628	23	3	phenytoin	phenytoin	NOUN
ajlm-1628	23	4	;	;	PUNCT
ajlm-1628	23	5	valproic	valproic	ADJ
ajlm-1628	23	6	acid	acid	NOUN
ajlm-1628	23	7	;	;	PUNCT
ajlm-1628	23	8	critically	critically	ADV
ajlm-1628	23	9	ill	ill	ADJ
ajlm-1628	23	10	patients	patient	NOUN
ajlm-1628	23	11	;	;	PUNCT
ajlm-1628	23	12	therapeutic	therapeutic	ADJ
ajlm-1628	23	13	drug	drug	NOUN
ajlm-1628	23	14	monitoring	monitoring	NOUN
ajlm-1628	23	15	;	;	PUNCT
ajlm-1628	23	16	unbound	unbound	NOUN
ajlm-1628	23	17	concentration	concentration	NOUN
ajlm-1628	23	18	.	.	PUNCT
ajlm-1628	24	1	introduction	introduction	NOUN
ajlm-1628	24	2	the	the	DET
ajlm-1628	24	3	incidence	incidence	NOUN
ajlm-1628	24	4	of	of	ADP
ajlm-1628	24	5	seizures	seizure	NOUN
ajlm-1628	24	6	in	in	ADP
ajlm-1628	24	7	north	north	ADJ
ajlm-1628	24	8	american	american	ADJ
ajlm-1628	24	9	general	general	ADJ
ajlm-1628	24	10	intensive	intensive	ADJ
ajlm-1628	24	11	care	care	NOUN
ajlm-1628	24	12	units	unit	NOUN
ajlm-1628	24	13	(	(	PUNCT
ajlm-1628	24	14	icus	icus	NOUN
ajlm-1628	24	15	)	)	PUNCT
ajlm-1628	24	16	was	be	AUX
ajlm-1628	24	17	reported	report	VERB
ajlm-1628	24	18	in	in	ADP
ajlm-1628	24	19	2013	2013	NUM
ajlm-1628	24	20	to	to	PART
ajlm-1628	24	21	range	range	VERB
ajlm-1628	24	22	from	from	ADP
ajlm-1628	24	23	3.3	3.3	NUM
ajlm-1628	24	24	%	%	NOUN
ajlm-1628	24	25	to	to	ADP
ajlm-1628	24	26	34.0%.1	34.0%.1	NUM
ajlm-1628	24	27	risk	risk	NOUN
ajlm-1628	24	28	factors	factor	NOUN
ajlm-1628	24	29	of	of	ADP
ajlm-1628	24	30	seizures	seizure	NOUN
ajlm-1628	24	31	include	include	VERB
ajlm-1628	24	32	head	head	NOUN
ajlm-1628	24	33	trauma	trauma	NOUN
ajlm-1628	24	34	,	,	PUNCT
ajlm-1628	24	35	stroke	stroke	NOUN
ajlm-1628	24	36	,	,	PUNCT
ajlm-1628	24	37	brain	brain	NOUN
ajlm-1628	24	38	tumour	tumour	NOUN
ajlm-1628	24	39	,	,	PUNCT
ajlm-1628	24	40	infections	infection	NOUN
ajlm-1628	24	41	,	,	PUNCT
ajlm-1628	24	42	hypoglycaemia	hypoglycaemia	NOUN
ajlm-1628	24	43	,	,	PUNCT
ajlm-1628	24	44	electrolyte	electrolyte	ADJ
ajlm-1628	24	45	abnormalities	abnormality	NOUN
ajlm-1628	24	46	,	,	PUNCT
ajlm-1628	24	47	and	and	CCONJ
ajlm-1628	24	48	drug	drug	NOUN
ajlm-1628	24	49	overdose	overdose	NOUN
ajlm-1628	24	50	.	.	PUNCT
ajlm-1628	25	1	phenytoin	phenytoin	NOUN
ajlm-1628	25	2	and	and	CCONJ
ajlm-1628	25	3	valproic	valproic	ADJ
ajlm-1628	25	4	acid	acid	NOUN
ajlm-1628	25	5	are	be	AUX
ajlm-1628	25	6	anticonvulsants	anticonvulsant	NOUN
ajlm-1628	25	7	frequently	frequently	ADV
ajlm-1628	25	8	used	use	VERB
ajlm-1628	25	9	to	to	PART
ajlm-1628	25	10	prophylax	prophylax	VERB
ajlm-1628	25	11	or	or	CCONJ
ajlm-1628	25	12	treat	treat	VERB
ajlm-1628	25	13	seizures	seizure	NOUN
ajlm-1628	25	14	in	in	ADP
ajlm-1628	25	15	critically	critically	ADV
ajlm-1628	25	16	ill	ill	ADJ
ajlm-1628	25	17	patients.2,3	patients.2,3	ADJ
ajlm-1628	25	18	however	however	ADV
ajlm-1628	25	19	,	,	PUNCT
ajlm-1628	25	20	both	both	DET
ajlm-1628	25	21	drugs	drug	NOUN
ajlm-1628	25	22	have	have	VERB
ajlm-1628	25	23	a	a	DET
ajlm-1628	25	24	low	low	ADJ
ajlm-1628	25	25	therapeutic	therapeutic	ADJ
ajlm-1628	25	26	index	index	NOUN
ajlm-1628	25	27	;	;	PUNCT
ajlm-1628	25	28	thus	thus	ADV
ajlm-1628	25	29	,	,	PUNCT
ajlm-1628	25	30	drug	drug	NOUN
ajlm-1628	25	31	monitoring	monitoring	NOUN
ajlm-1628	25	32	is	be	AUX
ajlm-1628	25	33	required	require	VERB
ajlm-1628	25	34	to	to	PART
ajlm-1628	25	35	minimise	minimise	VERB
ajlm-1628	25	36	the	the	DET
ajlm-1628	25	37	risk	risk	NOUN
ajlm-1628	25	38	of	of	ADP
ajlm-1628	25	39	toxicity	toxicity	NOUN
ajlm-1628	25	40	and	and	CCONJ
ajlm-1628	25	41	optimise	optimise	NOUN
ajlm-1628	25	42	therapeutic	therapeutic	ADJ
ajlm-1628	25	43	efficacy.4,5,6	efficacy.4,5,6	NOUN
ajlm-1628	25	44	following	follow	VERB
ajlm-1628	25	45	oral	oral	ADJ
ajlm-1628	25	46	administration	administration	NOUN
ajlm-1628	25	47	,	,	PUNCT
ajlm-1628	25	48	both	both	DET
ajlm-1628	25	49	drugs	drug	NOUN
ajlm-1628	25	50	are	be	AUX
ajlm-1628	25	51	well	well	ADV
ajlm-1628	25	52	-	-	PUNCT
ajlm-1628	25	53	absorbed	absorb	VERB
ajlm-1628	25	54	,	,	PUNCT
ajlm-1628	25	55	highly	highly	ADV
ajlm-1628	25	56	bound	bind	VERB
ajlm-1628	25	57	to	to	PART
ajlm-1628	25	58	plasma	plasma	VERB
ajlm-1628	25	59	albumin	albumin	NOUN
ajlm-1628	25	60	and	and	CCONJ
ajlm-1628	25	61	eliminated	eliminate	VERB
ajlm-1628	25	62	by	by	ADP
ajlm-1628	25	63	metabolism.2,4,5	metabolism.2,4,5	NOUN
ajlm-1628	25	64	the	the	DET
ajlm-1628	25	65	cytochrome	cytochrome	NOUN
ajlm-1628	25	66	p450	p450	PROPN
ajlm-1628	25	67	2c9	2c9	NUM
ajlm-1628	25	68	and	and	CCONJ
ajlm-1628	25	69	2c19	2c19	NUM
ajlm-1628	25	70	enzymes	enzyme	NOUN
ajlm-1628	25	71	metabolise	metabolise	AUX
ajlm-1628	25	72	phenytoin	phenytoin	VERB
ajlm-1628	25	73	to	to	ADP
ajlm-1628	25	74	the	the	DET
ajlm-1628	25	75	inactive	inactive	ADJ
ajlm-1628	25	76	hydroxy	hydroxy	NOUN
ajlm-1628	25	77	-	-	PUNCT
ajlm-1628	25	78	phenytoin	phenytoin	NOUN
ajlm-1628	25	79	,	,	PUNCT
ajlm-1628	25	80	following	follow	VERB
ajlm-1628	25	81	first	first	ADJ
ajlm-1628	25	82	-	-	PUNCT
ajlm-1628	25	83	order	order	NOUN
ajlm-1628	25	84	kinetics	kinetic	NOUN
ajlm-1628	25	85	.	.	PUNCT
ajlm-1628	26	1	however	however	ADV
ajlm-1628	26	2	,	,	PUNCT
ajlm-1628	26	3	at	at	ADP
ajlm-1628	26	4	therapeutic	therapeutic	ADJ
ajlm-1628	26	5	concentrations	concentration	NOUN
ajlm-1628	26	6	,	,	PUNCT
ajlm-1628	26	7	the	the	DET
ajlm-1628	26	8	rate	rate	NOUN
ajlm-1628	26	9	of	of	ADP
ajlm-1628	26	10	phenytoin	phenytoin	ADJ
ajlm-1628	26	11	metabolism	metabolism	NOUN
ajlm-1628	26	12	approaches	approach	VERB
ajlm-1628	26	13	saturation	saturation	NOUN
ajlm-1628	26	14	and	and	CCONJ
ajlm-1628	26	15	hence	hence	ADV
ajlm-1628	26	16	shows	show	VERB
ajlm-1628	26	17	capacity	capacity	NOUN
ajlm-1628	26	18	-	-	PUNCT
ajlm-1628	26	19	limited	limit	VERB
ajlm-1628	26	20	elimination	elimination	NOUN
ajlm-1628	26	21	(	(	PUNCT
ajlm-1628	26	22	zero	zero	NUM
ajlm-1628	26	23	-	-	PUNCT
ajlm-1628	26	24	order	order	NOUN
ajlm-1628	26	25	kinetics).5	kinetics).5	PROPN
ajlm-1628	26	26	metabolism	metabolism	NOUN
ajlm-1628	26	27	of	of	ADP
ajlm-1628	26	28	valproic	valproic	ADJ
ajlm-1628	26	29	acid	acid	NOUN
ajlm-1628	26	30	proceeds	proceed	NOUN
ajlm-1628	26	31	mainly	mainly	ADV
ajlm-1628	26	32	by	by	ADP
ajlm-1628	26	33	glucuronidation	glucuronidation	NOUN
ajlm-1628	26	34	(	(	PUNCT
ajlm-1628	26	35	50.0	50.0	NUM
ajlm-1628	26	36	%	%	NOUN
ajlm-1628	26	37	)	)	PUNCT
ajlm-1628	26	38	and	and	CCONJ
ajlm-1628	26	39	βand	βand	NOUN
ajlm-1628	27	1	ω	ω	VERB
ajlm-1628	27	2	-	-	NOUN
ajlm-1628	27	3	oxidation	oxidation	NOUN
ajlm-1628	27	4	(	(	PUNCT
ajlm-1628	27	5	40.0	40.0	NUM
ajlm-1628	27	6	%	%	NOUN
ajlm-1628	27	7	)	)	PUNCT
ajlm-1628	27	8	and	and	CCONJ
ajlm-1628	27	9	,	,	PUNCT
ajlm-1628	27	10	to	to	ADP
ajlm-1628	27	11	a	a	DET
ajlm-1628	27	12	much	much	ADV
ajlm-1628	27	13	lesser	less	ADJ
ajlm-1628	27	14	extent	extent	NOUN
ajlm-1628	27	15	,	,	PUNCT
ajlm-1628	27	16	by	by	ADP
ajlm-1628	27	17	cytochrome	cytochrome	ADJ
ajlm-1628	27	18	p450	p450	VERB
ajlm-1628	27	19	-	-	PUNCT
ajlm-1628	27	20	catalysed	catalyse	VERB
ajlm-1628	27	21	oxidation	oxidation	NOUN
ajlm-1628	27	22	(	(	PUNCT
ajlm-1628	27	23	10.0%).6	10.0%).6	NUM
ajlm-1628	27	24	the	the	DET
ajlm-1628	27	25	β	β	NOUN
ajlm-1628	27	26	-	-	NOUN
ajlm-1628	27	27	oxidation	oxidation	NOUN
ajlm-1628	27	28	of	of	ADP
ajlm-1628	27	29	valproic	valproic	ADJ
ajlm-1628	27	30	acid	acid	NOUN
ajlm-1628	27	31	has	have	AUX
ajlm-1628	27	32	been	be	AUX
ajlm-1628	27	33	reported	report	VERB
ajlm-1628	27	34	to	to	PART
ajlm-1628	27	35	be	be	AUX
ajlm-1628	27	36	saturable	saturable	ADJ
ajlm-1628	27	37	and	and	CCONJ
ajlm-1628	27	38	subject	subject	ADJ
ajlm-1628	27	39	to	to	ADP
ajlm-1628	27	40	autoinduction.6	autoinduction.6	NOUN
ajlm-1628	27	41	the	the	DET
ajlm-1628	27	42	pharmacokinetic	pharmacokinetic	ADJ
ajlm-1628	27	43	behaviour	behaviour	NOUN
ajlm-1628	27	44	of	of	ADP
ajlm-1628	27	45	phenytoin	phenytoin	NOUN
ajlm-1628	27	46	and	and	CCONJ
ajlm-1628	27	47	valproic	valproic	ADJ
ajlm-1628	27	48	acid	acid	NOUN
ajlm-1628	27	49	is	be	AUX
ajlm-1628	27	50	complicated	complicated	ADJ
ajlm-1628	27	51	because	because	SCONJ
ajlm-1628	27	52	their	their	PRON
ajlm-1628	27	53	elimination	elimination	NOUN
ajlm-1628	27	54	kinetics	kinetic	NOUN
ajlm-1628	27	55	are	be	AUX
ajlm-1628	27	56	nonlinear	nonlinear	ADJ
ajlm-1628	27	57	.	.	PUNCT
ajlm-1628	28	1	in	in	ADP
ajlm-1628	28	2	addition	addition	NOUN
ajlm-1628	28	3	,	,	PUNCT
ajlm-1628	28	4	the	the	DET
ajlm-1628	28	5	pharmacokinetics	pharmacokinetic	NOUN
ajlm-1628	28	6	of	of	ADP
ajlm-1628	28	7	both	both	DET
ajlm-1628	28	8	drugs	drug	NOUN
ajlm-1628	28	9	show	show	VERB
ajlm-1628	28	10	a	a	DET
ajlm-1628	28	11	high	high	ADJ
ajlm-1628	28	12	degree	degree	NOUN
ajlm-1628	28	13	of	of	ADP
ajlm-1628	28	14	interindividual	interindividual	ADJ
ajlm-1628	28	15	variability	variability	NOUN
ajlm-1628	28	16	as	as	ADP
ajlm-1628	28	17	a	a	DET
ajlm-1628	28	18	result	result	NOUN
ajlm-1628	28	19	of	of	ADP
ajlm-1628	28	20	pharmacogenetic	pharmacogenetic	ADJ
ajlm-1628	28	21	differences	difference	NOUN
ajlm-1628	28	22	in	in	ADP
ajlm-1628	28	23	enzyme	enzyme	NOUN
ajlm-1628	28	24	and	and	CCONJ
ajlm-1628	28	25	transporter	transporter	NOUN
ajlm-1628	28	26	activities	activity	NOUN
ajlm-1628	28	27	,	,	PUNCT
ajlm-1628	28	28	as	as	ADV
ajlm-1628	28	29	well	well	ADV
ajlm-1628	28	30	as	as	ADP
ajlm-1628	28	31	high	high	ADJ
ajlm-1628	28	32	interpatient	interpatient	NOUN
ajlm-1628	28	33	variability	variability	NOUN
ajlm-1628	28	34	in	in	ADP
ajlm-1628	28	35	plasma	plasma	NOUN
ajlm-1628	28	36	protein	protein	NOUN
ajlm-1628	28	37	binding	bind	VERB
ajlm-1628	28	38	,	,	PUNCT
ajlm-1628	28	39	in	in	ADP
ajlm-1628	28	40	the	the	DET
ajlm-1628	28	41	case	case	NOUN
ajlm-1628	28	42	of	of	ADP
ajlm-1628	28	43	valproic	valproic	ADJ
ajlm-1628	28	44	acid.7,8,9	acid.7,8,9	NOUN
ajlm-1628	28	45	as	as	ADP
ajlm-1628	28	46	a	a	DET
ajlm-1628	28	47	result	result	NOUN
ajlm-1628	28	48	of	of	ADP
ajlm-1628	28	49	this	this	DET
ajlm-1628	28	50	high	high	ADJ
ajlm-1628	28	51	interpatient	interpatient	NOUN
ajlm-1628	28	52	variability	variability	NOUN
ajlm-1628	28	53	,	,	PUNCT
ajlm-1628	28	54	there	there	PRON
ajlm-1628	28	55	is	be	VERB
ajlm-1628	28	56	a	a	DET
ajlm-1628	28	57	poor	poor	ADJ
ajlm-1628	28	58	correlation	correlation	NOUN
ajlm-1628	28	59	between	between	ADP
ajlm-1628	28	60	the	the	DET
ajlm-1628	28	61	dose	dose	NOUN
ajlm-1628	28	62	of	of	ADP
ajlm-1628	28	63	these	these	DET
ajlm-1628	28	64	drugs	drug	NOUN
ajlm-1628	28	65	and	and	CCONJ
ajlm-1628	28	66	patient	patient	ADJ
ajlm-1628	28	67	plasma	plasma	NOUN
ajlm-1628	28	68	concentrations	concentration	NOUN
ajlm-1628	28	69	.	.	PUNCT
ajlm-1628	29	1	hence	hence	ADV
ajlm-1628	29	2	,	,	PUNCT
ajlm-1628	29	3	monitoring	monitor	VERB
ajlm-1628	29	4	patients	patient	NOUN
ajlm-1628	29	5	’	'	PUNCT
ajlm-1628	29	6	phenytoin	phenytoin	NOUN
ajlm-1628	29	7	or	or	CCONJ
ajlm-1628	29	8	valproic	valproic	ADJ
ajlm-1628	29	9	acid	acid	NOUN
ajlm-1628	29	10	plasma	plasma	NOUN
ajlm-1628	29	11	concentrations	concentration	NOUN
ajlm-1628	29	12	is	be	AUX
ajlm-1628	29	13	common	common	ADJ
ajlm-1628	29	14	,	,	PUNCT
ajlm-1628	29	15	even	even	ADV
ajlm-1628	29	16	in	in	ADP
ajlm-1628	29	17	critically	critically	ADV
ajlm-1628	29	18	ill	ill	ADJ
ajlm-1628	29	19	patients.2,7	patients.2,7	ADJ
ajlm-1628	29	20	phenytoin	phenytoin	NOUN
ajlm-1628	29	21	and	and	CCONJ
ajlm-1628	29	22	valproic	valproic	ADJ
ajlm-1628	29	23	acid	acid	NOUN
ajlm-1628	29	24	are	be	AUX
ajlm-1628	29	25	highly	highly	ADV
ajlm-1628	29	26	bound	bind	VERB
ajlm-1628	29	27	to	to	PART
ajlm-1628	29	28	serum	serum	VERB
ajlm-1628	29	29	albumin	albumin	NOUN
ajlm-1628	29	30	(	(	PUNCT
ajlm-1628	29	31	≥	≥	NUM
ajlm-1628	29	32	90	90	NUM
ajlm-1628	29	33	%	%	NOUN
ajlm-1628	29	34	)	)	PUNCT
ajlm-1628	29	35	.	.	PUNCT
ajlm-1628	30	1	the	the	DET
ajlm-1628	30	2	binding	binding	NOUN
ajlm-1628	30	3	of	of	ADP
ajlm-1628	30	4	these	these	DET
ajlm-1628	30	5	drugs	drug	NOUN
ajlm-1628	30	6	depends	depend	VERB
ajlm-1628	30	7	on	on	ADP
ajlm-1628	30	8	the	the	DET
ajlm-1628	30	9	drug	drug	NOUN
ajlm-1628	30	10	plasma	plasma	NOUN
ajlm-1628	30	11	and	and	CCONJ
ajlm-1628	30	12	albumin	albumin	ADJ
ajlm-1628	30	13	concentrations	concentration	NOUN
ajlm-1628	30	14	and	and	CCONJ
ajlm-1628	30	15	the	the	DET
ajlm-1628	30	16	presence	presence	NOUN
ajlm-1628	30	17	of	of	ADP
ajlm-1628	30	18	other	other	ADJ
ajlm-1628	30	19	albumin	albumin	ADJ
ajlm-1628	30	20	-	-	PUNCT
ajlm-1628	30	21	binding	bind	VERB
ajlm-1628	30	22	substances	substance	NOUN
ajlm-1628	30	23	that	that	PRON
ajlm-1628	30	24	may	may	AUX
ajlm-1628	30	25	compete	compete	VERB
ajlm-1628	30	26	for	for	ADP
ajlm-1628	30	27	binding	bind	VERB
ajlm-1628	30	28	sites	site	NOUN
ajlm-1628	30	29	with	with	ADP
ajlm-1628	30	30	these	these	DET
ajlm-1628	30	31	drugs.10	drugs.10	PROPN
ajlm-1628	30	32	thus	thus	ADV
ajlm-1628	30	33	,	,	PUNCT
ajlm-1628	30	34	hypoalbuminaemia	hypoalbuminaemia	INTJ
ajlm-1628	30	35	,	,	PUNCT
ajlm-1628	30	36	a	a	DET
ajlm-1628	30	37	condition	condition	NOUN
ajlm-1628	30	38	in	in	ADP
ajlm-1628	30	39	which	which	PRON
ajlm-1628	30	40	concentrations	concentration	NOUN
ajlm-1628	30	41	of	of	ADP
ajlm-1628	30	42	the	the	DET
ajlm-1628	30	43	plasma	plasma	NOUN
ajlm-1628	30	44	protein	protein	NOUN
ajlm-1628	30	45	albumin	albumin	NOUN
ajlm-1628	30	46	are	be	AUX
ajlm-1628	30	47	lower	low	ADJ
ajlm-1628	30	48	than	than	ADP
ajlm-1628	30	49	35	35	NUM
ajlm-1628	30	50	g	g	NOUN
ajlm-1628	30	51	/	/	SYM
ajlm-1628	30	52	l	l	NOUN
ajlm-1628	30	53	,	,	PUNCT
ajlm-1628	30	54	increases	increase	VERB
ajlm-1628	30	55	the	the	DET
ajlm-1628	30	56	unbound	unbound	NOUN
ajlm-1628	30	57	proportion	proportion	NOUN
ajlm-1628	30	58	of	of	ADP
ajlm-1628	30	59	these	these	DET
ajlm-1628	30	60	drugs	drug	NOUN
ajlm-1628	30	61	because	because	SCONJ
ajlm-1628	30	62	of	of	ADP
ajlm-1628	30	63	the	the	DET
ajlm-1628	30	64	decreased	decrease	VERB
ajlm-1628	30	65	albumin	albumin	NOUN
ajlm-1628	30	66	(	(	PUNCT
ajlm-1628	30	67	binding	bind	VERB
ajlm-1628	30	68	sites	site	NOUN
ajlm-1628	30	69	)	)	PUNCT
ajlm-1628	30	70	concentrations.11,12,13	concentrations.11,12,13	ADV
ajlm-1628	30	71	hence	hence	ADV
ajlm-1628	30	72	,	,	PUNCT
ajlm-1628	30	73	monitoring	monitor	VERB
ajlm-1628	30	74	total	total	ADJ
ajlm-1628	30	75	plasma	plasma	NOUN
ajlm-1628	30	76	concentrations	concentration	NOUN
ajlm-1628	30	77	of	of	ADP
ajlm-1628	30	78	phenytoin	phenytoin	NOUN
ajlm-1628	30	79	and	and	CCONJ
ajlm-1628	30	80	valproic	valproic	ADJ
ajlm-1628	30	81	acid	acid	NOUN
ajlm-1628	30	82	hypoalbuminaemia	hypoalbuminaemia	NOUN
ajlm-1628	30	83	patients	patient	NOUN
ajlm-1628	30	84	,	,	PUNCT
ajlm-1628	30	85	such	such	ADJ
ajlm-1628	30	86	as	as	ADP
ajlm-1628	30	87	critically	critically	ADV
ajlm-1628	30	88	ill	ill	ADJ
ajlm-1628	30	89	patients	patient	NOUN
ajlm-1628	30	90	,	,	PUNCT
ajlm-1628	30	91	as	as	ADP
ajlm-1628	30	92	the	the	DET
ajlm-1628	30	93	clinical	clinical	ADJ
ajlm-1628	30	94	indicator	indicator	NOUN
ajlm-1628	30	95	for	for	ADP
ajlm-1628	30	96	therapeutic	therapeutic	ADJ
ajlm-1628	30	97	efficacy	efficacy	NOUN
ajlm-1628	30	98	and	and	CCONJ
ajlm-1628	30	99	safety	safety	NOUN
ajlm-1628	30	100	,	,	PUNCT
ajlm-1628	30	101	is	be	AUX
ajlm-1628	30	102	not	not	PART
ajlm-1628	30	103	as	as	ADV
ajlm-1628	30	104	reliable	reliable	ADJ
ajlm-1628	30	105	as	as	ADP
ajlm-1628	30	106	utilising	utilise	VERB
ajlm-1628	30	107	the	the	DET
ajlm-1628	30	108	unbound	unbound	NOUN
ajlm-1628	30	109	concentrations.14,15	concentrations.14,15	NOUN
ajlm-1628	30	110	since	since	SCONJ
ajlm-1628	30	111	it	it	PRON
ajlm-1628	30	112	is	be	AUX
ajlm-1628	30	113	only	only	ADV
ajlm-1628	30	114	the	the	DET
ajlm-1628	30	115	unbound	unbound	NOUN
ajlm-1628	30	116	drug	drug	NOUN
ajlm-1628	30	117	that	that	PRON
ajlm-1628	30	118	can	can	AUX
ajlm-1628	30	119	cross	cross	VERB
ajlm-1628	30	120	biological	biological	ADJ
ajlm-1628	30	121	membranes	membrane	NOUN
ajlm-1628	30	122	and	and	CCONJ
ajlm-1628	30	123	cause	cause	VERB
ajlm-1628	30	124	pharmacological	pharmacological	ADJ
ajlm-1628	30	125	action	action	NOUN
ajlm-1628	30	126	through	through	ADP
ajlm-1628	30	127	interaction	interaction	NOUN
ajlm-1628	30	128	with	with	ADP
ajlm-1628	30	129	the	the	DET
ajlm-1628	30	130	drug	drug	NOUN
ajlm-1628	30	131	target	target	NOUN
ajlm-1628	30	132	,	,	PUNCT
ajlm-1628	30	133	the	the	DET
ajlm-1628	30	134	therapeutic	therapeutic	ADJ
ajlm-1628	30	135	range	range	NOUN
ajlm-1628	30	136	and	and	CCONJ
ajlm-1628	30	137	dosage	dosage	NOUN
ajlm-1628	30	138	individualisation	individualisation	NOUN
ajlm-1628	30	139	in	in	ADP
ajlm-1628	30	140	hypoalbuminaemia	hypoalbuminaemia	NOUN
ajlm-1628	30	141	patients	patient	NOUN
ajlm-1628	30	142	should	should	AUX
ajlm-1628	30	143	be	be	AUX
ajlm-1628	30	144	informed	inform	VERB
ajlm-1628	30	145	by	by	ADP
ajlm-1628	30	146	the	the	DET
ajlm-1628	30	147	unbound	unbound	NOUN
ajlm-1628	30	148	plasma	plasma	NOUN
ajlm-1628	30	149	drug	drug	NOUN
ajlm-1628	30	150	concentrations	concentration	NOUN
ajlm-1628	30	151	to	to	PART
ajlm-1628	30	152	prevent	prevent	VERB
ajlm-1628	30	153	toxicity	toxicity	NOUN
ajlm-1628	30	154	or	or	CCONJ
ajlm-1628	30	155	therapeutic	therapeutic	ADJ
ajlm-1628	30	156	failure.10,12,16,17	failure.10,12,16,17	ADJ
ajlm-1628	30	157	unbound	unbound	NOUN
ajlm-1628	30	158	plasma	plasma	NOUN
ajlm-1628	30	159	concentrations	concentration	NOUN
ajlm-1628	30	160	can	can	AUX
ajlm-1628	30	161	be	be	AUX
ajlm-1628	30	162	determined	determine	VERB
ajlm-1628	30	163	by	by	ADP
ajlm-1628	30	164	equilibrium	equilibrium	NOUN
ajlm-1628	30	165	dialysis	dialysis	NOUN
ajlm-1628	30	166	and	and	CCONJ
ajlm-1628	30	167	ultrafiltration	ultrafiltration	NOUN
ajlm-1628	30	168	.	.	PUNCT
ajlm-1628	31	1	however	however	ADV
ajlm-1628	31	2	,	,	PUNCT
ajlm-1628	31	3	the	the	DET
ajlm-1628	31	4	use	use	NOUN
ajlm-1628	31	5	of	of	ADP
ajlm-1628	31	6	unbound	unbound	NOUN
ajlm-1628	31	7	plasma	plasma	NOUN
ajlm-1628	31	8	concentrations	concentration	NOUN
ajlm-1628	31	9	in	in	ADP
ajlm-1628	31	10	clinical	clinical	ADJ
ajlm-1628	31	11	practice	practice	NOUN
ajlm-1628	31	12	is	be	AUX
ajlm-1628	31	13	limited	limit	VERB
ajlm-1628	31	14	because	because	SCONJ
ajlm-1628	31	15	it	it	PRON
ajlm-1628	31	16	is	be	AUX
ajlm-1628	31	17	time	time	NOUN
ajlm-1628	31	18	consuming	consume	VERB
ajlm-1628	31	19	and	and	CCONJ
ajlm-1628	31	20	costly	costly	ADJ
ajlm-1628	31	21	.	.	PUNCT
ajlm-1628	32	1	therefore	therefore	ADV
ajlm-1628	32	2	,	,	PUNCT
ajlm-1628	32	3	equations	equation	NOUN
ajlm-1628	32	4	have	have	AUX
ajlm-1628	32	5	been	be	AUX
ajlm-1628	32	6	formulated	formulate	VERB
ajlm-1628	32	7	to	to	PART
ajlm-1628	32	8	estimate	estimate	VERB
ajlm-1628	32	9	the	the	DET
ajlm-1628	32	10	unbound	unbound	NOUN
ajlm-1628	32	11	concentrations	concentration	NOUN
ajlm-1628	32	12	of	of	ADP
ajlm-1628	32	13	phenytoin	phenytoin	NOUN
ajlm-1628	32	14	and	and	CCONJ
ajlm-1628	32	15	valproic	valproic	ADJ
ajlm-1628	32	16	acid	acid	NOUN
ajlm-1628	32	17	using	use	VERB
ajlm-1628	32	18	a	a	DET
ajlm-1628	32	19	patient	patient	NOUN
ajlm-1628	32	20	’s	’s	PART
ajlm-1628	32	21	measured	measure	VERB
ajlm-1628	32	22	total	total	ADJ
ajlm-1628	32	23	drug	drug	NOUN
ajlm-1628	32	24	plasma	plasma	NOUN
ajlm-1628	32	25	concentration	concentration	NOUN
ajlm-1628	32	26	and	and	CCONJ
ajlm-1628	32	27	serum	serum	NOUN
ajlm-1628	32	28	albumin	albumin	NOUN
ajlm-1628	32	29	level.5,18,19,20,21,22	level.5,18,19,20,21,22	VERB
ajlm-1628	32	30	the	the	DET
ajlm-1628	32	31	therapeutic	therapeutic	ADJ
ajlm-1628	32	32	range	range	NOUN
ajlm-1628	32	33	for	for	ADP
ajlm-1628	32	34	the	the	DET
ajlm-1628	32	35	total	total	ADJ
ajlm-1628	32	36	phenytoin	phenytoin	NOUN
ajlm-1628	32	37	plasma	plasma	NOUN
ajlm-1628	32	38	concentration	concentration	NOUN
ajlm-1628	32	39	is	be	AUX
ajlm-1628	32	40	10	10	NUM
ajlm-1628	32	41	μg	μg	NOUN
ajlm-1628	32	42	/	/	SYM
ajlm-1628	32	43	ml	ml	NOUN
ajlm-1628	32	44	to	to	ADP
ajlm-1628	32	45	20	20	NUM
ajlm-1628	32	46	μg	μg	NOUN
ajlm-1628	32	47	/	/	SYM
ajlm-1628	32	48	ml	ml	PROPN
ajlm-1628	32	49	,	,	PUNCT
ajlm-1628	32	50	and	and	CCONJ
ajlm-1628	32	51	1	1	NUM
ajlm-1628	32	52	μg	μg	NOUN
ajlm-1628	32	53	/	/	SYM
ajlm-1628	32	54	ml	ml	NOUN
ajlm-1628	32	55	to	to	ADP
ajlm-1628	32	56	2	2	NUM
ajlm-1628	32	57	μg	μg	NOUN
ajlm-1628	32	58	/	/	SYM
ajlm-1628	32	59	ml	ml	X
ajlm-1628	32	60	for	for	ADP
ajlm-1628	32	61	the	the	DET
ajlm-1628	32	62	unbound	unbound	PROPN
ajlm-1628	32	63	phenytoin	phenytoin	NOUN
ajlm-1628	32	64	plasma	plasma	NOUN
ajlm-1628	32	65	concentration.4,5	concentration.4,5	NOUN
ajlm-1628	32	66	for	for	ADP
ajlm-1628	32	67	valproic	valproic	ADJ
ajlm-1628	32	68	acid	acid	NOUN
ajlm-1628	32	69	,	,	PUNCT
ajlm-1628	32	70	the	the	DET
ajlm-1628	32	71	therapeutic	therapeutic	ADJ
ajlm-1628	32	72	range	range	NOUN
ajlm-1628	32	73	for	for	ADP
ajlm-1628	32	74	the	the	DET
ajlm-1628	32	75	total	total	ADJ
ajlm-1628	32	76	plasma	plasma	NOUN
ajlm-1628	32	77	drug	drug	NOUN
ajlm-1628	32	78	concentration	concentration	NOUN
ajlm-1628	32	79	is	be	AUX
ajlm-1628	32	80	50	50	NUM
ajlm-1628	32	81	μg	μg	NOUN
ajlm-1628	32	82	/	/	SYM
ajlm-1628	32	83	ml	ml	NOUN
ajlm-1628	32	84	to	to	ADP
ajlm-1628	32	85	100	100	NUM
ajlm-1628	32	86	μg	μg	NOUN
ajlm-1628	32	87	/	/	SYM
ajlm-1628	32	88	ml	ml	NOUN
ajlm-1628	32	89	;	;	PUNCT
ajlm-1628	32	90	for	for	ADP
ajlm-1628	32	91	the	the	DET
ajlm-1628	32	92	unbound	unbound	NOUN
ajlm-1628	32	93	plasma	plasma	NOUN
ajlm-1628	32	94	concentration	concentration	NOUN
ajlm-1628	32	95	,	,	PUNCT
ajlm-1628	32	96	a	a	DET
ajlm-1628	32	97	therapeutic	therapeutic	ADJ
ajlm-1628	32	98	range	range	NOUN
ajlm-1628	32	99	of	of	ADP
ajlm-1628	32	100	2.5	2.5	NUM
ajlm-1628	32	101	μg	μg	NOUN
ajlm-1628	32	102	/	/	SYM
ajlm-1628	32	103	ml	ml	NOUN
ajlm-1628	32	104	to	to	ADP
ajlm-1628	32	105	20	20	NUM
ajlm-1628	32	106	μg	μg	NOUN
ajlm-1628	32	107	/	/	SYM
ajlm-1628	32	108	ml	ml	PROPN
ajlm-1628	32	109	has	have	AUX
ajlm-1628	32	110	been	be	AUX
ajlm-1628	32	111	suggested.4,5	suggested.4,5	PROPN
ajlm-1628	32	112	the	the	DET
ajlm-1628	32	113	windhoek	windhoek	PROPN
ajlm-1628	32	114	central	central	ADJ
ajlm-1628	32	115	hospital	hospital	NOUN
ajlm-1628	32	116	in	in	ADP
ajlm-1628	32	117	windhoek	windhoek	PROPN
ajlm-1628	32	118	(	(	PUNCT
ajlm-1628	32	119	namibia	namibia	PROPN
ajlm-1628	32	120	)	)	PUNCT
ajlm-1628	32	121	conducts	conduct	VERB
ajlm-1628	32	122	therapeutic	therapeutic	ADJ
ajlm-1628	32	123	phenytoin	phenytoin	NOUN
ajlm-1628	32	124	and	and	CCONJ
ajlm-1628	32	125	valproic	valproic	ADJ
ajlm-1628	32	126	acid	acid	NOUN
ajlm-1628	32	127	monitoring	monitoring	NOUN
ajlm-1628	32	128	in	in	ADP
ajlm-1628	32	129	critically	critically	ADV
ajlm-1628	32	130	ill	ill	ADJ
ajlm-1628	32	131	patients	patient	NOUN
ajlm-1628	32	132	in	in	ADP
ajlm-1628	32	133	the	the	DET
ajlm-1628	32	134	icu	icu	PROPN
ajlm-1628	32	135	facility	facility	NOUN
ajlm-1628	32	136	by	by	ADP
ajlm-1628	32	137	measuring	measure	VERB
ajlm-1628	32	138	only	only	ADV
ajlm-1628	32	139	total	total	ADJ
ajlm-1628	32	140	plasma	plasma	NOUN
ajlm-1628	32	141	concentrations	concentration	NOUN
ajlm-1628	32	142	of	of	ADP
ajlm-1628	32	143	the	the	DET
ajlm-1628	32	144	drugs	drug	NOUN
ajlm-1628	32	145	.	.	PUNCT
ajlm-1628	33	1	this	this	DET
ajlm-1628	33	2	study	study	NOUN
ajlm-1628	33	3	aimed	aim	VERB
ajlm-1628	33	4	to	to	PART
ajlm-1628	33	5	retrospectively	retrospectively	ADV
ajlm-1628	33	6	estimate	estimate	VERB
ajlm-1628	33	7	unbound	unbound	NOUN
ajlm-1628	33	8	plasma	plasma	NOUN
ajlm-1628	33	9	concentrations	concentration	NOUN
ajlm-1628	33	10	as	as	ADP
ajlm-1628	33	11	a	a	DET
ajlm-1628	33	12	more	more	ADV
ajlm-1628	33	13	accurate	accurate	ADJ
ajlm-1628	33	14	measure	measure	NOUN
ajlm-1628	33	15	of	of	ADP
ajlm-1628	33	16	the	the	DET
ajlm-1628	33	17	therapeutic	therapeutic	ADJ
ajlm-1628	33	18	plasma	plasma	NOUN
ajlm-1628	33	19	levels	level	NOUN
ajlm-1628	33	20	of	of	ADP
ajlm-1628	33	21	two	two	NUM
ajlm-1628	33	22	drugs	drug	NOUN
ajlm-1628	33	23	.	.	PUNCT
ajlm-1628	34	1	methods	method	NOUN
ajlm-1628	34	2	ethical	ethical	ADJ
ajlm-1628	34	3	considerations	consideration	NOUN
ajlm-1628	34	4	the	the	DET
ajlm-1628	34	5	research	research	NOUN
ajlm-1628	34	6	and	and	CCONJ
ajlm-1628	34	7	ethics	ethic	NOUN
ajlm-1628	34	8	committees	committee	NOUN
ajlm-1628	34	9	of	of	ADP
ajlm-1628	34	10	the	the	DET
ajlm-1628	34	11	ministry	ministry	PROPN
ajlm-1628	34	12	of	of	ADP
ajlm-1628	34	13	health	health	PROPN
ajlm-1628	34	14	and	and	CCONJ
ajlm-1628	34	15	social	social	ADJ
ajlm-1628	34	16	services	service	NOUN
ajlm-1628	34	17	,	,	PUNCT
ajlm-1628	34	18	the	the	DET
ajlm-1628	34	19	republic	republic	NOUN
ajlm-1628	34	20	of	of	ADP
ajlm-1628	34	21	namibia	namibia	PROPN
ajlm-1628	34	22	,	,	PUNCT
ajlm-1628	34	23	approved	approve	VERB
ajlm-1628	34	24	this	this	DET
ajlm-1628	34	25	study	study	NOUN
ajlm-1628	34	26	;	;	PUNCT
ajlm-1628	34	27	reference	reference	NOUN
ajlm-1628	34	28	numbers	number	NOUN
ajlm-1628	34	29	hm2019	hm2019	PROPN
ajlm-1628	34	30	and	and	CCONJ
ajlm-1628	34	31	lni2019	lni2019	VERB
ajlm-1628	34	32	.	.	PUNCT
ajlm-1628	35	1	data	datum	NOUN
ajlm-1628	35	2	were	be	AUX
ajlm-1628	35	3	retrieved	retrieve	VERB
ajlm-1628	35	4	from	from	ADP
ajlm-1628	35	5	patient	patient	ADJ
ajlm-1628	35	6	record	record	NOUN
ajlm-1628	35	7	archives	archive	NOUN
ajlm-1628	35	8	;	;	PUNCT
ajlm-1628	35	9	no	no	DET
ajlm-1628	35	10	patients	patient	NOUN
ajlm-1628	35	11	were	be	AUX
ajlm-1628	35	12	required	require	VERB
ajlm-1628	35	13	to	to	PART
ajlm-1628	35	14	participate	participate	VERB
ajlm-1628	35	15	in	in	ADP
ajlm-1628	35	16	the	the	DET
ajlm-1628	35	17	data	data	NOUN
ajlm-1628	35	18	collection	collection	NOUN
ajlm-1628	35	19	procedure	procedure	NOUN
ajlm-1628	35	20	of	of	ADP
ajlm-1628	35	21	this	this	DET
ajlm-1628	35	22	study	study	NOUN
ajlm-1628	35	23	,	,	PUNCT
ajlm-1628	35	24	and	and	CCONJ
ajlm-1628	35	25	the	the	DET
ajlm-1628	35	26	ethics	ethic	NOUN
ajlm-1628	35	27	committee	committee	PROPN
ajlm-1628	35	28	waived	waive	VERB
ajlm-1628	35	29	the	the	DET
ajlm-1628	35	30	requirement	requirement	NOUN
ajlm-1628	35	31	to	to	PART
ajlm-1628	35	32	obtain	obtain	VERB
ajlm-1628	35	33	consent	consent	NOUN
ajlm-1628	35	34	from	from	ADP
ajlm-1628	35	35	patients	patient	NOUN
ajlm-1628	35	36	before	before	ADP
ajlm-1628	35	37	accessing	access	VERB
ajlm-1628	35	38	their	their	PRON
ajlm-1628	35	39	records	record	NOUN
ajlm-1628	35	40	.	.	PUNCT
ajlm-1628	36	1	furthermore	furthermore	ADV
ajlm-1628	36	2	,	,	PUNCT
ajlm-1628	36	3	names	name	NOUN
ajlm-1628	36	4	were	be	AUX
ajlm-1628	36	5	excluded	exclude	VERB
ajlm-1628	36	6	from	from	ADP
ajlm-1628	36	7	the	the	DET
ajlm-1628	36	8	data	datum	NOUN
ajlm-1628	36	9	collected	collect	VERB
ajlm-1628	36	10	for	for	ADP
ajlm-1628	36	11	this	this	DET
ajlm-1628	36	12	study	study	NOUN
ajlm-1628	36	13	to	to	PART
ajlm-1628	36	14	protect	protect	VERB
ajlm-1628	36	15	patients	patient	NOUN
ajlm-1628	36	16	’	'	PUNCT
ajlm-1628	36	17	privacy	privacy	NOUN
ajlm-1628	36	18	.	.	PUNCT
ajlm-1628	37	1	patient	patient	ADJ
ajlm-1628	37	2	population	population	NOUN
ajlm-1628	37	3	and	and	CCONJ
ajlm-1628	37	4	data	datum	NOUN
ajlm-1628	37	5	collection	collection	NOUN
ajlm-1628	37	6	this	this	DET
ajlm-1628	37	7	retrospective	retrospective	ADJ
ajlm-1628	37	8	analysis	analysis	NOUN
ajlm-1628	37	9	utilised	utilise	VERB
ajlm-1628	37	10	data	datum	NOUN
ajlm-1628	37	11	from	from	ADP
ajlm-1628	37	12	the	the	DET
ajlm-1628	37	13	icu	icu	PROPN
ajlm-1628	37	14	of	of	ADP
ajlm-1628	37	15	windhoek	windhoek	PROPN
ajlm-1628	37	16	central	central	PROPN
ajlm-1628	37	17	hospital	hospital	PROPN
ajlm-1628	37	18	,	,	PUNCT
ajlm-1628	37	19	namibia	namibia	PROPN
ajlm-1628	37	20	.	.	PUNCT
ajlm-1628	38	1	records	record	NOUN
ajlm-1628	38	2	of	of	ADP
ajlm-1628	38	3	patients	patient	NOUN
ajlm-1628	38	4	admitted	admit	VERB
ajlm-1628	38	5	between	between	ADP
ajlm-1628	38	6	january	january	PROPN
ajlm-1628	38	7	2013	2013	NUM
ajlm-1628	38	8	and	and	CCONJ
ajlm-1628	38	9	july	july	PROPN
ajlm-1628	38	10	2019	2019	NUM
ajlm-1628	38	11	were	be	AUX
ajlm-1628	38	12	reviewed	review	VERB
ajlm-1628	38	13	.	.	PUNCT
ajlm-1628	39	1	patients	patient	NOUN
ajlm-1628	39	2	who	who	PRON
ajlm-1628	39	3	received	receive	VERB
ajlm-1628	39	4	phenytoin	phenytoin	NOUN
ajlm-1628	39	5	or	or	CCONJ
ajlm-1628	39	6	valproic	valproic	ADJ
ajlm-1628	39	7	acid	acid	NOUN
ajlm-1628	39	8	while	while	SCONJ
ajlm-1628	39	9	at	at	ADP
ajlm-1628	39	10	the	the	DET
ajlm-1628	39	11	icu	icu	PROPN
ajlm-1628	39	12	and	and	CCONJ
ajlm-1628	39	13	whose	whose	DET
ajlm-1628	39	14	anticonvulsant	anticonvulsant	ADJ
ajlm-1628	39	15	plasma	plasma	NOUN
ajlm-1628	39	16	concentrations	concentration	NOUN
ajlm-1628	39	17	and	and	CCONJ
ajlm-1628	39	18	serum	serum	NOUN
ajlm-1628	39	19	albumin	albumin	ADJ
ajlm-1628	39	20	levels	level	NOUN
ajlm-1628	39	21	had	have	AUX
ajlm-1628	39	22	been	be	AUX
ajlm-1628	39	23	recorded	record	VERB
ajlm-1628	39	24	were	be	AUX
ajlm-1628	39	25	included	include	VERB
ajlm-1628	39	26	in	in	ADP
ajlm-1628	39	27	the	the	DET
ajlm-1628	39	28	study	study	NOUN
ajlm-1628	39	29	.	.	PUNCT
ajlm-1628	40	1	the	the	DET
ajlm-1628	40	2	following	follow	VERB
ajlm-1628	40	3	information	information	NOUN
ajlm-1628	40	4	was	be	AUX
ajlm-1628	40	5	extracted	extract	VERB
ajlm-1628	40	6	from	from	ADP
ajlm-1628	40	7	the	the	DET
ajlm-1628	40	8	records	record	NOUN
ajlm-1628	40	9	:	:	PUNCT
ajlm-1628	40	10	age	age	NOUN
ajlm-1628	40	11	,	,	PUNCT
ajlm-1628	40	12	gender	gender	NOUN
ajlm-1628	40	13	,	,	PUNCT
ajlm-1628	40	14	diagnosis	diagnosis	NOUN
ajlm-1628	40	15	,	,	PUNCT
ajlm-1628	40	16	total	total	ADJ
ajlm-1628	40	17	plasma	plasma	NOUN
ajlm-1628	40	18	concentrations	concentration	NOUN
ajlm-1628	40	19	of	of	ADP
ajlm-1628	40	20	phenytoin	phenytoin	NOUN
ajlm-1628	40	21	or	or	CCONJ
ajlm-1628	40	22	valproic	valproic	ADJ
ajlm-1628	40	23	acid	acid	NOUN
ajlm-1628	40	24	,	,	PUNCT
ajlm-1628	40	25	serum	serum	NOUN
ajlm-1628	40	26	albumin	albumin	ADJ
ajlm-1628	40	27	concentration	concentration	NOUN
ajlm-1628	40	28	,	,	PUNCT
ajlm-1628	40	29	and	and	CCONJ
ajlm-1628	40	30	concomitant	concomitant	ADJ
ajlm-1628	40	31	medication	medication	NOUN
ajlm-1628	40	32	.	.	PUNCT
ajlm-1628	41	1	serum	serum	PROPN
ajlm-1628	41	2	albumin	albumin	ADJ
ajlm-1628	41	3	concentrations	concentration	NOUN
ajlm-1628	41	4	were	be	AUX
ajlm-1628	41	5	measured	measure	VERB
ajlm-1628	41	6	at	at	ADP
ajlm-1628	41	7	the	the	DET
ajlm-1628	41	8	namibia	namibia	PROPN
ajlm-1628	41	9	institute	institute	PROPN
ajlm-1628	41	10	of	of	ADP
ajlm-1628	41	11	pathology	pathology	PROPN
ajlm-1628	41	12	using	use	VERB
ajlm-1628	41	13	the	the	DET
ajlm-1628	41	14	bromocresol	bromocresol	ADJ
ajlm-1628	41	15	purple	purple	ADJ
ajlm-1628	41	16	method	method	NOUN
ajlm-1628	41	17	(	(	PUNCT
ajlm-1628	41	18	cobas	cobas	NUM
ajlm-1628	41	19	®	®	NOUN
ajlm-1628	41	20	6000	6000	NUM
ajlm-1628	41	21	analyser	analyser	NOUN
ajlm-1628	41	22	,	,	PUNCT
ajlm-1628	41	23	roche	roche	PROPN
ajlm-1628	41	24	diagnostics	diagnostic	NOUN
ajlm-1628	41	25	international	international	ADJ
ajlm-1628	41	26	,	,	PUNCT
ajlm-1628	41	27	rotkreuz	rotkreuz	PROPN
ajlm-1628	41	28	,	,	PUNCT
ajlm-1628	41	29	switzerland	switzerland	PROPN
ajlm-1628	41	30	)	)	PUNCT
ajlm-1628	41	31	.	.	PUNCT
ajlm-1628	42	1	the	the	DET
ajlm-1628	42	2	total	total	ADJ
ajlm-1628	42	3	plasma	plasma	NOUN
ajlm-1628	42	4	concentrations	concentration	NOUN
ajlm-1628	42	5	of	of	ADP
ajlm-1628	42	6	phenytoin	phenytoin	NOUN
ajlm-1628	42	7	and	and	CCONJ
ajlm-1628	42	8	valproic	valproic	ADJ
ajlm-1628	42	9	acid	acid	NOUN
ajlm-1628	42	10	were	be	AUX
ajlm-1628	42	11	measured	measure	VERB
ajlm-1628	42	12	by	by	ADP
ajlm-1628	42	13	fluorescence	fluorescence	ADJ
ajlm-1628	42	14	polarisation	polarisation	NOUN
ajlm-1628	42	15	immunoassay	immunoassay	PROPN
ajlm-1628	42	16	(	(	PUNCT
ajlm-1628	42	17	abbott	abbott	PROPN
ajlm-1628	42	18	architect	architect	PROPN
ajlm-1628	42	19	i2000	i2000	PROPN
ajlm-1628	42	20	,	,	PUNCT
ajlm-1628	42	21	abbott	abbott	PROPN
ajlm-1628	42	22	laboratories	laboratories	PROPN
ajlm-1628	42	23	,	,	PUNCT
ajlm-1628	42	24	chicago	chicago	PROPN
ajlm-1628	42	25	,	,	PUNCT
ajlm-1628	42	26	illinois	illinois	PROPN
ajlm-1628	42	27	,	,	PUNCT
ajlm-1628	42	28	united	united	PROPN
ajlm-1628	42	29	states	states	PROPN
ajlm-1628	42	30	)	)	PUNCT
ajlm-1628	42	31	.	.	PUNCT
ajlm-1628	43	1	data	datum	NOUN
ajlm-1628	43	2	analysis	analysis	NOUN
ajlm-1628	43	3	for	for	ADP
ajlm-1628	43	4	each	each	DET
ajlm-1628	43	5	patient	patient	NOUN
ajlm-1628	43	6	,	,	PUNCT
ajlm-1628	43	7	the	the	DET
ajlm-1628	43	8	unbound	unbound	NOUN
ajlm-1628	43	9	plasma	plasma	NOUN
ajlm-1628	43	10	concentration	concentration	NOUN
ajlm-1628	43	11	of	of	ADP
ajlm-1628	43	12	phenytoin	phenytoin	NOUN
ajlm-1628	43	13	(	(	PUNCT
ajlm-1628	43	14	cu	cu	PROPN
ajlm-1628	43	15	pht	pht	PROPN
ajlm-1628	43	16	)	)	PUNCT
ajlm-1628	43	17	was	be	AUX
ajlm-1628	43	18	calculated	calculate	VERB
ajlm-1628	43	19	based	base	VERB
ajlm-1628	43	20	on	on	ADP
ajlm-1628	43	21	the	the	DET
ajlm-1628	43	22	measured	measure	VERB
ajlm-1628	43	23	total	total	ADJ
ajlm-1628	43	24	plasma	plasma	NOUN
ajlm-1628	43	25	concentration	concentration	NOUN
ajlm-1628	43	26	of	of	ADP
ajlm-1628	43	27	phenytoin	phenytoin	NOUN
ajlm-1628	43	28	(	(	PUNCT
ajlm-1628	43	29	cp	cp	PROPN
ajlm-1628	43	30	pht	pht	PROPN
ajlm-1628	43	31	)	)	PUNCT
ajlm-1628	43	32	and	and	CCONJ
ajlm-1628	43	33	the	the	DET
ajlm-1628	43	34	serum	serum	NOUN
ajlm-1628	43	35	albumin	albumin	ADJ
ajlm-1628	43	36	concentration	concentration	NOUN
ajlm-1628	43	37	(	(	PUNCT
ajlm-1628	43	38	alb	alb	PROPN
ajlm-1628	43	39	)	)	PUNCT
ajlm-1628	43	40	,	,	PUNCT
ajlm-1628	43	41	in	in	ADP
ajlm-1628	43	42	grams	gram	NOUN
ajlm-1628	43	43	/	/	SYM
ajlm-1628	43	44	decilitre	decilitre	NOUN
ajlm-1628	43	45	,	,	PUNCT
ajlm-1628	43	46	by	by	ADP
ajlm-1628	43	47	using	use	VERB
ajlm-1628	43	48	the	the	DET
ajlm-1628	43	49	original	original	ADJ
ajlm-1628	43	50	winter	winter	NOUN
ajlm-1628	43	51	-	-	PUNCT
ajlm-1628	43	52	tozer	tozer	PROPN
ajlm-1628	43	53	equation5	equation5	PROPN
ajlm-1628	43	54	(	(	PUNCT
ajlm-1628	43	55	equation	equation	NOUN
ajlm-1628	43	56	1	1	NUM
ajlm-1628	43	57	)	)	PUNCT
ajlm-1628	43	58	.	.	PUNCT
ajlm-1628	44	1	the	the	DET
ajlm-1628	44	2	therapeutic	therapeutic	ADJ
ajlm-1628	44	3	range	range	NOUN
ajlm-1628	44	4	for	for	ADP
ajlm-1628	44	5	the	the	DET
ajlm-1628	44	6	total	total	ADJ
ajlm-1628	44	7	phenytoin	phenytoin	NOUN
ajlm-1628	44	8	plasma	plasma	NOUN
ajlm-1628	44	9	concentration	concentration	NOUN
ajlm-1628	44	10	is	be	AUX
ajlm-1628	44	11	10	10	NUM
ajlm-1628	44	12	μg	μg	NOUN
ajlm-1628	44	13	/	/	SYM
ajlm-1628	44	14	ml	ml	NOUN
ajlm-1628	44	15	to	to	ADP
ajlm-1628	44	16	20	20	NUM
ajlm-1628	44	17	μg	μg	NOUN
ajlm-1628	44	18	/	/	SYM
ajlm-1628	44	19	ml	ml	PROPN
ajlm-1628	44	20	,	,	PUNCT
ajlm-1628	44	21	and	and	CCONJ
ajlm-1628	44	22	1	1	NUM
ajlm-1628	44	23	μg	μg	NOUN
ajlm-1628	44	24	/	/	SYM
ajlm-1628	44	25	ml	ml	NOUN
ajlm-1628	44	26	to	to	ADP
ajlm-1628	44	27	2	2	NUM
ajlm-1628	44	28	μg	μg	NOUN
ajlm-1628	44	29	/	/	SYM
ajlm-1628	44	30	ml	ml	X
ajlm-1628	44	31	for	for	ADP
ajlm-1628	44	32	the	the	DET
ajlm-1628	44	33	unbound	unbound	PROPN
ajlm-1628	44	34	phenytoin	phenytoin	NOUN
ajlm-1628	44	35	plasma	plasma	NOUN
ajlm-1628	44	36	concentration:4,5	concentration:4,5	PUNCT
ajlm-1628	44	37	the	the	DET
ajlm-1628	44	38	unbound	unbound	NOUN
ajlm-1628	44	39	plasma	plasma	NOUN
ajlm-1628	44	40	fraction	fraction	NOUN
ajlm-1628	44	41	of	of	ADP
ajlm-1628	44	42	valproic	valproic	ADJ
ajlm-1628	44	43	acid	acid	NOUN
ajlm-1628	44	44	(	(	PUNCT
ajlm-1628	44	45	α	α	PROPN
ajlm-1628	44	46	vpa	vpa	PROPN
ajlm-1628	44	47	)	)	PUNCT
ajlm-1628	44	48	was	be	AUX
ajlm-1628	44	49	calculated	calculate	VERB
ajlm-1628	44	50	based	base	VERB
ajlm-1628	44	51	on	on	ADP
ajlm-1628	44	52	the	the	DET
ajlm-1628	44	53	serum	serum	NOUN
ajlm-1628	44	54	albumin	albumin	ADJ
ajlm-1628	44	55	concentration	concentration	NOUN
ajlm-1628	44	56	(	(	PUNCT
ajlm-1628	44	57	alb	alb	NOUN
ajlm-1628	44	58	)	)	PUNCT
ajlm-1628	44	59	in	in	ADP
ajlm-1628	44	60	μmol	μmol	PROPN
ajlm-1628	44	61	/	/	SYM
ajlm-1628	44	62	l	l	NOUN
ajlm-1628	44	63	,	,	PUNCT
ajlm-1628	44	64	by	by	ADP
ajlm-1628	44	65	use	use	NOUN
ajlm-1628	44	66	of	of	ADP
ajlm-1628	44	67	the	the	DET
ajlm-1628	44	68	hyperbolic	hyperbolic	ADJ
ajlm-1628	44	69	equation	equation	NOUN
ajlm-1628	44	70	proposed	propose	VERB
ajlm-1628	44	71	by	by	ADP
ajlm-1628	44	72	parent	parent	NOUN
ajlm-1628	44	73	et	et	NOUN
ajlm-1628	44	74	al.16,17	al.16,17	NOUN
ajlm-1628	44	75	(	(	PUNCT
ajlm-1628	44	76	equation	equation	NOUN
ajlm-1628	44	77	2	2	NUM
ajlm-1628	44	78	):	):	PUNCT
ajlm-1628	44	79	the	the	DET
ajlm-1628	44	80	unbound	unbound	NOUN
ajlm-1628	44	81	plasma	plasma	NOUN
ajlm-1628	44	82	concentration	concentration	NOUN
ajlm-1628	44	83	of	of	ADP
ajlm-1628	44	84	valproic	valproic	ADJ
ajlm-1628	44	85	acid	acid	NOUN
ajlm-1628	44	86	(	(	PUNCT
ajlm-1628	44	87	cu	cu	PROPN
ajlm-1628	44	88	vpa	vpa	PROPN
ajlm-1628	44	89	)	)	PUNCT
ajlm-1628	44	90	was	be	AUX
ajlm-1628	44	91	then	then	ADV
ajlm-1628	44	92	estimated	estimate	VERB
ajlm-1628	44	93	for	for	ADP
ajlm-1628	44	94	each	each	DET
ajlm-1628	44	95	patient	patient	NOUN
ajlm-1628	44	96	based	base	VERB
ajlm-1628	44	97	on	on	ADP
ajlm-1628	44	98	the	the	DET
ajlm-1628	44	99	measured	measure	VERB
ajlm-1628	44	100	total	total	ADJ
ajlm-1628	44	101	valproic	valproic	ADJ
ajlm-1628	44	102	acid	acid	NOUN
ajlm-1628	44	103	plasma	plasma	NOUN
ajlm-1628	44	104	concentration	concentration	NOUN
ajlm-1628	44	105	(	(	PUNCT
ajlm-1628	44	106	cp	cp	X
ajlm-1628	44	107	vpa	vpa	PROPN
ajlm-1628	44	108	)	)	PUNCT
ajlm-1628	45	1	(	(	PUNCT
ajlm-1628	45	2	equation	equation	NOUN
ajlm-1628	45	3	3	3	NUM
ajlm-1628	45	4	)	)	PUNCT
ajlm-1628	45	5	.	.	PUNCT
ajlm-1628	46	1	the	the	DET
ajlm-1628	46	2	therapeutic	therapeutic	ADJ
ajlm-1628	46	3	ranges	range	NOUN
ajlm-1628	46	4	were	be	AUX
ajlm-1628	46	5	50	50	NUM
ajlm-1628	46	6	μg	μg	NOUN
ajlm-1628	46	7	/	/	SYM
ajlm-1628	46	8	ml	ml	NOUN
ajlm-1628	46	9	to	to	ADP
ajlm-1628	46	10	100	100	NUM
ajlm-1628	46	11	μg	μg	NOUN
ajlm-1628	46	12	/	/	SYM
ajlm-1628	46	13	ml	ml	X
ajlm-1628	46	14	for	for	ADP
ajlm-1628	46	15	total	total	ADJ
ajlm-1628	46	16	valproic	valproic	ADJ
ajlm-1628	46	17	acid	acid	NOUN
ajlm-1628	46	18	plasma	plasma	NOUN
ajlm-1628	46	19	concentration	concentration	NOUN
ajlm-1628	46	20	and	and	CCONJ
ajlm-1628	46	21	2.5	2.5	NUM
ajlm-1628	46	22	μg	μg	NOUN
ajlm-1628	46	23	/	/	SYM
ajlm-1628	46	24	ml	ml	NOUN
ajlm-1628	46	25	to	to	ADP
ajlm-1628	46	26	20.0	20.0	NUM
ajlm-1628	46	27	μg	μg	NOUN
ajlm-1628	46	28	/	/	SYM
ajlm-1628	46	29	ml	ml	X
ajlm-1628	46	30	for	for	ADP
ajlm-1628	46	31	unbound	unbound	NOUN
ajlm-1628	46	32	valproic	valproic	ADJ
ajlm-1628	46	33	acid	acid	NOUN
ajlm-1628	46	34	plasma	plasma	NOUN
ajlm-1628	46	35	concentration:4,5	concentration:4,5	PUNCT
ajlm-1628	46	36	descriptive	descriptive	ADJ
ajlm-1628	46	37	statistics	statistic	NOUN
ajlm-1628	46	38	were	be	AUX
ajlm-1628	46	39	used	use	VERB
ajlm-1628	46	40	to	to	PART
ajlm-1628	46	41	summarise	summarise	VERB
ajlm-1628	46	42	the	the	DET
ajlm-1628	46	43	results	result	NOUN
ajlm-1628	46	44	.	.	PUNCT
ajlm-1628	47	1	all	all	DET
ajlm-1628	47	2	statistical	statistical	ADJ
ajlm-1628	47	3	calculations	calculation	NOUN
ajlm-1628	47	4	were	be	AUX
ajlm-1628	47	5	carried	carry	VERB
ajlm-1628	47	6	out	out	ADP
ajlm-1628	47	7	using	use	VERB
ajlm-1628	47	8	the	the	DET
ajlm-1628	47	9	excel	excel	NOUN
ajlm-1628	47	10	software	software	NOUN
ajlm-1628	47	11	package	package	NOUN
ajlm-1628	47	12	of	of	ADP
ajlm-1628	47	13	windows	window	NOUN
ajlm-1628	47	14	10	10	NUM
ajlm-1628	47	15	(	(	PUNCT
ajlm-1628	47	16	microsoft	microsoft	PROPN
ajlm-1628	47	17	corporation	corporation	PROPN
ajlm-1628	47	18	,	,	PUNCT
ajlm-1628	47	19	redmond	redmond	PROPN
ajlm-1628	47	20	,	,	PUNCT
ajlm-1628	47	21	washington	washington	PROPN
ajlm-1628	47	22	,	,	PUNCT
ajlm-1628	47	23	united	united	PROPN
ajlm-1628	47	24	states	states	PROPN
ajlm-1628	47	25	)	)	PUNCT
ajlm-1628	47	26	.	.	PUNCT
ajlm-1628	48	1	results	result	NOUN
ajlm-1628	48	2	in	in	ADP
ajlm-1628	48	3	total	total	ADJ
ajlm-1628	48	4	,	,	PUNCT
ajlm-1628	48	5	1661	1661	NUM
ajlm-1628	48	6	files	file	NOUN
ajlm-1628	48	7	of	of	ADP
ajlm-1628	48	8	patients	patient	NOUN
ajlm-1628	48	9	hospitalised	hospitalise	VERB
ajlm-1628	48	10	between	between	ADP
ajlm-1628	48	11	january	january	PROPN
ajlm-1628	48	12	2013	2013	NUM
ajlm-1628	48	13	and	and	CCONJ
ajlm-1628	48	14	july	july	PROPN
ajlm-1628	48	15	2019	2019	NUM
ajlm-1628	48	16	at	at	ADP
ajlm-1628	48	17	the	the	DET
ajlm-1628	48	18	icu	icu	PROPN
ajlm-1628	48	19	of	of	ADP
ajlm-1628	48	20	windhoek	windhoek	PROPN
ajlm-1628	48	21	central	central	PROPN
ajlm-1628	48	22	hospital	hospital	NOUN
ajlm-1628	48	23	were	be	AUX
ajlm-1628	48	24	reviewed	review	VERB
ajlm-1628	48	25	.	.	PUNCT
ajlm-1628	49	1	fifty	fifty	NUM
ajlm-1628	49	2	-	-	PUNCT
ajlm-1628	49	3	six	six	NUM
ajlm-1628	49	4	patients	patient	NOUN
ajlm-1628	49	5	,	,	PUNCT
ajlm-1628	49	6	given	give	VERB
ajlm-1628	49	7	phenytoin	phenytoin	NOUN
ajlm-1628	49	8	and	and	CCONJ
ajlm-1628	49	9	93	93	NUM
ajlm-1628	49	10	patients	patient	NOUN
ajlm-1628	49	11	given	give	VERB
ajlm-1628	49	12	valproic	valproic	ADJ
ajlm-1628	49	13	acid	acid	NOUN
ajlm-1628	49	14	,	,	PUNCT
ajlm-1628	49	15	who	who	PRON
ajlm-1628	49	16	had	have	VERB
ajlm-1628	49	17	data	datum	NOUN
ajlm-1628	49	18	recorded	record	VERB
ajlm-1628	49	19	for	for	ADP
ajlm-1628	49	20	total	total	ADJ
ajlm-1628	49	21	plasma	plasma	NOUN
ajlm-1628	49	22	concentrations	concentration	NOUN
ajlm-1628	49	23	and	and	CCONJ
ajlm-1628	49	24	serum	serum	NOUN
ajlm-1628	49	25	albumin	albumin	ADJ
ajlm-1628	49	26	levels	level	NOUN
ajlm-1628	49	27	,	,	PUNCT
ajlm-1628	49	28	were	be	AUX
ajlm-1628	49	29	included	include	VERB
ajlm-1628	49	30	in	in	ADP
ajlm-1628	49	31	the	the	DET
ajlm-1628	49	32	study	study	NOUN
ajlm-1628	49	33	.	.	PUNCT
ajlm-1628	50	1	patients	patient	NOUN
ajlm-1628	50	2	were	be	AUX
ajlm-1628	50	3	admitted	admit	VERB
ajlm-1628	50	4	to	to	ADP
ajlm-1628	50	5	the	the	DET
ajlm-1628	50	6	icu	icu	PROPN
ajlm-1628	50	7	for	for	ADP
ajlm-1628	50	8	the	the	DET
ajlm-1628	50	9	following	follow	VERB
ajlm-1628	50	10	conditions	condition	NOUN
ajlm-1628	50	11	:	:	PUNCT
ajlm-1628	50	12	head	head	NOUN
ajlm-1628	50	13	trauma	trauma	NOUN
ajlm-1628	50	14	,	,	PUNCT
ajlm-1628	50	15	hypoxic	hypoxic	ADJ
ajlm-1628	50	16	brain	brain	NOUN
ajlm-1628	50	17	injury	injury	NOUN
ajlm-1628	50	18	,	,	PUNCT
ajlm-1628	50	19	infectious	infectious	ADJ
ajlm-1628	50	20	diseases	disease	NOUN
ajlm-1628	50	21	such	such	ADJ
ajlm-1628	50	22	as	as	ADP
ajlm-1628	50	23	meningitis	meningitis	NOUN
ajlm-1628	50	24	and	and	CCONJ
ajlm-1628	50	25	acute	acute	ADJ
ajlm-1628	50	26	gastroenteritis	gastroenteritis	NOUN
ajlm-1628	50	27	,	,	PUNCT
ajlm-1628	50	28	renal	renal	ADJ
ajlm-1628	50	29	failure	failure	NOUN
ajlm-1628	50	30	,	,	PUNCT
ajlm-1628	50	31	and	and	CCONJ
ajlm-1628	50	32	hepatic	hepatic	ADJ
ajlm-1628	50	33	failure	failure	NOUN
ajlm-1628	50	34	.	.	PUNCT
ajlm-1628	51	1	the	the	DET
ajlm-1628	51	2	age	age	NOUN
ajlm-1628	51	3	of	of	ADP
ajlm-1628	51	4	the	the	DET
ajlm-1628	51	5	patients	patient	NOUN
ajlm-1628	51	6	ranged	range	VERB
ajlm-1628	51	7	from	from	ADP
ajlm-1628	51	8	two	two	NUM
ajlm-1628	51	9	months	month	NOUN
ajlm-1628	51	10	to	to	ADP
ajlm-1628	51	11	66	66	NUM
ajlm-1628	51	12	years	year	NOUN
ajlm-1628	51	13	.	.	PUNCT
ajlm-1628	52	1	the	the	DET
ajlm-1628	52	2	mean	mean	ADJ
ajlm-1628	52	3	serum	serum	NOUN
ajlm-1628	52	4	albumin	albumin	ADJ
ajlm-1628	52	5	levels	level	NOUN
ajlm-1628	52	6	were	be	AUX
ajlm-1628	52	7	below	below	ADP
ajlm-1628	52	8	35	35	NUM
ajlm-1628	52	9	g	g	NOUN
ajlm-1628	52	10	/	/	SYM
ajlm-1628	52	11	l	l	NOUN
ajlm-1628	52	12	in	in	ADP
ajlm-1628	52	13	both	both	DET
ajlm-1628	52	14	sets	set	NOUN
ajlm-1628	52	15	of	of	ADP
ajlm-1628	52	16	patients	patient	NOUN
ajlm-1628	52	17	(	(	PUNCT
ajlm-1628	52	18	mean	mean	PROPN
ajlm-1628	52	19	±	±	NUM
ajlm-1628	52	20	s.d	s.d	PROPN
ajlm-1628	52	21	.	.	PUNCT
ajlm-1628	52	22	:	:	PUNCT
ajlm-1628	53	1	23.5	23.5	NUM
ajlm-1628	53	2	±	±	NUM
ajlm-1628	53	3	5.00	5.00	NUM
ajlm-1628	53	4	g	g	NOUN
ajlm-1628	53	5	/	/	SYM
ajlm-1628	53	6	l	l	NOUN
ajlm-1628	53	7	for	for	ADP
ajlm-1628	53	8	phenytoin	phenytoin	NOUN
ajlm-1628	53	9	,	,	PUNCT
ajlm-1628	53	10	mean	mean	VERB
ajlm-1628	53	11	±	±	NUM
ajlm-1628	53	12	s.d	s.d	PROPN
ajlm-1628	53	13	.	.	PUNCT
ajlm-1628	53	14	:	:	PUNCT
ajlm-1628	53	15	23.8	23.8	NUM
ajlm-1628	53	16	±	±	NUM
ajlm-1628	53	17	5.9	5.9	NUM
ajlm-1628	53	18	g	g	NOUN
ajlm-1628	53	19	/	/	SYM
ajlm-1628	53	20	l	l	NOUN
ajlm-1628	53	21	for	for	ADP
ajlm-1628	53	22	valproic	valproic	ADJ
ajlm-1628	53	23	acid	acid	NOUN
ajlm-1628	53	24	)	)	PUNCT
ajlm-1628	53	25	(	(	PUNCT
ajlm-1628	53	26	table	table	NOUN
ajlm-1628	53	27	1	1	NUM
ajlm-1628	53	28	)	)	PUNCT
ajlm-1628	53	29	.	.	PUNCT
ajlm-1628	54	1	forty	forty	NUM
ajlm-1628	54	2	-	-	PUNCT
ajlm-1628	54	3	five	five	NUM
ajlm-1628	54	4	percent	percent	NOUN
ajlm-1628	54	5	of	of	ADP
ajlm-1628	54	6	patients	patient	NOUN
ajlm-1628	54	7	on	on	ADP
ajlm-1628	54	8	phenytoin	phenytoin	NOUN
ajlm-1628	54	9	were	be	AUX
ajlm-1628	54	10	also	also	ADV
ajlm-1628	54	11	receiving	receive	VERB
ajlm-1628	54	12	drugs	drug	NOUN
ajlm-1628	54	13	known	know	VERB
ajlm-1628	54	14	to	to	PART
ajlm-1628	54	15	interfere	interfere	VERB
ajlm-1628	54	16	with	with	ADP
ajlm-1628	54	17	its	its	PRON
ajlm-1628	54	18	plasma	plasma	NOUN
ajlm-1628	54	19	binding	bind	VERB
ajlm-1628	54	20	or	or	CCONJ
ajlm-1628	54	21	metabolism	metabolism	NOUN
ajlm-1628	54	22	.	.	PUNCT
ajlm-1628	55	1	for	for	ADP
ajlm-1628	55	2	valproic	valproic	ADJ
ajlm-1628	55	3	acid	acid	NOUN
ajlm-1628	55	4	,	,	PUNCT
ajlm-1628	55	5	28	28	NUM
ajlm-1628	55	6	%	%	NOUN
ajlm-1628	55	7	of	of	ADP
ajlm-1628	55	8	patients	patient	NOUN
ajlm-1628	55	9	were	be	AUX
ajlm-1628	55	10	concomitantly	concomitantly	ADV
ajlm-1628	55	11	treated	treat	VERB
ajlm-1628	55	12	with	with	ADP
ajlm-1628	55	13	drugs	drug	NOUN
ajlm-1628	55	14	interfering	interfere	VERB
ajlm-1628	55	15	with	with	ADP
ajlm-1628	55	16	its	its	PRON
ajlm-1628	55	17	plasma	plasma	NOUN
ajlm-1628	55	18	binding	bind	VERB
ajlm-1628	55	19	or	or	CCONJ
ajlm-1628	55	20	metabolism	metabolism	NOUN
ajlm-1628	55	21	.	.	PUNCT
ajlm-1628	56	1	table	table	NOUN
ajlm-1628	56	2	1	1	NUM
ajlm-1628	56	3	:	:	PUNCT
ajlm-1628	56	4	 	 	SPACE
ajlm-1628	56	5	patient	patient	ADJ
ajlm-1628	56	6	characteristics	characteristic	NOUN
ajlm-1628	56	7	and	and	CCONJ
ajlm-1628	56	8	total	total	ADJ
ajlm-1628	56	9	and	and	CCONJ
ajlm-1628	56	10	predicted	predict	VERB
ajlm-1628	56	11	plasma	plasma	NOUN
ajlm-1628	56	12	concentrations	concentration	NOUN
ajlm-1628	56	13	of	of	ADP
ajlm-1628	56	14	phenytoin	phenytoin	NOUN
ajlm-1628	56	15	and	and	CCONJ
ajlm-1628	56	16	valproic	valproic	ADJ
ajlm-1628	56	17	acid	acid	NOUN
ajlm-1628	56	18	in	in	ADP
ajlm-1628	56	19	critically	critically	ADV
ajlm-1628	56	20	ill	ill	ADJ
ajlm-1628	56	21	patients	patient	NOUN
ajlm-1628	56	22	in	in	ADP
ajlm-1628	56	23	the	the	DET
ajlm-1628	56	24	intensive	intensive	ADJ
ajlm-1628	56	25	care	care	NOUN
ajlm-1628	56	26	unit	unit	NOUN
ajlm-1628	56	27	at	at	ADP
ajlm-1628	56	28	windhoek	windhoek	PROPN
ajlm-1628	56	29	central	central	PROPN
ajlm-1628	56	30	hospital	hospital	PROPN
ajlm-1628	56	31	(	(	PUNCT
ajlm-1628	56	32	windhoek	windhoek	PROPN
ajlm-1628	56	33	,	,	PUNCT
ajlm-1628	56	34	namibia	namibia	PROPN
ajlm-1628	56	35	)	)	PUNCT
ajlm-1628	56	36	from	from	ADP
ajlm-1628	56	37	2013	2013	NUM
ajlm-1628	56	38	to	to	ADP
ajlm-1628	56	39	2019	2019	NUM
ajlm-1628	56	40	.	.	PUNCT
ajlm-1628	57	1	the	the	DET
ajlm-1628	57	2	total	total	ADJ
ajlm-1628	57	3	plasma	plasma	NOUN
ajlm-1628	57	4	concentration	concentration	NOUN
ajlm-1628	57	5	of	of	ADP
ajlm-1628	57	6	phenytoin	phenytoin	NOUN
ajlm-1628	57	7	recorded	record	VERB
ajlm-1628	57	8	for	for	ADP
ajlm-1628	57	9	56	56	NUM
ajlm-1628	57	10	patients	patient	NOUN
ajlm-1628	57	11	ranged	range	VERB
ajlm-1628	57	12	from	from	ADP
ajlm-1628	57	13	0.1	0.1	NUM
ajlm-1628	57	14	μg	μg	NOUN
ajlm-1628	57	15	/	/	SYM
ajlm-1628	57	16	ml	ml	NOUN
ajlm-1628	57	17	to	to	ADP
ajlm-1628	57	18	43.0	43.0	NUM
ajlm-1628	57	19	μg	μg	NOUN
ajlm-1628	57	20	/	/	SYM
ajlm-1628	57	21	ml	ml	PROPN
ajlm-1628	57	22	,	,	PUNCT
ajlm-1628	57	23	with	with	ADP
ajlm-1628	57	24	an	an	DET
ajlm-1628	57	25	average	average	NOUN
ajlm-1628	57	26	of	of	ADP
ajlm-1628	57	27	12.6	12.6	NUM
ajlm-1628	57	28	±	±	NUM
ajlm-1628	57	29	8.20	8.20	NUM
ajlm-1628	57	30	μg	μg	PROPN
ajlm-1628	57	31	/	/	SYM
ajlm-1628	57	32	ml	ml	PROPN
ajlm-1628	57	33	(	(	PUNCT
ajlm-1628	57	34	table	table	NOUN
ajlm-1628	57	35	1	1	NUM
ajlm-1628	57	36	)	)	PUNCT
ajlm-1628	57	37	.	.	PUNCT
ajlm-1628	58	1	in	in	ADP
ajlm-1628	58	2	23	23	NUM
ajlm-1628	58	3	patients	patient	NOUN
ajlm-1628	58	4	(	(	PUNCT
ajlm-1628	58	5	41.1	41.1	NUM
ajlm-1628	58	6	%	%	NOUN
ajlm-1628	58	7	)	)	PUNCT
ajlm-1628	58	8	,	,	PUNCT
ajlm-1628	58	9	the	the	DET
ajlm-1628	58	10	phenytoin	phenytoin	ADJ
ajlm-1628	58	11	total	total	ADJ
ajlm-1628	58	12	plasma	plasma	NOUN
ajlm-1628	58	13	concentration	concentration	NOUN
ajlm-1628	58	14	was	be	AUX
ajlm-1628	58	15	within	within	ADP
ajlm-1628	58	16	the	the	DET
ajlm-1628	58	17	therapeutic	therapeutic	ADJ
ajlm-1628	58	18	range	range	NOUN
ajlm-1628	58	19	(	(	PUNCT
ajlm-1628	58	20	10	10	NUM
ajlm-1628	58	21	μg	μg	NOUN
ajlm-1628	58	22	/	/	SYM
ajlm-1628	58	23	ml	ml	NOUN
ajlm-1628	58	24	to	to	ADP
ajlm-1628	58	25	20	20	NUM
ajlm-1628	58	26	μg	μg	NOUN
ajlm-1628	58	27	/	/	SYM
ajlm-1628	58	28	ml	ml	NOUN
ajlm-1628	58	29	)	)	PUNCT
ajlm-1628	58	30	(	(	PUNCT
ajlm-1628	58	31	figure	figure	NOUN
ajlm-1628	58	32	1	1	NUM
ajlm-1628	58	33	)	)	PUNCT
ajlm-1628	58	34	.	.	PUNCT
ajlm-1628	59	1	in	in	ADP
ajlm-1628	59	2	26	26	NUM
ajlm-1628	59	3	patients	patient	NOUN
ajlm-1628	59	4	(	(	PUNCT
ajlm-1628	59	5	46.4	46.4	NUM
ajlm-1628	59	6	%	%	NOUN
ajlm-1628	59	7	)	)	PUNCT
ajlm-1628	59	8	,	,	PUNCT
ajlm-1628	59	9	the	the	DET
ajlm-1628	59	10	plasma	plasma	NOUN
ajlm-1628	59	11	concentrations	concentration	NOUN
ajlm-1628	59	12	were	be	AUX
ajlm-1628	59	13	subtherapeutic	subtherapeutic	ADJ
ajlm-1628	59	14	,	,	PUNCT
ajlm-1628	59	15	that	that	ADV
ajlm-1628	59	16	is	is	ADV
ajlm-1628	59	17	,	,	PUNCT
ajlm-1628	59	18	below	below	ADP
ajlm-1628	59	19	10	10	NUM
ajlm-1628	59	20	μg	μg	NOUN
ajlm-1628	59	21	/	/	SYM
ajlm-1628	59	22	ml	ml	PROPN
ajlm-1628	59	23	,	,	PUNCT
ajlm-1628	59	24	and	and	CCONJ
ajlm-1628	59	25	in	in	ADP
ajlm-1628	59	26	seven	seven	NUM
ajlm-1628	59	27	patients	patient	NOUN
ajlm-1628	59	28	(	(	PUNCT
ajlm-1628	59	29	12.5	12.5	NUM
ajlm-1628	59	30	%	%	NOUN
ajlm-1628	59	31	)	)	PUNCT
ajlm-1628	59	32	they	they	PRON
ajlm-1628	59	33	were	be	AUX
ajlm-1628	59	34	above	above	ADP
ajlm-1628	59	35	20	20	NUM
ajlm-1628	59	36	μg	μg	NOUN
ajlm-1628	59	37	/	/	SYM
ajlm-1628	59	38	ml	ml	NOUN
ajlm-1628	59	39	.	.	PUNCT
ajlm-1628	60	1	in	in	ADP
ajlm-1628	60	2	16	16	NUM
ajlm-1628	60	3	patients	patient	NOUN
ajlm-1628	60	4	(	(	PUNCT
ajlm-1628	60	5	28.6	28.6	NUM
ajlm-1628	60	6	%	%	NOUN
ajlm-1628	60	7	)	)	PUNCT
ajlm-1628	60	8	,	,	PUNCT
ajlm-1628	60	9	the	the	DET
ajlm-1628	60	10	predicted	predict	VERB
ajlm-1628	60	11	unbound	unbound	NOUN
ajlm-1628	60	12	plasma	plasma	NOUN
ajlm-1628	60	13	concentration	concentration	NOUN
ajlm-1628	60	14	of	of	ADP
ajlm-1628	60	15	phenytoin	phenytoin	NOUN
ajlm-1628	60	16	was	be	AUX
ajlm-1628	60	17	within	within	ADP
ajlm-1628	60	18	the	the	DET
ajlm-1628	60	19	therapeutic	therapeutic	ADJ
ajlm-1628	60	20	range	range	NOUN
ajlm-1628	60	21	(	(	PUNCT
ajlm-1628	60	22	1	1	NUM
ajlm-1628	60	23	μg	μg	NOUN
ajlm-1628	60	24	/	/	SYM
ajlm-1628	60	25	ml	ml	NOUN
ajlm-1628	60	26	to	to	ADP
ajlm-1628	60	27	2	2	NUM
ajlm-1628	60	28	μg	μg	NOUN
ajlm-1628	60	29	/	/	SYM
ajlm-1628	60	30	ml	ml	NOUN
ajlm-1628	60	31	)	)	PUNCT
ajlm-1628	60	32	.	.	PUNCT
ajlm-1628	61	1	the	the	DET
ajlm-1628	61	2	unbound	unbound	NOUN
ajlm-1628	61	3	plasma	plasma	NOUN
ajlm-1628	61	4	concentration	concentration	NOUN
ajlm-1628	61	5	of	of	ADP
ajlm-1628	61	6	phenytoin	phenytoin	NOUN
ajlm-1628	61	7	was	be	AUX
ajlm-1628	61	8	subtherapeutic	subtherapeutic	ADJ
ajlm-1628	61	9	in	in	ADP
ajlm-1628	61	10	eight	eight	NUM
ajlm-1628	61	11	patients	patient	NOUN
ajlm-1628	61	12	(	(	PUNCT
ajlm-1628	61	13	14.3	14.3	NUM
ajlm-1628	61	14	%	%	NOUN
ajlm-1628	61	15	)	)	PUNCT
ajlm-1628	61	16	and	and	CCONJ
ajlm-1628	61	17	supratherapeutic	supratherapeutic	ADJ
ajlm-1628	61	18	in	in	ADP
ajlm-1628	61	19	32	32	NUM
ajlm-1628	61	20	patients	patient	NOUN
ajlm-1628	61	21	(	(	PUNCT
ajlm-1628	61	22	57.1	57.1	NUM
ajlm-1628	61	23	%	%	NOUN
ajlm-1628	61	24	)	)	PUNCT
ajlm-1628	61	25	.	.	PUNCT
ajlm-1628	62	1	figure	figure	VERB
ajlm-1628	62	2	1	1	NUM
ajlm-1628	62	3	:	:	PUNCT
ajlm-1628	62	4	plasma	plasma	NOUN
ajlm-1628	62	5	concentrations	concentration	NOUN
ajlm-1628	62	6	of	of	ADP
ajlm-1628	62	7	(	(	PUNCT
ajlm-1628	62	8	a	a	NOUN
ajlm-1628	62	9	)	)	PUNCT
ajlm-1628	62	10	total	total	NOUN
ajlm-1628	62	11	and	and	CCONJ
ajlm-1628	62	12	(	(	PUNCT
ajlm-1628	62	13	b	b	NOUN
ajlm-1628	62	14	)	)	PUNCT
ajlm-1628	62	15	unbound	unbound	NOUN
ajlm-1628	62	16	phenytoin	phenytoin	NOUN
ajlm-1628	62	17	plasma	plasma	NOUN
ajlm-1628	62	18	concentration	concentration	NOUN
ajlm-1628	62	19	in	in	ADP
ajlm-1628	62	20	56	56	NUM
ajlm-1628	62	21	critically	critically	ADV
ajlm-1628	62	22	ill	ill	ADJ
ajlm-1628	62	23	patients	patient	NOUN
ajlm-1628	62	24	in	in	ADP
ajlm-1628	62	25	the	the	DET
ajlm-1628	62	26	intensive	intensive	ADJ
ajlm-1628	62	27	care	care	NOUN
ajlm-1628	62	28	unit	unit	NOUN
ajlm-1628	62	29	at	at	ADP
ajlm-1628	62	30	windhoek	windhoek	PROPN
ajlm-1628	62	31	central	central	PROPN
ajlm-1628	62	32	hospital	hospital	PROPN
ajlm-1628	62	33	(	(	PUNCT
ajlm-1628	62	34	windhoek	windhoek	PROPN
ajlm-1628	62	35	,	,	PUNCT
ajlm-1628	62	36	namibia	namibia	PROPN
ajlm-1628	62	37	)	)	PUNCT
ajlm-1628	62	38	from	from	ADP
ajlm-1628	62	39	january	january	PROPN
ajlm-1628	62	40	2013	2013	NUM
ajlm-1628	62	41	to	to	ADP
ajlm-1628	62	42	july	july	PROPN
ajlm-1628	62	43	2019	2019	NUM
ajlm-1628	62	44	.	.	PUNCT
ajlm-1628	63	1	the	the	DET
ajlm-1628	63	2	therapeutic	therapeutic	ADJ
ajlm-1628	63	3	range	range	NOUN
ajlm-1628	63	4	is	be	AUX
ajlm-1628	63	5	indicated	indicate	VERB
ajlm-1628	63	6	by	by	ADP
ajlm-1628	63	7	dashed	dash	VERB
ajlm-1628	63	8	lines	line	NOUN
ajlm-1628	63	9	.	.	PUNCT
ajlm-1628	64	1	for	for	ADP
ajlm-1628	64	2	valproic	valproic	ADJ
ajlm-1628	64	3	acid	acid	NOUN
ajlm-1628	64	4	,	,	PUNCT
ajlm-1628	64	5	in	in	ADP
ajlm-1628	64	6	81	81	NUM
ajlm-1628	64	7	patients	patient	NOUN
ajlm-1628	64	8	(	(	PUNCT
ajlm-1628	64	9	87.1	87.1	NUM
ajlm-1628	64	10	%	%	NOUN
ajlm-1628	64	11	)	)	PUNCT
ajlm-1628	64	12	,	,	PUNCT
ajlm-1628	64	13	the	the	DET
ajlm-1628	64	14	total	total	ADJ
ajlm-1628	64	15	plasma	plasma	NOUN
ajlm-1628	64	16	concentration	concentration	NOUN
ajlm-1628	64	17	was	be	AUX
ajlm-1628	64	18	below	below	ADP
ajlm-1628	64	19	the	the	DET
ajlm-1628	64	20	therapeutic	therapeutic	ADJ
ajlm-1628	64	21	range	range	NOUN
ajlm-1628	64	22	of	of	ADP
ajlm-1628	64	23	50	50	NUM
ajlm-1628	64	24	μg	μg	NOUN
ajlm-1628	64	25	/	/	SYM
ajlm-1628	64	26	ml	ml	NOUN
ajlm-1628	64	27	to	to	ADP
ajlm-1628	64	28	100	100	NUM
ajlm-1628	64	29	μg	μg	NOUN
ajlm-1628	64	30	/	/	SYM
ajlm-1628	64	31	ml	ml	PROPN
ajlm-1628	64	32	(	(	PUNCT
ajlm-1628	64	33	figure	figure	NOUN
ajlm-1628	64	34	2	2	NUM
ajlm-1628	64	35	)	)	PUNCT
ajlm-1628	64	36	.	.	PUNCT
ajlm-1628	65	1	binding	bind	VERB
ajlm-1628	65	2	of	of	ADP
ajlm-1628	65	3	valproic	valproic	ADJ
ajlm-1628	65	4	acid	acid	NOUN
ajlm-1628	65	5	to	to	ADP
ajlm-1628	65	6	albumin	albumin	NOUN
ajlm-1628	65	7	in	in	ADP
ajlm-1628	65	8	individual	individual	ADJ
ajlm-1628	65	9	patients	patient	NOUN
ajlm-1628	65	10	ranged	range	VERB
ajlm-1628	65	11	from	from	ADP
ajlm-1628	65	12	9.0	9.0	NUM
ajlm-1628	65	13	%	%	NOUN
ajlm-1628	65	14	to	to	ADP
ajlm-1628	65	15	39.0	39.0	NUM
ajlm-1628	65	16	%	%	NOUN
ajlm-1628	65	17	.	.	PUNCT
ajlm-1628	66	1	in	in	ADP
ajlm-1628	66	2	12	12	NUM
ajlm-1628	66	3	patients	patient	NOUN
ajlm-1628	66	4	(	(	PUNCT
ajlm-1628	66	5	12.9	12.9	NUM
ajlm-1628	66	6	%	%	NOUN
ajlm-1628	66	7	)	)	PUNCT
ajlm-1628	66	8	,	,	PUNCT
ajlm-1628	66	9	the	the	DET
ajlm-1628	66	10	total	total	ADJ
ajlm-1628	66	11	plasma	plasma	NOUN
ajlm-1628	66	12	concentration	concentration	NOUN
ajlm-1628	66	13	was	be	AUX
ajlm-1628	66	14	within	within	ADP
ajlm-1628	66	15	the	the	DET
ajlm-1628	66	16	therapeutic	therapeutic	ADJ
ajlm-1628	66	17	window	window	NOUN
ajlm-1628	66	18	,	,	PUNCT
ajlm-1628	66	19	and	and	CCONJ
ajlm-1628	66	20	no	no	DET
ajlm-1628	66	21	patients	patient	NOUN
ajlm-1628	66	22	had	have	VERB
ajlm-1628	66	23	a	a	DET
ajlm-1628	66	24	total	total	ADJ
ajlm-1628	66	25	plasma	plasma	NOUN
ajlm-1628	66	26	concentration	concentration	NOUN
ajlm-1628	66	27	of	of	ADP
ajlm-1628	66	28	valproic	valproic	ADJ
ajlm-1628	66	29	acid	acid	NOUN
ajlm-1628	66	30	above	above	ADP
ajlm-1628	66	31	the	the	DET
ajlm-1628	66	32	therapeutic	therapeutic	ADJ
ajlm-1628	66	33	range	range	NOUN
ajlm-1628	66	34	.	.	PUNCT
ajlm-1628	67	1	the	the	DET
ajlm-1628	67	2	average	average	ADJ
ajlm-1628	67	3	estimated	estimate	VERB
ajlm-1628	67	4	unbound	unbound	NOUN
ajlm-1628	67	5	valproic	valproic	ADJ
ajlm-1628	67	6	acid	acid	NOUN
ajlm-1628	67	7	plasma	plasma	NOUN
ajlm-1628	67	8	concentration	concentration	NOUN
ajlm-1628	67	9	was	be	AUX
ajlm-1628	67	10	24.0	24.0	NUM
ajlm-1628	67	11	%	%	NOUN
ajlm-1628	67	12	(	(	PUNCT
ajlm-1628	67	13	7.0	7.0	NUM
ajlm-1628	67	14	%	%	NOUN
ajlm-1628	67	15	to	to	ADP
ajlm-1628	67	16	67.0	67.0	NUM
ajlm-1628	67	17	%	%	NOUN
ajlm-1628	67	18	)	)	PUNCT
ajlm-1628	67	19	.	.	PUNCT
ajlm-1628	68	1	in	in	ADP
ajlm-1628	68	2	the	the	DET
ajlm-1628	68	3	majority	majority	NOUN
ajlm-1628	68	4	of	of	ADP
ajlm-1628	68	5	patients	patient	NOUN
ajlm-1628	68	6	(	(	PUNCT
ajlm-1628	68	7	n	n	NOUN
ajlm-1628	68	8	=	=	SYM
ajlm-1628	68	9	85	85	NUM
ajlm-1628	68	10	,	,	PUNCT
ajlm-1628	68	11	91.4	91.4	NUM
ajlm-1628	68	12	%	%	NOUN
ajlm-1628	68	13	)	)	PUNCT
ajlm-1628	68	14	,	,	PUNCT
ajlm-1628	68	15	the	the	DET
ajlm-1628	68	16	unbound	unbound	NOUN
ajlm-1628	68	17	plasma	plasma	NOUN
ajlm-1628	68	18	concentration	concentration	NOUN
ajlm-1628	68	19	of	of	ADP
ajlm-1628	68	20	valproic	valproic	ADJ
ajlm-1628	68	21	acid	acid	NOUN
ajlm-1628	68	22	was	be	AUX
ajlm-1628	68	23	within	within	ADP
ajlm-1628	68	24	the	the	DET
ajlm-1628	68	25	therapeutic	therapeutic	ADJ
ajlm-1628	68	26	range	range	NOUN
ajlm-1628	68	27	(	(	PUNCT
ajlm-1628	68	28	2.5	2.5	NUM
ajlm-1628	68	29	μg	μg	NOUN
ajlm-1628	68	30	/	/	SYM
ajlm-1628	68	31	ml	ml	NOUN
ajlm-1628	68	32	to	to	ADP
ajlm-1628	68	33	20	20	NUM
ajlm-1628	68	34	μg	μg	NOUN
ajlm-1628	68	35	/	/	SYM
ajlm-1628	68	36	ml	ml	NOUN
ajlm-1628	68	37	)	)	PUNCT
ajlm-1628	68	38	.	.	PUNCT
ajlm-1628	69	1	in	in	ADP
ajlm-1628	69	2	seven	seven	NUM
ajlm-1628	69	3	patients	patient	NOUN
ajlm-1628	69	4	(	(	PUNCT
ajlm-1628	69	5	7.5	7.5	NUM
ajlm-1628	69	6	%	%	NOUN
ajlm-1628	69	7	)	)	PUNCT
ajlm-1628	69	8	,	,	PUNCT
ajlm-1628	69	9	the	the	DET
ajlm-1628	69	10	unbound	unbound	NOUN
ajlm-1628	69	11	plasma	plasma	NOUN
ajlm-1628	69	12	concentration	concentration	NOUN
ajlm-1628	69	13	was	be	AUX
ajlm-1628	69	14	below	below	ADP
ajlm-1628	69	15	the	the	DET
ajlm-1628	69	16	therapeutic	therapeutic	ADJ
ajlm-1628	69	17	range	range	NOUN
ajlm-1628	69	18	,	,	PUNCT
ajlm-1628	69	19	and	and	CCONJ
ajlm-1628	69	20	in	in	ADP
ajlm-1628	69	21	only	only	ADV
ajlm-1628	69	22	one	one	NUM
ajlm-1628	69	23	patient	patient	NOUN
ajlm-1628	69	24	(	(	PUNCT
ajlm-1628	69	25	1.1	1.1	NUM
ajlm-1628	69	26	%	%	NOUN
ajlm-1628	69	27	)	)	PUNCT
ajlm-1628	69	28	was	be	AUX
ajlm-1628	69	29	it	it	PRON
ajlm-1628	69	30	above	above	ADP
ajlm-1628	69	31	the	the	DET
ajlm-1628	69	32	therapeutic	therapeutic	ADJ
ajlm-1628	69	33	range	range	NOUN
ajlm-1628	69	34	.	.	PUNCT
ajlm-1628	70	1	figure	figure	NOUN
ajlm-1628	70	2	2	2	NUM
ajlm-1628	70	3	:	:	PUNCT
ajlm-1628	70	4	plasma	plasma	NOUN
ajlm-1628	70	5	concentrations	concentration	NOUN
ajlm-1628	70	6	of	of	ADP
ajlm-1628	70	7	(	(	PUNCT
ajlm-1628	70	8	a	a	NOUN
ajlm-1628	70	9	)	)	PUNCT
ajlm-1628	70	10	total	total	NOUN
ajlm-1628	70	11	and	and	CCONJ
ajlm-1628	70	12	(	(	PUNCT
ajlm-1628	70	13	b	b	NOUN
ajlm-1628	70	14	)	)	PUNCT
ajlm-1628	70	15	unbound	unbound	NOUN
ajlm-1628	70	16	valproic	valproic	ADJ
ajlm-1628	70	17	acid	acid	NOUN
ajlm-1628	70	18	plasma	plasma	NOUN
ajlm-1628	70	19	concentration	concentration	NOUN
ajlm-1628	70	20	in	in	ADP
ajlm-1628	70	21	93	93	NUM
ajlm-1628	70	22	critically	critically	ADV
ajlm-1628	70	23	ill	ill	ADJ
ajlm-1628	70	24	patients	patient	NOUN
ajlm-1628	70	25	in	in	ADP
ajlm-1628	70	26	the	the	DET
ajlm-1628	70	27	intensive	intensive	ADJ
ajlm-1628	70	28	care	care	NOUN
ajlm-1628	70	29	unit	unit	NOUN
ajlm-1628	70	30	at	at	ADP
ajlm-1628	70	31	windhoek	windhoek	PROPN
ajlm-1628	70	32	central	central	PROPN
ajlm-1628	70	33	hospital	hospital	PROPN
ajlm-1628	70	34	(	(	PUNCT
ajlm-1628	70	35	windhoek	windhoek	PROPN
ajlm-1628	70	36	,	,	PUNCT
ajlm-1628	70	37	namibia	namibia	PROPN
ajlm-1628	70	38	)	)	PUNCT
ajlm-1628	70	39	from	from	ADP
ajlm-1628	70	40	january	january	PROPN
ajlm-1628	70	41	2013	2013	NUM
ajlm-1628	70	42	to	to	ADP
ajlm-1628	70	43	july	july	PROPN
ajlm-1628	70	44	2019	2019	NUM
ajlm-1628	70	45	.	.	PUNCT
ajlm-1628	71	1	the	the	DET
ajlm-1628	71	2	therapeutic	therapeutic	ADJ
ajlm-1628	71	3	range	range	NOUN
ajlm-1628	71	4	is	be	AUX
ajlm-1628	71	5	indicated	indicate	VERB
ajlm-1628	71	6	by	by	ADP
ajlm-1628	71	7	dashed	dash	VERB
ajlm-1628	71	8	lines	line	NOUN
ajlm-1628	71	9	.	.	PUNCT
ajlm-1628	72	1	the	the	DET
ajlm-1628	72	2	suggested	suggest	VERB
ajlm-1628	72	3	therapeutic	therapeutic	ADJ
ajlm-1628	72	4	range	range	NOUN
ajlm-1628	72	5	for	for	ADP
ajlm-1628	72	6	unbound	unbound	NOUN
ajlm-1628	72	7	valproic	valproic	ADJ
ajlm-1628	72	8	acid	acid	NOUN
ajlm-1628	72	9	concentrations	concentration	NOUN
ajlm-1628	72	10	is	be	AUX
ajlm-1628	72	11	quite	quite	ADV
ajlm-1628	72	12	wide	wide	ADJ
ajlm-1628	72	13	because	because	SCONJ
ajlm-1628	72	14	the	the	DET
ajlm-1628	72	15	lower	low	ADJ
ajlm-1628	72	16	and	and	CCONJ
ajlm-1628	72	17	upper	upper	ADJ
ajlm-1628	72	18	limits	limit	NOUN
ajlm-1628	72	19	of	of	ADP
ajlm-1628	72	20	therapeutic	therapeutic	ADJ
ajlm-1628	72	21	ranges	range	NOUN
ajlm-1628	72	22	reported	report	VERB
ajlm-1628	72	23	in	in	ADP
ajlm-1628	72	24	the	the	DET
ajlm-1628	72	25	literature	literature	NOUN
ajlm-1628	72	26	differ	differ	VERB
ajlm-1628	72	27	substantially	substantially	ADV
ajlm-1628	72	28	.	.	PUNCT
ajlm-1628	73	1	discussion	discussion	NOUN
ajlm-1628	73	2	this	this	DET
ajlm-1628	73	3	retrospective	retrospective	ADJ
ajlm-1628	73	4	study	study	NOUN
ajlm-1628	73	5	determined	determine	VERB
ajlm-1628	73	6	the	the	DET
ajlm-1628	73	7	plasma	plasma	NOUN
ajlm-1628	73	8	concentrations	concentration	NOUN
ajlm-1628	73	9	of	of	ADP
ajlm-1628	73	10	phenytoin	phenytoin	NOUN
ajlm-1628	73	11	and	and	CCONJ
ajlm-1628	73	12	valproic	valproic	ADJ
ajlm-1628	73	13	acid	acid	NOUN
ajlm-1628	73	14	in	in	ADP
ajlm-1628	73	15	critically	critically	ADV
ajlm-1628	73	16	ill	ill	ADJ
ajlm-1628	73	17	patients	patient	NOUN
ajlm-1628	73	18	at	at	ADP
ajlm-1628	73	19	the	the	DET
ajlm-1628	73	20	icu	icu	PROPN
ajlm-1628	73	21	of	of	ADP
ajlm-1628	73	22	windhoek	windhoek	PROPN
ajlm-1628	73	23	central	central	PROPN
ajlm-1628	73	24	hospital	hospital	NOUN
ajlm-1628	73	25	and	and	CCONJ
ajlm-1628	73	26	found	find	VERB
ajlm-1628	73	27	that	that	SCONJ
ajlm-1628	73	28	the	the	DET
ajlm-1628	73	29	estimated	estimate	VERB
ajlm-1628	73	30	unbound	unbound	NOUN
ajlm-1628	73	31	plasma	plasma	NOUN
ajlm-1628	73	32	concentration	concentration	NOUN
ajlm-1628	73	33	is	be	AUX
ajlm-1628	73	34	a	a	DET
ajlm-1628	73	35	more	more	ADV
ajlm-1628	73	36	accurate	accurate	ADJ
ajlm-1628	73	37	measure	measure	NOUN
ajlm-1628	73	38	of	of	ADP
ajlm-1628	73	39	the	the	DET
ajlm-1628	73	40	therapeutic	therapeutic	ADJ
ajlm-1628	73	41	plasma	plasma	NOUN
ajlm-1628	73	42	levels	level	NOUN
ajlm-1628	73	43	for	for	ADP
ajlm-1628	73	44	the	the	DET
ajlm-1628	73	45	two	two	NUM
ajlm-1628	73	46	drugs	drug	NOUN
ajlm-1628	73	47	compared	compare	VERB
ajlm-1628	73	48	to	to	ADP
ajlm-1628	73	49	total	total	ADJ
ajlm-1628	73	50	plasma	plasma	NOUN
ajlm-1628	73	51	concentration	concentration	NOUN
ajlm-1628	73	52	.	.	PUNCT
ajlm-1628	74	1	using	use	VERB
ajlm-1628	74	2	the	the	DET
ajlm-1628	74	3	total	total	ADJ
ajlm-1628	74	4	plasma	plasma	NOUN
ajlm-1628	74	5	concentration	concentration	NOUN
ajlm-1628	74	6	,	,	PUNCT
ajlm-1628	74	7	most	most	ADJ
ajlm-1628	74	8	patients	patient	NOUN
ajlm-1628	74	9	were	be	AUX
ajlm-1628	74	10	within	within	ADP
ajlm-1628	74	11	or	or	CCONJ
ajlm-1628	74	12	below	below	ADP
ajlm-1628	74	13	the	the	DET
ajlm-1628	74	14	phenytoin	phenytoin	ADJ
ajlm-1628	74	15	therapeutic	therapeutic	ADJ
ajlm-1628	74	16	range	range	NOUN
ajlm-1628	74	17	.	.	PUNCT
ajlm-1628	75	1	in	in	ADP
ajlm-1628	75	2	contrast	contrast	NOUN
ajlm-1628	75	3	,	,	PUNCT
ajlm-1628	75	4	unbound	unbound	NOUN
ajlm-1628	75	5	plasma	plasma	NOUN
ajlm-1628	75	6	concentration	concentration	NOUN
ajlm-1628	75	7	showed	show	VERB
ajlm-1628	75	8	that	that	SCONJ
ajlm-1628	75	9	less	less	ADJ
ajlm-1628	75	10	than	than	ADP
ajlm-1628	75	11	one	one	NUM
ajlm-1628	75	12	-	-	PUNCT
ajlm-1628	75	13	third	third	NOUN
ajlm-1628	75	14	of	of	ADP
ajlm-1628	75	15	the	the	DET
ajlm-1628	75	16	patients	patient	NOUN
ajlm-1628	75	17	were	be	AUX
ajlm-1628	75	18	within	within	ADP
ajlm-1628	75	19	the	the	DET
ajlm-1628	75	20	therapeutic	therapeutic	ADJ
ajlm-1628	75	21	range	range	NOUN
ajlm-1628	75	22	and	and	CCONJ
ajlm-1628	75	23	over	over	ADP
ajlm-1628	75	24	half	half	NOUN
ajlm-1628	75	25	were	be	AUX
ajlm-1628	75	26	above	above	ADJ
ajlm-1628	75	27	.	.	PUNCT
ajlm-1628	76	1	for	for	ADP
ajlm-1628	76	2	valproic	valproic	ADJ
ajlm-1628	76	3	acid	acid	NOUN
ajlm-1628	76	4	,	,	PUNCT
ajlm-1628	76	5	total	total	ADJ
ajlm-1628	76	6	plasma	plasma	NOUN
ajlm-1628	76	7	concentrations	concentration	NOUN
ajlm-1628	76	8	placed	place	VERB
ajlm-1628	76	9	most	most	ADJ
ajlm-1628	76	10	patients	patient	NOUN
ajlm-1628	76	11	were	be	AUX
ajlm-1628	76	12	below	below	ADP
ajlm-1628	76	13	the	the	DET
ajlm-1628	76	14	therapeutic	therapeutic	ADJ
ajlm-1628	76	15	range	range	NOUN
ajlm-1628	76	16	.	.	PUNCT
ajlm-1628	77	1	however	however	ADV
ajlm-1628	77	2	,	,	PUNCT
ajlm-1628	77	3	unbound	unbound	NOUN
ajlm-1628	77	4	plasma	plasma	NOUN
ajlm-1628	77	5	concentrations	concentration	NOUN
ajlm-1628	77	6	placed	place	VERB
ajlm-1628	77	7	majority	majority	NOUN
ajlm-1628	77	8	within	within	ADP
ajlm-1628	77	9	the	the	DET
ajlm-1628	77	10	therapeutic	therapeutic	ADJ
ajlm-1628	77	11	range	range	NOUN
ajlm-1628	77	12	.	.	PUNCT
ajlm-1628	78	1	noval	noval	NOUN
ajlm-1628	78	2	et	et	PROPN
ajlm-1628	78	3	al	al	PROPN
ajlm-1628	78	4	.	.	PROPN
ajlm-1628	78	5	reported	report	VERB
ajlm-1628	78	6	a	a	DET
ajlm-1628	78	7	2	2	NUM
ajlm-1628	78	8	-	-	ADJ
ajlm-1628	78	9	fold	fold	ADJ
ajlm-1628	78	10	increase	increase	NOUN
ajlm-1628	78	11	in	in	ADP
ajlm-1628	78	12	critical	critical	ADJ
ajlm-1628	78	13	care	care	NOUN
ajlm-1628	78	14	patients	patient	NOUN
ajlm-1628	78	15	having	have	VERB
ajlm-1628	78	16	phenytoin	phenytoin	ADJ
ajlm-1628	78	17	concentrations	concentration	NOUN
ajlm-1628	78	18	falling	fall	VERB
ajlm-1628	78	19	within	within	ADP
ajlm-1628	78	20	the	the	DET
ajlm-1628	78	21	therapeutic	therapeutic	ADJ
ajlm-1628	78	22	range	range	NOUN
ajlm-1628	78	23	when	when	SCONJ
ajlm-1628	78	24	unbound	unbound	NOUN
ajlm-1628	78	25	concentrations	concentration	NOUN
ajlm-1628	78	26	instead	instead	ADV
ajlm-1628	78	27	of	of	ADP
ajlm-1628	78	28	total	total	ADJ
ajlm-1628	78	29	phenytoin	phenytoin	NOUN
ajlm-1628	78	30	concentrations	concentration	NOUN
ajlm-1628	78	31	were	be	AUX
ajlm-1628	78	32	considered	consider	VERB
ajlm-1628	78	33	for	for	ADP
ajlm-1628	78	34	dose	dose	NOUN
ajlm-1628	78	35	adjustment.23	adjustment.23	PROPN
ajlm-1628	78	36	in	in	ADP
ajlm-1628	78	37	our	our	PRON
ajlm-1628	78	38	study	study	NOUN
ajlm-1628	78	39	,	,	PUNCT
ajlm-1628	78	40	the	the	DET
ajlm-1628	78	41	percentage	percentage	NOUN
ajlm-1628	78	42	of	of	ADP
ajlm-1628	78	43	patients	patient	NOUN
ajlm-1628	78	44	within	within	ADP
ajlm-1628	78	45	therapeutic	therapeutic	ADJ
ajlm-1628	78	46	concentrations	concentration	NOUN
ajlm-1628	78	47	using	use	VERB
ajlm-1628	78	48	total	total	ADJ
ajlm-1628	78	49	plasma	plasma	NOUN
ajlm-1628	78	50	concentrations	concentration	NOUN
ajlm-1628	78	51	reduced	reduce	VERB
ajlm-1628	78	52	from	from	ADP
ajlm-1628	78	53	41.1	41.1	NUM
ajlm-1628	78	54	%	%	NOUN
ajlm-1628	78	55	to	to	ADP
ajlm-1628	78	56	28.6	28.6	NUM
ajlm-1628	78	57	%	%	NOUN
ajlm-1628	78	58	when	when	SCONJ
ajlm-1628	78	59	an	an	DET
ajlm-1628	78	60	unbound	unbound	NOUN
ajlm-1628	78	61	phenytoin	phenytoin	NOUN
ajlm-1628	78	62	concentration	concentration	NOUN
ajlm-1628	78	63	was	be	AUX
ajlm-1628	78	64	used	use	VERB
ajlm-1628	78	65	.	.	PUNCT
ajlm-1628	79	1	thus	thus	ADV
ajlm-1628	79	2	,	,	PUNCT
ajlm-1628	79	3	the	the	DET
ajlm-1628	79	4	use	use	NOUN
ajlm-1628	79	5	of	of	ADP
ajlm-1628	79	6	total	total	ADJ
ajlm-1628	79	7	phenytoin	phenytoin	ADJ
ajlm-1628	79	8	concentrations	concentration	NOUN
ajlm-1628	79	9	suggests	suggest	VERB
ajlm-1628	79	10	that	that	SCONJ
ajlm-1628	79	11	dosing	dose	VERB
ajlm-1628	79	12	in	in	ADP
ajlm-1628	79	13	these	these	DET
ajlm-1628	79	14	patients	patient	NOUN
ajlm-1628	79	15	was	be	AUX
ajlm-1628	79	16	at	at	ADP
ajlm-1628	79	17	target	target	NOUN
ajlm-1628	79	18	therapeutic	therapeutic	ADJ
ajlm-1628	79	19	concentrations	concentration	NOUN
ajlm-1628	79	20	,	,	PUNCT
ajlm-1628	79	21	suggesting	suggest	VERB
ajlm-1628	79	22	no	no	DET
ajlm-1628	79	23	optimal	optimal	ADJ
ajlm-1628	79	24	patient	patient	ADJ
ajlm-1628	79	25	dosage	dosage	NOUN
ajlm-1628	79	26	.	.	PUNCT
ajlm-1628	80	1	the	the	DET
ajlm-1628	80	2	high	high	ADJ
ajlm-1628	80	3	variability	variability	NOUN
ajlm-1628	80	4	in	in	ADP
ajlm-1628	80	5	the	the	DET
ajlm-1628	80	6	binding	binding	NOUN
ajlm-1628	80	7	of	of	ADP
ajlm-1628	80	8	valproic	valproic	ADJ
ajlm-1628	80	9	acid	acid	NOUN
ajlm-1628	80	10	to	to	ADP
ajlm-1628	80	11	albumin	albumin	NOUN
ajlm-1628	80	12	observed	observe	VERB
ajlm-1628	80	13	in	in	ADP
ajlm-1628	80	14	this	this	DET
ajlm-1628	80	15	study	study	NOUN
ajlm-1628	80	16	(	(	PUNCT
ajlm-1628	80	17	9.0	9.0	NUM
ajlm-1628	80	18	%	%	NOUN
ajlm-1628	80	19	–	–	PUNCT
ajlm-1628	80	20	39.0	39.0	NUM
ajlm-1628	80	21	%	%	NOUN
ajlm-1628	80	22	)	)	PUNCT
ajlm-1628	80	23	reflects	reflect	VERB
ajlm-1628	80	24	reports	report	NOUN
ajlm-1628	80	25	in	in	ADP
ajlm-1628	80	26	the	the	DET
ajlm-1628	80	27	literature	literature	NOUN
ajlm-1628	80	28	,	,	PUNCT
ajlm-1628	80	29	such	such	ADJ
ajlm-1628	80	30	as	as	ADP
ajlm-1628	80	31	the	the	DET
ajlm-1628	80	32	10.0	10.0	NUM
ajlm-1628	80	33	%	%	NOUN
ajlm-1628	80	34	–	–	PUNCT
ajlm-1628	80	35	60.0	60.0	NUM
ajlm-1628	80	36	%	%	NOUN
ajlm-1628	80	37	range	range	NOUN
ajlm-1628	80	38	reported	report	VERB
ajlm-1628	80	39	in	in	ADP
ajlm-1628	80	40	icu	icu	PROPN
ajlm-1628	80	41	patients	patient	NOUN
ajlm-1628	80	42	by	by	ADP
ajlm-1628	80	43	lagneau	lagneau	PROPN
ajlm-1628	80	44	et	et	PROPN
ajlm-1628	80	45	al.13	al.13	PROPN
ajlm-1628	80	46	and	and	CCONJ
ajlm-1628	80	47	the	the	DET
ajlm-1628	80	48	15.0	15.0	NUM
ajlm-1628	80	49	%	%	NOUN
ajlm-1628	80	50	–	–	PUNCT
ajlm-1628	80	51	89.0	89.0	NUM
ajlm-1628	80	52	%	%	NOUN
ajlm-1628	80	53	range	range	NOUN
ajlm-1628	80	54	reported	report	VERB
ajlm-1628	80	55	by	by	ADP
ajlm-1628	80	56	riker	riker	PROPN
ajlm-1628	80	57	et	et	PROPN
ajlm-1628	80	58	al.24	al.24	PROPN
ajlm-1628	80	59	this	this	DET
ajlm-1628	80	60	high	high	ADJ
ajlm-1628	80	61	variability	variability	NOUN
ajlm-1628	80	62	in	in	ADP
ajlm-1628	80	63	plasma	plasma	NOUN
ajlm-1628	80	64	protein	protein	NOUN
ajlm-1628	80	65	binding	bind	VERB
ajlm-1628	80	66	explains	explain	VERB
ajlm-1628	80	67	the	the	DET
ajlm-1628	80	68	marked	mark	VERB
ajlm-1628	80	69	difference	difference	NOUN
ajlm-1628	80	70	in	in	ADP
ajlm-1628	80	71	the	the	DET
ajlm-1628	80	72	percentage	percentage	NOUN
ajlm-1628	80	73	of	of	ADP
ajlm-1628	80	74	patients	patient	NOUN
ajlm-1628	80	75	having	have	VERB
ajlm-1628	80	76	concentrations	concentration	NOUN
ajlm-1628	80	77	that	that	PRON
ajlm-1628	80	78	were	be	AUX
ajlm-1628	80	79	within	within	ADP
ajlm-1628	80	80	the	the	DET
ajlm-1628	80	81	therapeutic	therapeutic	ADJ
ajlm-1628	80	82	range	range	NOUN
ajlm-1628	80	83	when	when	SCONJ
ajlm-1628	80	84	total	total	ADJ
ajlm-1628	80	85	valproic	valproic	ADJ
ajlm-1628	80	86	acid	acid	NOUN
ajlm-1628	80	87	was	be	AUX
ajlm-1628	80	88	considered	consider	VERB
ajlm-1628	80	89	(	(	PUNCT
ajlm-1628	80	90	12.9	12.9	NUM
ajlm-1628	80	91	%	%	NOUN
ajlm-1628	80	92	)	)	PUNCT
ajlm-1628	80	93	compared	compare	VERB
ajlm-1628	80	94	to	to	ADP
ajlm-1628	80	95	when	when	SCONJ
ajlm-1628	80	96	the	the	DET
ajlm-1628	80	97	unbound	unbound	ADJ
ajlm-1628	80	98	valproic	valproic	ADJ
ajlm-1628	80	99	acid	acid	NOUN
ajlm-1628	80	100	concentrations	concentration	NOUN
ajlm-1628	80	101	were	be	AUX
ajlm-1628	80	102	taken	take	VERB
ajlm-1628	80	103	into	into	ADP
ajlm-1628	80	104	account	account	NOUN
ajlm-1628	80	105	(	(	PUNCT
ajlm-1628	80	106	91.4	91.4	NUM
ajlm-1628	80	107	%	%	NOUN
ajlm-1628	80	108	)	)	PUNCT
ajlm-1628	80	109	.	.	PUNCT
ajlm-1628	81	1	total	total	ADJ
ajlm-1628	81	2	valproate	valproate	ADJ
ajlm-1628	81	3	concentration	concentration	NOUN
ajlm-1628	81	4	is	be	AUX
ajlm-1628	81	5	a	a	DET
ajlm-1628	81	6	poor	poor	ADJ
ajlm-1628	81	7	predictor	predictor	NOUN
ajlm-1628	81	8	of	of	ADP
ajlm-1628	81	9	the	the	DET
ajlm-1628	81	10	unbound	unbound	NOUN
ajlm-1628	81	11	drug	drug	NOUN
ajlm-1628	81	12	concentration	concentration	NOUN
ajlm-1628	81	13	,	,	PUNCT
ajlm-1628	81	14	even	even	ADV
ajlm-1628	81	15	when	when	SCONJ
ajlm-1628	81	16	correction	correction	NOUN
ajlm-1628	81	17	is	be	AUX
ajlm-1628	81	18	made	make	VERB
ajlm-1628	81	19	for	for	ADP
ajlm-1628	81	20	albumin.13	albumin.13	PROPN
ajlm-1628	81	21	therapeutic	therapeutic	ADJ
ajlm-1628	81	22	drug	drug	NOUN
ajlm-1628	81	23	monitoring	monitoring	NOUN
ajlm-1628	81	24	of	of	ADP
ajlm-1628	81	25	phenytoin	phenytoin	NOUN
ajlm-1628	81	26	and	and	CCONJ
ajlm-1628	81	27	valproic	valproic	ADJ
ajlm-1628	81	28	acid	acid	NOUN
ajlm-1628	81	29	by	by	ADP
ajlm-1628	81	30	measuring	measure	VERB
ajlm-1628	81	31	unbound	unbound	NOUN
ajlm-1628	81	32	plasma	plasma	NOUN
ajlm-1628	81	33	concentrations	concentration	NOUN
ajlm-1628	81	34	is	be	AUX
ajlm-1628	81	35	not	not	PART
ajlm-1628	81	36	widespread	widespread	ADJ
ajlm-1628	81	37	because	because	SCONJ
ajlm-1628	81	38	of	of	ADP
ajlm-1628	81	39	the	the	DET
ajlm-1628	81	40	additional	additional	ADJ
ajlm-1628	81	41	time	time	NOUN
ajlm-1628	81	42	and	and	CCONJ
ajlm-1628	81	43	cost	cost	NOUN
ajlm-1628	81	44	implications	implication	NOUN
ajlm-1628	81	45	.	.	PUNCT
ajlm-1628	82	1	thus	thus	ADV
ajlm-1628	82	2	,	,	PUNCT
ajlm-1628	82	3	some	some	DET
ajlm-1628	82	4	therapeutic	therapeutic	ADJ
ajlm-1628	82	5	drug	drug	NOUN
ajlm-1628	82	6	monitoring	monitoring	NOUN
ajlm-1628	82	7	services	service	NOUN
ajlm-1628	82	8	measure	measure	VERB
ajlm-1628	82	9	only	only	ADV
ajlm-1628	82	10	the	the	DET
ajlm-1628	82	11	total	total	ADJ
ajlm-1628	82	12	drug	drug	NOUN
ajlm-1628	82	13	plasma	plasma	NOUN
ajlm-1628	82	14	concentrations	concentration	NOUN
ajlm-1628	82	15	or	or	CCONJ
ajlm-1628	82	16	estimate	estimate	VERB
ajlm-1628	82	17	the	the	DET
ajlm-1628	82	18	unbound	unbound	NOUN
ajlm-1628	82	19	plasma	plasma	NOUN
ajlm-1628	82	20	drug	drug	NOUN
ajlm-1628	82	21	concentrations	concentration	NOUN
ajlm-1628	82	22	.	.	PUNCT
ajlm-1628	83	1	these	these	DET
ajlm-1628	83	2	equations	equation	NOUN
ajlm-1628	83	3	,	,	PUNCT
ajlm-1628	83	4	including	include	VERB
ajlm-1628	83	5	those	those	PRON
ajlm-1628	83	6	used	use	VERB
ajlm-1628	83	7	in	in	ADP
ajlm-1628	83	8	this	this	DET
ajlm-1628	83	9	study	study	NOUN
ajlm-1628	83	10	,	,	PUNCT
ajlm-1628	83	11	estimate	estimate	VERB
ajlm-1628	83	12	the	the	DET
ajlm-1628	83	13	unbound	unbound	NOUN
ajlm-1628	83	14	concentrations	concentration	NOUN
ajlm-1628	83	15	of	of	ADP
ajlm-1628	83	16	phenytoin	phenytoin	NOUN
ajlm-1628	83	17	and	and	CCONJ
ajlm-1628	83	18	valproic	valproic	ADJ
ajlm-1628	83	19	acid	acid	NOUN
ajlm-1628	83	20	based	base	VERB
ajlm-1628	83	21	on	on	ADP
ajlm-1628	83	22	the	the	DET
ajlm-1628	83	23	patient	patient	NOUN
ajlm-1628	83	24	’s	’s	PART
ajlm-1628	83	25	measured	measure	VERB
ajlm-1628	83	26	total	total	ADJ
ajlm-1628	83	27	drug	drug	NOUN
ajlm-1628	83	28	plasma	plasma	NOUN
ajlm-1628	83	29	concentration	concentration	NOUN
ajlm-1628	83	30	and	and	CCONJ
ajlm-1628	83	31	serum	serum	NOUN
ajlm-1628	83	32	albumin	albumin	NOUN
ajlm-1628	83	33	level.5,18,19,20,21,22	level.5,18,19,20,21,22	PUNCT
ajlm-1628	83	34	unfortunately	unfortunately	ADV
ajlm-1628	83	35	,	,	PUNCT
ajlm-1628	83	36	these	these	DET
ajlm-1628	83	37	equations	equation	NOUN
ajlm-1628	83	38	are	be	AUX
ajlm-1628	83	39	not	not	PART
ajlm-1628	83	40	very	very	ADV
ajlm-1628	83	41	accurate	accurate	ADJ
ajlm-1628	83	42	and	and	CCONJ
ajlm-1628	83	43	may	may	AUX
ajlm-1628	83	44	underestimate	underestimate	VERB
ajlm-1628	83	45	the	the	DET
ajlm-1628	83	46	unbound	unbound	NOUN
ajlm-1628	83	47	plasma	plasma	NOUN
ajlm-1628	83	48	concentrations	concentration	NOUN
ajlm-1628	83	49	of	of	ADP
ajlm-1628	83	50	phenytoin	phenytoin	NOUN
ajlm-1628	83	51	and	and	CCONJ
ajlm-1628	83	52	valproic	valproic	ADJ
ajlm-1628	83	53	acid	acid	NOUN
ajlm-1628	83	54	in	in	ADP
ajlm-1628	83	55	critically	critically	ADV
ajlm-1628	83	56	ill	ill	ADJ
ajlm-1628	83	57	patients.25,26,27,28,29,30	patients.25,26,27,28,29,30	NOUN
ajlm-1628	83	58	in	in	ADP
ajlm-1628	83	59	addition	addition	NOUN
ajlm-1628	83	60	,	,	PUNCT
ajlm-1628	83	61	although	although	SCONJ
ajlm-1628	83	62	the	the	DET
ajlm-1628	83	63	therapeutic	therapeutic	ADJ
ajlm-1628	83	64	plasma	plasma	NOUN
ajlm-1628	83	65	range	range	NOUN
ajlm-1628	83	66	for	for	ADP
ajlm-1628	83	67	unbound	unbound	NOUN
ajlm-1628	83	68	phenytoin	phenytoin	NOUN
ajlm-1628	83	69	is	be	AUX
ajlm-1628	83	70	relatively	relatively	ADV
ajlm-1628	83	71	established	establish	VERB
ajlm-1628	83	72	(	(	PUNCT
ajlm-1628	83	73	1	1	NUM
ajlm-1628	83	74	μg	μg	NOUN
ajlm-1628	83	75	/	/	SYM
ajlm-1628	83	76	ml	ml	PROPN
ajlm-1628	83	77	–	–	PUNCT
ajlm-1628	83	78	2	2	NUM
ajlm-1628	83	79	μg	μg	NOUN
ajlm-1628	83	80	/	/	SYM
ajlm-1628	83	81	ml	ml	NOUN
ajlm-1628	83	82	)	)	PUNCT
ajlm-1628	83	83	,	,	PUNCT
ajlm-1628	83	84	various	various	ADJ
ajlm-1628	83	85	therapeutic	therapeutic	ADJ
ajlm-1628	83	86	ranges	range	NOUN
ajlm-1628	83	87	for	for	ADP
ajlm-1628	83	88	the	the	DET
ajlm-1628	83	89	unbound	unbound	NOUN
ajlm-1628	83	90	plasma	plasma	NOUN
ajlm-1628	83	91	concentration	concentration	NOUN
ajlm-1628	83	92	of	of	ADP
ajlm-1628	83	93	valproic	valproic	ADJ
ajlm-1628	83	94	acid	acid	NOUN
ajlm-1628	83	95	have	have	AUX
ajlm-1628	83	96	been	be	AUX
ajlm-1628	83	97	proposed	propose	VERB
ajlm-1628	83	98	in	in	ADP
ajlm-1628	83	99	the	the	DET
ajlm-1628	83	100	literature	literature	NOUN
ajlm-1628	83	101	.	.	PUNCT
ajlm-1628	84	1	however	however	ADV
ajlm-1628	84	2	,	,	PUNCT
ajlm-1628	84	3	more	more	ADJ
ajlm-1628	84	4	research	research	NOUN
ajlm-1628	84	5	is	be	AUX
ajlm-1628	84	6	needed	need	VERB
ajlm-1628	84	7	to	to	PART
ajlm-1628	84	8	determine	determine	VERB
ajlm-1628	84	9	the	the	DET
ajlm-1628	84	10	optimal	optimal	ADJ
ajlm-1628	84	11	unbound	unbound	NOUN
ajlm-1628	84	12	plasma	plasma	NOUN
ajlm-1628	84	13	concentration	concentration	NOUN
ajlm-1628	84	14	range	range	NOUN
ajlm-1628	84	15	for	for	ADP
ajlm-1628	84	16	this	this	DET
ajlm-1628	84	17	anticonvulsant.31	anticonvulsant.31	NOUN
ajlm-1628	84	18	furthermore	furthermore	ADV
ajlm-1628	84	19	,	,	PUNCT
ajlm-1628	84	20	recent	recent	ADJ
ajlm-1628	84	21	investigations	investigation	NOUN
ajlm-1628	84	22	on	on	ADP
ajlm-1628	84	23	the	the	DET
ajlm-1628	84	24	predictive	predictive	ADJ
ajlm-1628	84	25	performance	performance	NOUN
ajlm-1628	84	26	of	of	ADP
ajlm-1628	84	27	these	these	DET
ajlm-1628	84	28	equations	equation	NOUN
ajlm-1628	84	29	led	lead	VERB
ajlm-1628	84	30	to	to	ADP
ajlm-1628	84	31	the	the	DET
ajlm-1628	84	32	conclusion	conclusion	NOUN
ajlm-1628	84	33	that	that	SCONJ
ajlm-1628	84	34	more	more	ADV
ajlm-1628	84	35	complex	complex	ADJ
ajlm-1628	84	36	,	,	PUNCT
ajlm-1628	84	37	multivariate	multivariate	ADJ
ajlm-1628	84	38	predictive	predictive	ADJ
ajlm-1628	84	39	equations	equation	NOUN
ajlm-1628	84	40	may	may	AUX
ajlm-1628	84	41	be	be	AUX
ajlm-1628	84	42	required	require	VERB
ajlm-1628	84	43	,	,	PUNCT
ajlm-1628	84	44	which	which	PRON
ajlm-1628	84	45	,	,	PUNCT
ajlm-1628	84	46	in	in	ADP
ajlm-1628	84	47	addition	addition	NOUN
ajlm-1628	84	48	to	to	ADP
ajlm-1628	84	49	the	the	DET
ajlm-1628	84	50	total	total	ADJ
ajlm-1628	84	51	drug	drug	NOUN
ajlm-1628	84	52	plasma	plasma	NOUN
ajlm-1628	84	53	concentration	concentration	NOUN
ajlm-1628	84	54	and	and	CCONJ
ajlm-1628	84	55	serum	serum	NOUN
ajlm-1628	84	56	albumin	albumin	ADJ
ajlm-1628	84	57	level	level	NOUN
ajlm-1628	84	58	,	,	PUNCT
ajlm-1628	84	59	considering	consider	VERB
ajlm-1628	84	60	the	the	DET
ajlm-1628	84	61	icu	icu	PROPN
ajlm-1628	84	62	status	status	NOUN
ajlm-1628	84	63	of	of	ADP
ajlm-1628	84	64	the	the	DET
ajlm-1628	84	65	patient	patient	NOUN
ajlm-1628	84	66	,	,	PUNCT
ajlm-1628	84	67	age	age	NOUN
ajlm-1628	84	68	,	,	PUNCT
ajlm-1628	84	69	and	and	CCONJ
ajlm-1628	84	70	blood	blood	NOUN
ajlm-1628	84	71	urea	urea	NOUN
ajlm-1628	84	72	nitrogen	nitrogen	PROPN
ajlm-1628	84	73	level.30,28	level.30,28	PROPN
ajlm-1628	84	74	therapeutic	therapeutic	ADJ
ajlm-1628	84	75	drug	drug	NOUN
ajlm-1628	84	76	monitoring	monitoring	NOUN
ajlm-1628	84	77	of	of	ADP
ajlm-1628	84	78	phenytoin	phenytoin	NOUN
ajlm-1628	84	79	and	and	CCONJ
ajlm-1628	84	80	valproic	valproic	ADJ
ajlm-1628	84	81	acid	acid	NOUN
ajlm-1628	84	82	should	should	AUX
ajlm-1628	84	83	be	be	AUX
ajlm-1628	84	84	based	base	VERB
ajlm-1628	84	85	on	on	ADP
ajlm-1628	84	86	unbound	unbound	NOUN
ajlm-1628	84	87	drug	drug	NOUN
ajlm-1628	84	88	concentrations	concentration	NOUN
ajlm-1628	84	89	.	.	PUNCT
ajlm-1628	85	1	the	the	DET
ajlm-1628	85	2	best	good	ADJ
ajlm-1628	85	3	way	way	NOUN
ajlm-1628	85	4	to	to	PART
ajlm-1628	85	5	monitor	monitor	VERB
ajlm-1628	85	6	the	the	DET
ajlm-1628	85	7	unbound	unbound	NOUN
ajlm-1628	85	8	drug	drug	NOUN
ajlm-1628	85	9	concentration	concentration	NOUN
ajlm-1628	85	10	would	would	AUX
ajlm-1628	85	11	be	be	AUX
ajlm-1628	85	12	by	by	ADP
ajlm-1628	85	13	measuring	measure	VERB
ajlm-1628	85	14	it	it	PRON
ajlm-1628	85	15	directly	directly	ADV
ajlm-1628	85	16	in	in	ADP
ajlm-1628	85	17	ultrafiltrate	ultrafiltrate	ADJ
ajlm-1628	85	18	obtained	obtain	VERB
ajlm-1628	85	19	from	from	ADP
ajlm-1628	85	20	serum	serum	NOUN
ajlm-1628	85	21	to	to	PART
ajlm-1628	85	22	ensure	ensure	VERB
ajlm-1628	85	23	that	that	SCONJ
ajlm-1628	85	24	the	the	DET
ajlm-1628	85	25	accurate	accurate	ADJ
ajlm-1628	85	26	concentration	concentration	NOUN
ajlm-1628	85	27	of	of	ADP
ajlm-1628	85	28	the	the	DET
ajlm-1628	85	29	free	free	ADJ
ajlm-1628	85	30	drug	drug	NOUN
ajlm-1628	85	31	is	be	AUX
ajlm-1628	85	32	determined	determine	VERB
ajlm-1628	85	33	and	and	CCONJ
ajlm-1628	85	34	used	use	VERB
ajlm-1628	85	35	to	to	PART
ajlm-1628	85	36	inform	inform	VERB
ajlm-1628	85	37	dosage	dosage	NOUN
ajlm-1628	85	38	adjustment	adjustment	NOUN
ajlm-1628	85	39	.	.	PUNCT
ajlm-1628	86	1	limitations	limitation	NOUN
ajlm-1628	86	2	the	the	DET
ajlm-1628	86	3	main	main	ADJ
ajlm-1628	86	4	limitation	limitation	NOUN
ajlm-1628	86	5	of	of	ADP
ajlm-1628	86	6	this	this	DET
ajlm-1628	86	7	retrospective	retrospective	ADJ
ajlm-1628	86	8	study	study	NOUN
ajlm-1628	86	9	is	be	AUX
ajlm-1628	86	10	that	that	SCONJ
ajlm-1628	86	11	the	the	DET
ajlm-1628	86	12	unbound	unbound	NOUN
ajlm-1628	86	13	plasma	plasma	NOUN
ajlm-1628	86	14	concentrations	concentration	NOUN
ajlm-1628	86	15	of	of	ADP
ajlm-1628	86	16	phenytoin	phenytoin	NOUN
ajlm-1628	86	17	and	and	CCONJ
ajlm-1628	86	18	valproic	valproic	ADJ
ajlm-1628	86	19	acid	acid	NOUN
ajlm-1628	86	20	were	be	AUX
ajlm-1628	86	21	not	not	PART
ajlm-1628	86	22	determined	determine	VERB
ajlm-1628	86	23	experimentally	experimentally	ADV
ajlm-1628	86	24	.	.	PUNCT
ajlm-1628	87	1	however	however	ADV
ajlm-1628	87	2	,	,	PUNCT
ajlm-1628	87	3	because	because	SCONJ
ajlm-1628	87	4	the	the	DET
ajlm-1628	87	5	albumin	albumin	NOUN
ajlm-1628	87	6	-	-	PUNCT
ajlm-1628	87	7	based	base	VERB
ajlm-1628	87	8	normalising	normalising	ADJ
ajlm-1628	87	9	equations	equation	NOUN
ajlm-1628	87	10	that	that	PRON
ajlm-1628	87	11	were	be	AUX
ajlm-1628	87	12	used	use	VERB
ajlm-1628	87	13	underestimate	underestimate	ADJ
ajlm-1628	87	14	the	the	DET
ajlm-1628	87	15	patient	patient	NOUN
ajlm-1628	87	16	’s	’s	PART
ajlm-1628	87	17	unbound	unbound	NOUN
ajlm-1628	87	18	plasma	plasma	NOUN
ajlm-1628	87	19	concentrations	concentration	NOUN
ajlm-1628	87	20	of	of	ADP
ajlm-1628	87	21	phenytoin	phenytoin	NOUN
ajlm-1628	87	22	and	and	CCONJ
ajlm-1628	87	23	valproic	valproic	ADJ
ajlm-1628	87	24	acid	acid	NOUN
ajlm-1628	87	25	,	,	PUNCT
ajlm-1628	87	26	the	the	DET
ajlm-1628	87	27	discordance	discordance	NOUN
ajlm-1628	87	28	between	between	ADP
ajlm-1628	87	29	total	total	ADJ
ajlm-1628	87	30	and	and	CCONJ
ajlm-1628	87	31	unbound	unbound	NOUN
ajlm-1628	87	32	concentrations	concentration	NOUN
ajlm-1628	87	33	is	be	AUX
ajlm-1628	87	34	less	less	ADV
ajlm-1628	87	35	pronounced	pronounced	ADJ
ajlm-1628	87	36	than	than	SCONJ
ajlm-1628	87	37	it	it	PRON
ajlm-1628	87	38	would	would	AUX
ajlm-1628	87	39	be	be	AUX
ajlm-1628	87	40	in	in	ADP
ajlm-1628	87	41	reality	reality	NOUN
ajlm-1628	87	42	.	.	PUNCT
ajlm-1628	88	1	in	in	ADP
ajlm-1628	88	2	addition	addition	NOUN
ajlm-1628	88	3	,	,	PUNCT
ajlm-1628	88	4	there	there	PRON
ajlm-1628	88	5	was	be	VERB
ajlm-1628	88	6	no	no	DET
ajlm-1628	88	7	follow	follow	NOUN
ajlm-1628	88	8	-	-	PUNCT
ajlm-1628	88	9	up	up	NOUN
ajlm-1628	88	10	to	to	PART
ajlm-1628	88	11	adjust	adjust	VERB
ajlm-1628	88	12	the	the	DET
ajlm-1628	88	13	dosage	dosage	NOUN
ajlm-1628	88	14	regimen	regiman	NOUN
ajlm-1628	88	15	of	of	ADP
ajlm-1628	88	16	these	these	DET
ajlm-1628	88	17	two	two	NUM
ajlm-1628	88	18	drugs	drug	NOUN
ajlm-1628	88	19	in	in	ADP
ajlm-1628	88	20	the	the	DET
ajlm-1628	88	21	individual	individual	ADJ
ajlm-1628	88	22	patients	patient	NOUN
ajlm-1628	88	23	based	base	VERB
ajlm-1628	88	24	on	on	ADP
ajlm-1628	88	25	the	the	DET
ajlm-1628	88	26	observed	observe	VERB
ajlm-1628	88	27	total	total	ADJ
ajlm-1628	88	28	plasma	plasma	NOUN
ajlm-1628	88	29	concentrations	concentration	NOUN
ajlm-1628	88	30	.	.	PUNCT
ajlm-1628	89	1	conclusion	conclusion	NOUN
ajlm-1628	89	2	in	in	ADP
ajlm-1628	89	3	conclusion	conclusion	NOUN
ajlm-1628	89	4	,	,	PUNCT
ajlm-1628	89	5	for	for	ADP
ajlm-1628	89	6	therapeutic	therapeutic	ADJ
ajlm-1628	89	7	drug	drug	NOUN
ajlm-1628	89	8	monitoring	monitoring	NOUN
ajlm-1628	89	9	of	of	ADP
ajlm-1628	89	10	phenytoin	phenytoin	NOUN
ajlm-1628	89	11	and	and	CCONJ
ajlm-1628	89	12	valproic	valproic	ADJ
ajlm-1628	89	13	acid	acid	NOUN
ajlm-1628	89	14	in	in	ADP
ajlm-1628	89	15	critically	critically	ADV
ajlm-1628	89	16	ill	ill	ADJ
ajlm-1628	89	17	patients	patient	NOUN
ajlm-1628	89	18	,	,	PUNCT
ajlm-1628	89	19	direct	direct	ADJ
ajlm-1628	89	20	measurement	measurement	NOUN
ajlm-1628	89	21	of	of	ADP
ajlm-1628	89	22	the	the	DET
ajlm-1628	89	23	unbound	unbound	NOUN
ajlm-1628	89	24	phenytoin	phenytoin	NOUN
ajlm-1628	89	25	and	and	CCONJ
ajlm-1628	89	26	valproic	valproic	ADJ
ajlm-1628	89	27	acid	acid	NOUN
ajlm-1628	89	28	concentration	concentration	NOUN
ajlm-1628	89	29	in	in	ADP
ajlm-1628	89	30	plasma	plasma	NOUN
ajlm-1628	89	31	would	would	AUX
ajlm-1628	89	32	be	be	AUX
ajlm-1628	89	33	the	the	DET
ajlm-1628	89	34	best	good	ADJ
ajlm-1628	89	35	approach	approach	NOUN
ajlm-1628	89	36	.	.	PUNCT
ajlm-1628	90	1	acknowledgements	acknowledgement	NOUN
ajlm-1628	90	2	competing	compete	VERB
ajlm-1628	90	3	interests	interest	NOUN
ajlm-1628	90	4	the	the	DET
ajlm-1628	90	5	authors	author	NOUN
ajlm-1628	90	6	declare	declare	VERB
ajlm-1628	90	7	that	that	SCONJ
ajlm-1628	90	8	they	they	PRON
ajlm-1628	90	9	have	have	VERB
ajlm-1628	90	10	no	no	DET
ajlm-1628	90	11	financial	financial	ADJ
ajlm-1628	90	12	or	or	CCONJ
ajlm-1628	90	13	personal	personal	ADJ
ajlm-1628	90	14	relationships	relationship	NOUN
ajlm-1628	90	15	that	that	PRON
ajlm-1628	90	16	may	may	AUX
ajlm-1628	90	17	have	have	AUX
ajlm-1628	90	18	inappropriately	inappropriately	ADV
ajlm-1628	90	19	influenced	influence	VERB
ajlm-1628	90	20	them	they	PRON
ajlm-1628	90	21	in	in	ADP
ajlm-1628	90	22	writing	write	VERB
ajlm-1628	90	23	this	this	DET
ajlm-1628	90	24	article	article	NOUN
ajlm-1628	90	25	.	.	PUNCT
ajlm-1628	91	1	authors	author	NOUN
ajlm-1628	91	2	’	’	PART
ajlm-1628	91	3	contributions	contribution	NOUN
ajlm-1628	91	4	b.s.s	b.s.	NOUN
ajlm-1628	91	5	.	.	PUNCT
ajlm-1628	91	6	supervised	supervise	VERB
ajlm-1628	91	7	the	the	DET
ajlm-1628	91	8	study	study	NOUN
ajlm-1628	91	9	and	and	CCONJ
ajlm-1628	91	10	reviewed	review	VERB
ajlm-1628	91	11	the	the	DET
ajlm-1628	91	12	write	write	NOUN
ajlm-1628	91	13	-	-	PUNCT
ajlm-1628	91	14	up	up	NOUN
ajlm-1628	91	15	of	of	ADP
ajlm-1628	91	16	the	the	DET
ajlm-1628	91	17	manuscript	manuscript	NOUN
ajlm-1628	91	18	.	.	PUNCT
ajlm-1628	92	1	h.m	h.m	PROPN
ajlm-1628	92	2	.	.	PROPN
ajlm-1628	92	3	and	and	CCONJ
ajlm-1628	92	4	l.i	l.i	PROPN
ajlm-1628	92	5	.	.	PROPN
ajlm-1628	92	6	collected	collect	VERB
ajlm-1628	92	7	the	the	DET
ajlm-1628	92	8	data	datum	NOUN
ajlm-1628	92	9	and	and	CCONJ
ajlm-1628	92	10	provided	provide	VERB
ajlm-1628	92	11	the	the	DET
ajlm-1628	92	12	draft	draft	NOUN
ajlm-1628	92	13	manuscript	manuscript	NOUN
ajlm-1628	92	14	.	.	PUNCT
ajlm-1628	93	1	r.k.v	r.k.v	PROPN
ajlm-1628	93	2	.	.	PROPN
ajlm-1628	94	1	was	be	AUX
ajlm-1628	94	2	the	the	DET
ajlm-1628	94	3	overall	overall	ADJ
ajlm-1628	94	4	supervisor	supervisor	NOUN
ajlm-1628	94	5	of	of	ADP
ajlm-1628	94	6	the	the	DET
ajlm-1628	94	7	project	project	NOUN
ajlm-1628	94	8	and	and	CCONJ
ajlm-1628	94	9	provided	provide	VERB
ajlm-1628	94	10	the	the	DET
ajlm-1628	94	11	final	final	ADJ
ajlm-1628	94	12	manuscript	manuscript	NOUN
ajlm-1628	94	13	.	.	PUNCT
ajlm-1628	95	1	sources	source	NOUN
ajlm-1628	95	2	of	of	ADP
ajlm-1628	95	3	support	support	NOUN
ajlm-1628	95	4	this	this	DET
ajlm-1628	95	5	research	research	NOUN
ajlm-1628	95	6	received	receive	VERB
ajlm-1628	95	7	no	no	DET
ajlm-1628	95	8	specific	specific	ADJ
ajlm-1628	95	9	grant	grant	NOUN
ajlm-1628	95	10	from	from	ADP
ajlm-1628	95	11	any	any	DET
ajlm-1628	95	12	funding	funding	NOUN
ajlm-1628	95	13	agency	agency	NOUN
ajlm-1628	95	14	in	in	ADP
ajlm-1628	95	15	the	the	DET
ajlm-1628	95	16	public	public	ADJ
ajlm-1628	95	17	,	,	PUNCT
ajlm-1628	95	18	commercial	commercial	ADJ
ajlm-1628	95	19	,	,	PUNCT
ajlm-1628	95	20	or	or	CCONJ
ajlm-1628	95	21	not	not	PART
ajlm-1628	95	22	-	-	PUNCT
ajlm-1628	95	23	for	for	ADP
ajlm-1628	95	24	-	-	PUNCT
ajlm-1628	95	25	profit	profit	NOUN
ajlm-1628	95	26	sectors	sector	NOUN
ajlm-1628	95	27	.	.	PUNCT
ajlm-1628	96	1	data	datum	NOUN
ajlm-1628	96	2	availability	availability	NOUN
ajlm-1628	96	3	data	datum	NOUN
ajlm-1628	96	4	supporting	support	VERB
ajlm-1628	96	5	the	the	DET
ajlm-1628	96	6	findings	finding	NOUN
ajlm-1628	96	7	of	of	ADP
ajlm-1628	96	8	this	this	DET
ajlm-1628	96	9	study	study	NOUN
ajlm-1628	96	10	are	be	AUX
ajlm-1628	96	11	available	available	ADJ
ajlm-1628	96	12	from	from	ADP
ajlm-1628	96	13	the	the	DET
ajlm-1628	96	14	corresponding	corresponding	ADJ
ajlm-1628	96	15	author	author	NOUN
ajlm-1628	96	16	,	,	PUNCT
ajlm-1628	96	17	b.s.s	b.s.s	PROPN
ajlm-1628	96	18	.	.	PUNCT
ajlm-1628	96	19	,	,	PUNCT
ajlm-1628	96	20	on	on	ADP
ajlm-1628	96	21	request	request	NOUN
ajlm-1628	96	22	.	.	PUNCT
ajlm-1628	97	1	disclaimer	disclaimer	VERB
ajlm-1628	97	2	the	the	DET
ajlm-1628	97	3	views	view	NOUN
ajlm-1628	97	4	and	and	CCONJ
ajlm-1628	97	5	opinions	opinion	NOUN
ajlm-1628	97	6	expressed	express	VERB
ajlm-1628	97	7	in	in	ADP
ajlm-1628	97	8	this	this	DET
ajlm-1628	97	9	article	article	NOUN
ajlm-1628	97	10	are	be	AUX
ajlm-1628	97	11	those	those	PRON
ajlm-1628	97	12	of	of	ADP
ajlm-1628	97	13	the	the	DET
ajlm-1628	97	14	authors	author	NOUN
ajlm-1628	97	15	and	and	CCONJ
ajlm-1628	97	16	do	do	AUX
ajlm-1628	97	17	not	not	PART
ajlm-1628	97	18	necessarily	necessarily	ADV
ajlm-1628	97	19	reflect	reflect	VERB
ajlm-1628	97	20	the	the	DET
ajlm-1628	97	21	official	official	ADJ
ajlm-1628	97	22	policiy	policiy	NOUN
ajlm-1628	97	23	or	or	CCONJ
ajlm-1628	97	24	position	position	NOUN
ajlm-1628	97	25	of	of	ADP
ajlm-1628	97	26	any	any	DET
ajlm-1628	97	27	affiliated	affiliated	ADJ
ajlm-1628	97	28	agency	agency	NOUN
ajlm-1628	97	29	of	of	ADP
ajlm-1628	97	30	the	the	DET
ajlm-1628	97	31	authors	author	NOUN
ajlm-1628	97	32	.	.	PUNCT
ajlm-1628	98	1	references	reference	NOUN
ajlm-1628	98	2	varelas	varelas	PROPN
ajlm-1628	98	3	pn	pn	PROPN
ajlm-1628	98	4	,	,	PUNCT
ajlm-1628	98	5	spanaki	spanaki	PROPN
ajlm-1628	98	6	mv	mv	PROPN
ajlm-1628	98	7	,	,	PUNCT
ajlm-1628	98	8	mirski	mirski	PROPN
ajlm-1628	98	9	ma	ma	PROPN
ajlm-1628	98	10	.	.	PROPN
ajlm-1628	98	11	seizures	seizure	NOUN
ajlm-1628	98	12	and	and	CCONJ
ajlm-1628	98	13	the	the	DET
ajlm-1628	98	14	neurosurgical	neurosurgical	ADJ
ajlm-1628	98	15	intensive	intensive	ADJ
ajlm-1628	98	16	care	care	NOUN
ajlm-1628	98	17	unit	unit	NOUN
ajlm-1628	98	18	.	.	PUNCT
ajlm-1628	99	1	neurosurg	neurosurg	PROPN
ajlm-1628	99	2	clin	clin	PROPN
ajlm-1628	99	3	n	n	PRON
ajlm-1628	99	4	am	be	AUX
ajlm-1628	99	5	.	.	PUNCT
ajlm-1628	100	1	2013;24(3):393–406	2013;24(3):393–406	NUM
ajlm-1628	100	2	.	.	PUNCT
ajlm-1628	100	3	https://doi.org/10.1016/j.nec.2013.03.005	https://doi.org/10.1016/j.nec.2013.03.005	PROPN
ajlm-1628	100	4	farrokh	farrokh	PROPN
ajlm-1628	100	5	s	s	PROPN
ajlm-1628	100	6	,	,	PUNCT
ajlm-1628	100	7	tahsili	tahsili	NOUN
ajlm-1628	100	8	-	-	PUNCT
ajlm-1628	100	9	fahadan	fahadan	NOUN
ajlm-1628	100	10	p	p	PROPN
ajlm-1628	100	11	,	,	PUNCT
ajlm-1628	100	12	ritzl	ritzl	PROPN
ajlm-1628	100	13	ek	ek	PROPN
ajlm-1628	100	14	,	,	PUNCT
ajlm-1628	100	15	lewin	lewin	PROPN
ajlm-1628	100	16	iii	iii	PROPN
ajlm-1628	100	17	jj	jj	PROPN
ajlm-1628	100	18	,	,	PUNCT
ajlm-1628	100	19	mirski	mirski	PROPN
ajlm-1628	100	20	ma	ma	PROPN
ajlm-1628	100	21	.	.	PROPN
ajlm-1628	101	1	antiepileptic	antiepileptic	ADJ
ajlm-1628	101	2	drugs	drug	NOUN
ajlm-1628	101	3	in	in	ADP
ajlm-1628	101	4	clinically	clinically	ADV
ajlm-1628	101	5	ill	ill	ADJ
ajlm-1628	101	6	patients	patient	NOUN
ajlm-1628	101	7	.	.	PUNCT
ajlm-1628	102	1	crit	crit	PROPN
ajlm-1628	102	2	care	care	NOUN
ajlm-1628	102	3	.	.	PUNCT
ajlm-1628	103	1	2018;22(1):153	2018;22(1):153	NUM
ajlm-1628	103	2	.	.	PUNCT
ajlm-1628	104	1	https://doi.org/10.1186/s13054-018-2066-1	https://doi.org/10.1186/s13054-018-2066-1	NOUN
ajlm-1628	104	2	allen	allen	PROPN
ajlm-1628	104	3	b	b	PROPN
ajlm-1628	104	4	,	,	PUNCT
ajlm-1628	104	5	vespa	vespa	PROPN
ajlm-1628	104	6	pm	pm	PROPN
ajlm-1628	104	7	.	.	PUNCT
ajlm-1628	105	1	antiseizure	antiseizure	NOUN
ajlm-1628	105	2	medications	medication	NOUN
ajlm-1628	105	3	in	in	ADP
ajlm-1628	105	4	critical	critical	ADJ
ajlm-1628	105	5	care	care	NOUN
ajlm-1628	105	6	:	:	PUNCT
ajlm-1628	105	7	an	an	DET
ajlm-1628	105	8	update	update	NOUN
ajlm-1628	105	9	.	.	PUNCT
ajlm-1628	106	1	curr	curr	PROPN
ajlm-1628	106	2	opin	opin	PROPN
ajlm-1628	106	3	crit	crit	PROPN
ajlm-1628	106	4	care	care	NOUN
ajlm-1628	106	5	.	.	PUNCT
ajlm-1628	107	1	2019;25(2):117–125	2019;25(2):117–125	X
ajlm-1628	107	2	.	.	PUNCT
ajlm-1628	108	1	https://doi.org/10.1097/mcc.0000000000000587	https://doi.org/10.1097/mcc.0000000000000587	PRON
ajlm-1628	108	2	garnet	garnet	NOUN
ajlm-1628	108	3	wr	wr	PROPN
ajlm-1628	108	4	,	,	PUNCT
ajlm-1628	108	5	anderson	anderson	PROPN
ajlm-1628	108	6	gd	gd	PROPN
ajlm-1628	108	7	,	,	PUNCT
ajlm-1628	108	8	collins	collins	PROPN
ajlm-1628	108	9	rj	rj	PROPN
ajlm-1628	108	10	.	.	PUNCT
ajlm-1628	109	1	antiepileptic	antiepileptic	ADJ
ajlm-1628	109	2	drugs	drug	NOUN
ajlm-1628	109	3	.	.	PUNCT
ajlm-1628	110	1	in	in	ADP
ajlm-1628	110	2	:	:	PUNCT
ajlm-1628	110	3	burton	burton	PROPN
ajlm-1628	110	4	me	me	PROPN
ajlm-1628	110	5	,	,	PUNCT
ajlm-1628	110	6	shaw	shaw	PROPN
ajlm-1628	110	7	lm	lm	PROPN
ajlm-1628	110	8	,	,	PUNCT
ajlm-1628	110	9	schentag	schentag	PROPN
ajlm-1628	110	10	jj	jj	PROPN
ajlm-1628	110	11	,	,	PUNCT
ajlm-1628	110	12	evans	evans	PROPN
ajlm-1628	110	13	we	we	PRON
ajlm-1628	110	14	,	,	PUNCT
ajlm-1628	110	15	editors	editor	NOUN
ajlm-1628	110	16	.	.	PUNCT
ajlm-1628	110	17	applied	apply	VERB
ajlm-1628	110	18	pharmacokinetics	pharmacokinetic	NOUN
ajlm-1628	110	19	&	&	CCONJ
ajlm-1628	110	20	pharmacodynamics	pharmacodynamic	NOUN
ajlm-1628	110	21	:	:	PUNCT
ajlm-1628	110	22	principles	principle	NOUN
ajlm-1628	110	23	of	of	ADP
ajlm-1628	110	24	therapeutic	therapeutic	ADJ
ajlm-1628	110	25	drug	drug	NOUN
ajlm-1628	110	26	monitoring	monitoring	NOUN
ajlm-1628	110	27	.	.	PUNCT
ajlm-1628	111	1	4th	4th	ADJ
ajlm-1628	111	2	ed	ed	NOUN
ajlm-1628	111	3	.	.	PUNCT
ajlm-1628	111	4	philadelphia	philadelphia	PROPN
ajlm-1628	111	5	,	,	PUNCT
ajlm-1628	111	6	pa	pa	PROPN
ajlm-1628	111	7	:	:	PUNCT
ajlm-1628	111	8	lippincott	lippincott	PROPN
ajlm-1628	111	9	williams	williams	PROPN
ajlm-1628	111	10	&	&	CCONJ
ajlm-1628	111	11	wilkins	wilkins	PROPN
ajlm-1628	111	12	;	;	PUNCT
ajlm-1628	111	13	2006	2006	NUM
ajlm-1628	111	14	,	,	PUNCT
ajlm-1628	111	15	pp	pp	ADV
ajlm-1628	111	16	.	.	PUNCT
ajlm-1628	112	1	491–511	491–511	NUM
ajlm-1628	112	2	.	.	PUNCT
ajlm-1628	113	1	winter	winter	NOUN
ajlm-1628	113	2	me	i	PRON
ajlm-1628	113	3	,	,	PUNCT
ajlm-1628	113	4	tozer	tozer	PROPN
ajlm-1628	113	5	tn	tn	PROPN
ajlm-1628	113	6	.	.	PROPN
ajlm-1628	113	7	phenytoin	phenytoin	PROPN
ajlm-1628	113	8	.	.	PUNCT
ajlm-1628	114	1	in	in	ADP
ajlm-1628	114	2	:	:	PUNCT
ajlm-1628	114	3	burton	burton	PROPN
ajlm-1628	114	4	me	me	PROPN
ajlm-1628	114	5	,	,	PUNCT
ajlm-1628	114	6	shaw	shaw	PROPN
ajlm-1628	114	7	lm	lm	PROPN
ajlm-1628	114	8	,	,	PUNCT
ajlm-1628	114	9	schentag	schentag	PROPN
ajlm-1628	114	10	jj	jj	PROPN
ajlm-1628	114	11	,	,	PUNCT
ajlm-1628	114	12	evans	evans	PROPN
ajlm-1628	114	13	we	we	PRON
ajlm-1628	114	14	,	,	PUNCT
ajlm-1628	114	15	editors	editor	NOUN
ajlm-1628	114	16	.	.	PUNCT
ajlm-1628	114	17	applied	apply	VERB
ajlm-1628	114	18	pharmacokinetics	pharmacokinetic	NOUN
ajlm-1628	114	19	&	&	CCONJ
ajlm-1628	114	20	pharmacodynamics	pharmacodynamic	NOUN
ajlm-1628	114	21	:	:	PUNCT
ajlm-1628	114	22	principles	principle	NOUN
ajlm-1628	114	23	of	of	ADP
ajlm-1628	114	24	therapeutic	therapeutic	ADJ
ajlm-1628	114	25	drug	drug	NOUN
ajlm-1628	114	26	monitoring	monitoring	NOUN
ajlm-1628	114	27	.	.	PUNCT
ajlm-1628	115	1	4th	4th	ADJ
ajlm-1628	115	2	ed	ed	NOUN
ajlm-1628	115	3	.	.	PUNCT
ajlm-1628	115	4	philadelphia	philadelphia	PROPN
ajlm-1628	115	5	,	,	PUNCT
ajlm-1628	115	6	pa	pa	PROPN
ajlm-1628	115	7	:	:	PUNCT
ajlm-1628	115	8	lippincott	lippincott	PROPN
ajlm-1628	115	9	williams	williams	PROPN
ajlm-1628	115	10	&	&	CCONJ
ajlm-1628	115	11	wilkins	wilkins	PROPN
ajlm-1628	115	12	;	;	PUNCT
ajlm-1628	115	13	2006	2006	NUM
ajlm-1628	115	14	.	.	PUNCT
ajlm-1628	116	1	pp	pp	X
ajlm-1628	116	2	.	.	PUNCT
ajlm-1628	117	1	463–490	463–490	NUM
ajlm-1628	117	2	.	.	PUNCT
ajlm-1628	117	3	ghodke	ghodke	NOUN
ajlm-1628	117	4	-	-	PUNCT
ajlm-1628	117	5	puranic	puranic	NOUN
ajlm-1628	117	6	y	y	PROPN
ajlm-1628	117	7	,	,	PUNCT
ajlm-1628	117	8	thorn	thorn	NOUN
ajlm-1628	117	9	cf	cf	NOUN
ajlm-1628	117	10	,	,	PUNCT
ajlm-1628	117	11	lamba	lamba	PROPN
ajlm-1628	117	12	jk	jk	PROPN
ajlm-1628	117	13	,	,	PUNCT
ajlm-1628	117	14	et	et	PROPN
ajlm-1628	117	15	al	al	PROPN
ajlm-1628	117	16	.	.	PUNCT
ajlm-1628	117	17	valproic	valproic	ADJ
ajlm-1628	117	18	acid	acid	NOUN
ajlm-1628	117	19	pathways	pathway	NOUN
ajlm-1628	117	20	:	:	PUNCT
ajlm-1628	117	21	pharmacokinetics	pharmacokinetic	NOUN
ajlm-1628	117	22	and	and	CCONJ
ajlm-1628	117	23	pharmacodynamics	pharmacodynamic	NOUN
ajlm-1628	117	24	.	.	PUNCT
ajlm-1628	118	1	pharmacogenet	pharmacogenet	NOUN
ajlm-1628	118	2	genomics	genomic	NOUN
ajlm-1628	118	3	.	.	PUNCT
ajlm-1628	119	1	2013;23(4):236–241	2013;23(4):236–241	X
ajlm-1628	119	2	.	.	PUNCT
ajlm-1628	120	1	https://doi.org/10.1097/fpc.0b013e32835ea0b2	https://doi.org/10.1097/fpc.0b013e32835ea0b2	PROPN
ajlm-1628	120	2	patsalos	patsalos	PROPN
ajlm-1628	120	3	pn	pn	PROPN
ajlm-1628	120	4	,	,	PUNCT
ajlm-1628	120	5	berry	berry	VERB
ajlm-1628	120	6	dj	dj	NOUN
ajlm-1628	120	7	,	,	PUNCT
ajlm-1628	120	8	bourgeois	bourgeois	PROPN
ajlm-1628	120	9	bf	bf	NOUN
ajlm-1628	120	10	,	,	PUNCT
ajlm-1628	120	11	et	et	PROPN
ajlm-1628	120	12	al	al	PROPN
ajlm-1628	120	13	.	.	PUNCT
ajlm-1628	121	1	antiepileptic	antiepileptic	ADJ
ajlm-1628	121	2	drugs	drug	NOUN
ajlm-1628	121	3	–	–	PUNCT
ajlm-1628	121	4	best	good	ADJ
ajlm-1628	121	5	practice	practice	NOUN
ajlm-1628	121	6	guidelines	guideline	NOUN
ajlm-1628	121	7	for	for	ADP
ajlm-1628	121	8	therapeutic	therapeutic	ADJ
ajlm-1628	121	9	drug	drug	NOUN
ajlm-1628	121	10	monitoring	monitoring	NOUN
ajlm-1628	121	11	:	:	PUNCT
ajlm-1628	121	12	a	a	DET
ajlm-1628	121	13	position	position	NOUN
ajlm-1628	121	14	paper	paper	NOUN
ajlm-1628	121	15	by	by	ADP
ajlm-1628	121	16	the	the	DET
ajlm-1628	121	17	subcommission	subcommission	NOUN
ajlm-1628	121	18	on	on	ADP
ajlm-1628	121	19	therapeutic	therapeutic	ADJ
ajlm-1628	121	20	drug	drug	NOUN
ajlm-1628	121	21	monitoring	monitoring	NOUN
ajlm-1628	121	22	,	,	PUNCT
ajlm-1628	121	23	ilae	ilae	NOUN
ajlm-1628	121	24	commission	commission	NOUN
ajlm-1628	121	25	on	on	ADP
ajlm-1628	121	26	therapeutic	therapeutic	ADJ
ajlm-1628	121	27	strategies	strategy	NOUN
ajlm-1628	121	28	.	.	PUNCT
ajlm-1628	122	1	epilepsia	epilepsia	NOUN
ajlm-1628	122	2	.	.	PUNCT
ajlm-1628	123	1	2008;49(7):1239–1276	2008;49(7):1239–1276	NOUN
ajlm-1628	123	2	.	.	PUNCT
ajlm-1628	124	1	https://doi.org/10.1111/j.1528-1167.2008.01561.x	https://doi.org/10.1111/j.1528-1167.2008.01561.x	PROPN
ajlm-1628	124	2	thorn	thorn	NOUN
ajlm-1628	124	3	cf	cf	NOUN
ajlm-1628	124	4	,	,	PUNCT
ajlm-1628	124	5	whirl	whirl	NOUN
ajlm-1628	124	6	-	-	PUNCT
ajlm-1628	124	7	carillo	carillo	PROPN
ajlm-1628	124	8	m	m	PROPN
ajlm-1628	124	9	,	,	PUNCT
ajlm-1628	124	10	leeder	leeder	PROPN
ajlm-1628	124	11	js	js	PROPN
ajlm-1628	124	12	,	,	PUNCT
ajlm-1628	124	13	klein	klein	PROPN
ajlm-1628	124	14	te	te	PROPN
ajlm-1628	124	15	,	,	PUNCT
ajlm-1628	124	16	altman	altman	PROPN
ajlm-1628	124	17	rb	rb	PROPN
ajlm-1628	124	18	.	.	PUNCT
ajlm-1628	125	1	pharmgkb	pharmgkb	PROPN
ajlm-1628	125	2	summary	summary	NOUN
ajlm-1628	125	3	:	:	PUNCT
ajlm-1628	125	4	phenytoin	phenytoin	NOUN
ajlm-1628	125	5	pathway	pathway	NOUN
ajlm-1628	125	6	.	.	PUNCT
ajlm-1628	126	1	pharmacogenet	pharmacogenet	NOUN
ajlm-1628	126	2	genomics	genomic	NOUN
ajlm-1628	126	3	.	.	PUNCT
ajlm-1628	127	1	2012;22(6):466–470	2012;22(6):466–470	X
ajlm-1628	127	2	.	.	PUNCT
ajlm-1628	127	3	https://doi.org/10.1097/fpc.0b013e32834aeedb	https://doi.org/10.1097/fpc.0b013e32834aeedb	PROPN
ajlm-1628	127	4	gomez	gomez	PROPN
ajlm-1628	127	5	bellver	bellver	PROPN
ajlm-1628	127	6	mj	mj	PROPN
ajlm-1628	127	7	,	,	PUNCT
ajlm-1628	127	8	garcia	garcia	PROPN
ajlm-1628	127	9	sanchez	sanchez	PROPN
ajlm-1628	127	10	mj	mj	PROPN
ajlm-1628	127	11	,	,	PUNCT
ajlm-1628	127	12	alonso	alonso	PROPN
ajlm-1628	127	13	gonzales	gonzales	PROPN
ajlm-1628	127	14	ac	ac	PROPN
ajlm-1628	127	15	,	,	PUNCT
ajlm-1628	127	16	santos	santos	PROPN
ajlm-1628	127	17	buelga	buelga	ADP
ajlm-1628	127	18	c	c	PROPN
ajlm-1628	127	19	,	,	PUNCT
ajlm-1628	127	20	dominguez	dominguez	PROPN
ajlm-1628	127	21	-	-	PUNCT
ajlm-1628	127	22	gil	gil	PROPN
ajlm-1628	127	23	a.	a.	NOUN
ajlm-1628	127	24	plasma	plasma	NOUN
ajlm-1628	127	25	protein	protein	NOUN
ajlm-1628	127	26	binding	bind	VERB
ajlm-1628	127	27	kinetics	kinetic	NOUN
ajlm-1628	127	28	of	of	ADP
ajlm-1628	127	29	valproic	valproic	ADJ
ajlm-1628	127	30	acid	acid	NOUN
ajlm-1628	127	31	over	over	ADP
ajlm-1628	127	32	a	a	DET
ajlm-1628	127	33	broad	broad	ADJ
ajlm-1628	127	34	dosage	dosage	NOUN
ajlm-1628	127	35	range	range	NOUN
ajlm-1628	127	36	:	:	PUNCT
ajlm-1628	127	37	therapeutic	therapeutic	ADJ
ajlm-1628	127	38	implications	implication	NOUN
ajlm-1628	127	39	.	.	PUNCT
ajlm-1628	128	1	j	j	PROPN
ajlm-1628	128	2	clin	clin	PROPN
ajlm-1628	128	3	pharm	pharm	PROPN
ajlm-1628	128	4	ther	ther	ADV
ajlm-1628	128	5	.	.	PUNCT
ajlm-1628	129	1	1993;18(3):191–197	1993;18(3):191–197	X
ajlm-1628	129	2	.	.	PUNCT
ajlm-1628	130	1	https://doi.org/10.1111/j.1365-2710.1993.tb00612.x	https://doi.org/10.1111/j.1365-2710.1993.tb00612.x	PROPN
ajlm-1628	130	2	rowland	rowland	PROPN
ajlm-1628	130	3	m.	m.	NOUN
ajlm-1628	130	4	plasma	plasma	NOUN
ajlm-1628	130	5	protein	protein	NOUN
ajlm-1628	130	6	binding	bind	VERB
ajlm-1628	130	7	and	and	CCONJ
ajlm-1628	130	8	therapeutic	therapeutic	ADJ
ajlm-1628	130	9	drug	drug	NOUN
ajlm-1628	130	10	monitoring	monitoring	NOUN
ajlm-1628	130	11	.	.	PUNCT
ajlm-1628	131	1	ther	ther	PROPN
ajlm-1628	131	2	drug	drug	PROPN
ajlm-1628	131	3	monit	monit	PROPN
ajlm-1628	131	4	.	.	PUNCT
ajlm-1628	132	1	1980	1980	NUM
ajlm-1628	132	2	;	;	PUNCT
ajlm-1628	132	3	2(1):29–37	2(1):29–37	NUM
ajlm-1628	132	4	.	.	PUNCT
ajlm-1628	133	1	https://doi.org/10.1097/00007691-198001000-00005	https://doi.org/10.1097/00007691-198001000-00005	PROPN
ajlm-1628	133	2	wiedermann	wiedermann	PROPN
ajlm-1628	133	3	cj	cj	X
ajlm-1628	133	4	.	.	PUNCT
ajlm-1628	134	1	hypoalbuminemia	hypoalbuminemia	PROPN
ajlm-1628	134	2	as	as	ADP
ajlm-1628	134	3	surrogate	surrogate	ADJ
ajlm-1628	134	4	and	and	CCONJ
ajlm-1628	134	5	culprit	culprit	NOUN
ajlm-1628	134	6	of	of	ADP
ajlm-1628	134	7	infections	infection	NOUN
ajlm-1628	134	8	.	.	PUNCT
ajlm-1628	135	1	int	int	PROPN
ajlm-1628	135	2	j	j	PROPN
ajlm-1628	135	3	mol	mol	ADP
ajlm-1628	135	4	sci	sci	PROPN
ajlm-1628	135	5	.	.	PUNCT
ajlm-1628	136	1	2021;22(9):4496	2021;22(9):4496	PROPN
ajlm-1628	136	2	.	.	PUNCT
ajlm-1628	137	1	https://doi.org/10.3390/ijms22094496	https://doi.org/10.3390/ijms22094496	PROPN
ajlm-1628	137	2	von	von	PROPN
ajlm-1628	137	3	winckelmann	winckelmann	PROPN
ajlm-1628	137	4	sl	sl	PROPN
ajlm-1628	137	5	,	,	PUNCT
ajlm-1628	137	6	spriet	spriet	PROPN
ajlm-1628	137	7	i	i	PROPN
ajlm-1628	137	8	,	,	PUNCT
ajlm-1628	137	9	willems	willems	PROPN
ajlm-1628	137	10	l.	l.	PROPN
ajlm-1628	138	1	therapeutic	therapeutic	ADJ
ajlm-1628	138	2	drug	drug	NOUN
ajlm-1628	138	3	monitoring	monitoring	NOUN
ajlm-1628	138	4	of	of	ADP
ajlm-1628	138	5	phenytoin	phenytoin	NOUN
ajlm-1628	138	6	in	in	ADP
ajlm-1628	138	7	critically	critically	ADV
ajlm-1628	138	8	ill	ill	ADJ
ajlm-1628	138	9	patients	patient	NOUN
ajlm-1628	138	10	.	.	PUNCT
ajlm-1628	139	1	pharmacotherapy	pharmacotherapy	NOUN
ajlm-1628	139	2	.	.	PUNCT
ajlm-1628	140	1	2008;28(11):1391–1400	2008;28(11):1391–1400	X
ajlm-1628	140	2	.	.	PUNCT
ajlm-1628	141	1	https://doi.org/10.1592/phco.28.11.1391	https://doi.org/10.1592/phco.28.11.1391	PROPN
ajlm-1628	141	2	riker	riker	PROPN
ajlm-1628	141	3	rr	rr	PROPN
ajlm-1628	141	4	,	,	PUNCT
ajlm-1628	141	5	gagnon	gagnon	PROPN
ajlm-1628	141	6	dj	dj	PROPN
ajlm-1628	141	7	,	,	PUNCT
ajlm-1628	141	8	hatton	hatton	PROPN
ajlm-1628	141	9	c	c	AUX
ajlm-1628	141	10	,	,	PUNCT
ajlm-1628	141	11	et	et	PROPN
ajlm-1628	141	12	al	al	PROPN
ajlm-1628	141	13	.	.	PUNCT
ajlm-1628	142	1	valproate	valproate	ADJ
ajlm-1628	142	2	protein	protein	NOUN
ajlm-1628	142	3	binding	bind	VERB
ajlm-1628	142	4	is	be	AUX
ajlm-1628	142	5	highly	highly	ADV
ajlm-1628	142	6	variable	variable	ADJ
ajlm-1628	142	7	in	in	ADP
ajlm-1628	142	8	icu	icu	PROPN
ajlm-1628	142	9	patients	patient	NOUN
ajlm-1628	142	10	and	and	CCONJ
ajlm-1628	142	11	not	not	PART
ajlm-1628	142	12	predicted	predict	VERB
ajlm-1628	142	13	by	by	ADP
ajlm-1628	142	14	total	total	ADJ
ajlm-1628	142	15	serum	serum	NOUN
ajlm-1628	142	16	concentrations	concentration	NOUN
ajlm-1628	142	17	:	:	PUNCT
ajlm-1628	142	18	a	a	DET
ajlm-1628	142	19	case	case	NOUN
ajlm-1628	142	20	series	series	NOUN
ajlm-1628	142	21	and	and	CCONJ
ajlm-1628	142	22	literature	literature	PROPN
ajlm-1628	142	23	review	review	PROPN
ajlm-1628	142	24	.	.	PUNCT
ajlm-1628	143	1	pharmacotherapy	pharmacotherapy	NOUN
ajlm-1628	143	2	.	.	PUNCT
ajlm-1628	144	1	2017;37(4):500–508	2017;37(4):500–508	NUM
ajlm-1628	144	2	.	.	NOUN
ajlm-1628	144	3	https://doi.org/10.1002/phar.1912	https://doi.org/10.1002/phar.1912	NOUN
ajlm-1628	144	4	perucca	perucca	NOUN
ajlm-1628	144	5	e.	e.	PROPN
ajlm-1628	144	6	plasma	plasma	PROPN
ajlm-1628	144	7	protein	protein	NOUN
ajlm-1628	144	8	binding	bind	VERB
ajlm-1628	144	9	of	of	ADP
ajlm-1628	144	10	phenytoin	phenytoin	NOUN
ajlm-1628	144	11	in	in	ADP
ajlm-1628	144	12	health	health	NOUN
ajlm-1628	144	13	and	and	CCONJ
ajlm-1628	144	14	disease	disease	NOUN
ajlm-1628	144	15	:	:	PUNCT
ajlm-1628	144	16	relevance	relevance	NOUN
ajlm-1628	144	17	to	to	ADP
ajlm-1628	144	18	therapeutic	therapeutic	ADJ
ajlm-1628	144	19	drug	drug	NOUN
ajlm-1628	144	20	monitoring	monitoring	NOUN
ajlm-1628	144	21	.	.	PUNCT
ajlm-1628	145	1	ther	ther	PROPN
ajlm-1628	145	2	drug	drug	PROPN
ajlm-1628	145	3	monit	monit	PROPN
ajlm-1628	145	4	.	.	PUNCT
ajlm-1628	146	1	1980;2(4):331344	1980;2(4):331344	X
ajlm-1628	146	2	.	.	PUNCT
ajlm-1628	147	1	https://doi.org/10.1097/00007691-198010000-00005	https://doi.org/10.1097/00007691-198010000-00005	PROPN
ajlm-1628	147	2	hatton	hatton	PROPN
ajlm-1628	147	3	c	c	PROPN
ajlm-1628	147	4	,	,	PUNCT
ajlm-1628	147	5	riker	riker	PROPN
ajlm-1628	147	6	rr	rr	PROPN
ajlm-1628	147	7	,	,	PUNCT
ajlm-1628	147	8	gagnon	gagnon	PROPN
ajlm-1628	147	9	dj	dj	PROPN
ajlm-1628	147	10	,	,	PUNCT
ajlm-1628	147	11	may	may	PROPN
ajlm-1628	147	12	t	t	PROPN
ajlm-1628	147	13	,	,	PUNCT
ajlm-1628	147	14	seder	seder	NOUN
ajlm-1628	147	15	db	db	PROPN
ajlm-1628	147	16	,	,	PUNCT
ajlm-1628	147	17	fraser	fraser	PROPN
ajlm-1628	147	18	gl	gl	PROPN
ajlm-1628	147	19	.	.	PROPN
ajlm-1628	147	20	free	free	PROPN
ajlm-1628	147	21	serum	serum	PROPN
ajlm-1628	147	22	valproate	valproate	ADJ
ajlm-1628	147	23	concentration	concentration	NOUN
ajlm-1628	147	24	more	more	ADV
ajlm-1628	147	25	reliable	reliable	ADJ
ajlm-1628	147	26	than	than	ADP
ajlm-1628	147	27	total	total	ADJ
ajlm-1628	147	28	concentration	concentration	NOUN
ajlm-1628	147	29	in	in	ADP
ajlm-1628	147	30	critically	critically	ADV
ajlm-1628	147	31	ill	ill	ADJ
ajlm-1628	147	32	patients	patient	NOUN
ajlm-1628	147	33	.	.	PUNCT
ajlm-1628	148	1	resuscitation	resuscitation	NOUN
ajlm-1628	148	2	.	.	PUNCT
ajlm-1628	149	1	2016;10	2016;10	NOUN
ajlm-1628	149	2	:	:	PUNCT
ajlm-1628	149	3	e15e16	e15e16	ADJ
ajlm-1628	149	4	.	.	PUNCT
ajlm-1628	150	1	https://doi.org/10.1016/j.resuscitation.2016.05.027	https://doi.org/10.1016/j.resuscitation.2016.05.027	PROPN
ajlm-1628	150	2	heuberger	heuberger	PROPN
ajlm-1628	150	3	j	j	PROPN
ajlm-1628	150	4	,	,	PUNCT
ajlm-1628	150	5	schmidt	schmidt	PROPN
ajlm-1628	150	6	s	s	PROPN
ajlm-1628	150	7	,	,	PUNCT
ajlm-1628	150	8	derendorf	derendorf	PROPN
ajlm-1628	150	9	h.	h.	PROPN
ajlm-1628	150	10	when	when	SCONJ
ajlm-1628	150	11	is	be	AUX
ajlm-1628	150	12	protein	protein	NOUN
ajlm-1628	150	13	binding	bind	VERB
ajlm-1628	150	14	important	important	ADJ
ajlm-1628	150	15	?	?	PUNCT
ajlm-1628	151	1	j	j	PROPN
ajlm-1628	151	2	pharm	pharm	PROPN
ajlm-1628	151	3	sci	sci	PROPN
ajlm-1628	151	4	.	.	PUNCT
ajlm-1628	152	1	2013;102(9):3458–3467	2013;102(9):3458–3467	NUM
ajlm-1628	152	2	.	.	PUNCT
ajlm-1628	153	1	https://doi.org/10.1002/jps.23559	https://doi.org/10.1002/jps.23559	PROPN
ajlm-1628	153	2	lenn	lenn	PROPN
ajlm-1628	153	3	nj	nj	PROPN
ajlm-1628	153	4	,	,	PUNCT
ajlm-1628	153	5	robertson	robertson	PROPN
ajlm-1628	153	6	m.	m.	PROPN
ajlm-1628	153	7	clinical	clinical	ADJ
ajlm-1628	153	8	utility	utility	NOUN
ajlm-1628	153	9	of	of	ADP
ajlm-1628	153	10	unbound	unbound	ADJ
ajlm-1628	153	11	antiepileptic	antiepileptic	ADJ
ajlm-1628	153	12	drug	drug	NOUN
ajlm-1628	153	13	blood	blood	NOUN
ajlm-1628	153	14	levels	level	NOUN
ajlm-1628	153	15	in	in	ADP
ajlm-1628	153	16	the	the	DET
ajlm-1628	153	17	management	management	NOUN
ajlm-1628	153	18	of	of	ADP
ajlm-1628	153	19	epilepsy	epilepsy	PROPN
ajlm-1628	153	20	.	.	PUNCT
ajlm-1628	154	1	neurology	neurology	NOUN
ajlm-1628	154	2	.	.	PUNCT
ajlm-1628	155	1	1992;42(5):988–990	1992;42(5):988–990	NUM
ajlm-1628	155	2	.	.	PUNCT
ajlm-1628	156	1	https://doi.org/10.1212/wnl.42.5.988	https://doi.org/10.1212/wnl.42.5.988	NOUN
ajlm-1628	156	2	parent	parent	NOUN
ajlm-1628	156	3	x	x	NOUN
ajlm-1628	156	4	,	,	PUNCT
ajlm-1628	156	5	marzullo	marzullo	PROPN
ajlm-1628	156	6	c	c	PROPN
ajlm-1628	156	7	,	,	PUNCT
ajlm-1628	156	8	gutbub	gutbub	PROPN
ajlm-1628	156	9	am	be	AUX
ajlm-1628	156	10	.	.	PUNCT
ajlm-1628	157	1	acide	acide	PROPN
ajlm-1628	157	2	valproique	valproique	NOUN
ajlm-1628	157	3	:	:	PUNCT
ajlm-1628	157	4	estimation	estimation	NOUN
ajlm-1628	157	5	simple	simple	ADJ
ajlm-1628	157	6	de	de	X
ajlm-1628	157	7	la	la	X
ajlm-1628	157	8	concentration	concentration	NOUN
ajlm-1628	157	9	sérique	sérique	ADJ
ajlm-1628	157	10	libre	libre	PROPN
ajlm-1628	157	11	.	.	PUNCT
ajlm-1628	158	1	ann	ann	PROPN
ajlm-1628	158	2	biol	biol	PROPN
ajlm-1628	158	3	clin	clin	PROPN
ajlm-1628	158	4	(	(	PUNCT
ajlm-1628	158	5	paris	paris	PROPN
ajlm-1628	158	6	)	)	PUNCT
ajlm-1628	158	7	.	.	PUNCT
ajlm-1628	159	1	1993;51(6):649–650	1993;51(6):649–650	X
ajlm-1628	159	2	.	.	PUNCT
ajlm-1628	159	3	hermida	hermida	PROPN
ajlm-1628	159	4	j	j	PROPN
ajlm-1628	159	5	,	,	PUNCT
ajlm-1628	159	6	tutor	tutor	PROPN
ajlm-1628	159	7	jc	jc	PROPN
ajlm-1628	159	8	.	.	PUNCT
ajlm-1628	160	1	a	a	DET
ajlm-1628	160	2	theoretical	theoretical	ADJ
ajlm-1628	160	3	method	method	NOUN
ajlm-1628	160	4	for	for	ADP
ajlm-1628	160	5	normalising	normalise	VERB
ajlm-1628	160	6	total	total	ADJ
ajlm-1628	160	7	serum	serum	NOUN
ajlm-1628	160	8	valproic	valproic	ADJ
ajlm-1628	160	9	acid	acid	NOUN
ajlm-1628	160	10	concentration	concentration	NOUN
ajlm-1628	160	11	in	in	ADP
ajlm-1628	160	12	hypoalbuminemic	hypoalbuminemic	ADJ
ajlm-1628	160	13	patients	patient	NOUN
ajlm-1628	160	14	.	.	PUNCT
ajlm-1628	161	1	j	j	PROPN
ajlm-1628	161	2	pharmacol	pharmacol	PROPN
ajlm-1628	161	3	sci	sci	PROPN
ajlm-1628	161	4	.	.	PUNCT
ajlm-1628	162	1	2005;97(4):489–493	2005;97(4):489–493	NUM
ajlm-1628	162	2	.	.	PUNCT
ajlm-1628	163	1	https://doi.org/10.1254/jphs.fpe04007x	https://doi.org/10.1254/jphs.fpe04007x	PROPN
ajlm-1628	163	2	sheiner	sheiner	PROPN
ajlm-1628	163	3	lb	lb	PROPN
ajlm-1628	163	4	,	,	PUNCT
ajlm-1628	163	5	tozer	tozer	PROPN
ajlm-1628	163	6	tn	tn	PROPN
ajlm-1628	163	7	.	.	PUNCT
ajlm-1628	164	1	clinical	clinical	ADJ
ajlm-1628	164	2	pharmacokinetics	pharmacokinetic	NOUN
ajlm-1628	164	3	:	:	PUNCT
ajlm-1628	164	4	the	the	DET
ajlm-1628	164	5	use	use	NOUN
ajlm-1628	164	6	of	of	ADP
ajlm-1628	164	7	plasma	plasma	NOUN
ajlm-1628	164	8	concentrations	concentration	NOUN
ajlm-1628	164	9	.	.	PUNCT
ajlm-1628	165	1	in	in	ADP
ajlm-1628	165	2	:	:	PUNCT
ajlm-1628	165	3	melmon	melmon	PROPN
ajlm-1628	165	4	kl	kl	PROPN
ajlm-1628	165	5	,	,	PUNCT
ajlm-1628	165	6	morelli	morelli	PROPN
ajlm-1628	165	7	hf	hf	NOUN
ajlm-1628	165	8	,	,	PUNCT
ajlm-1628	165	9	editors	editor	NOUN
ajlm-1628	165	10	.	.	PUNCT
ajlm-1628	166	1	clinical	clinical	ADJ
ajlm-1628	166	2	pharmacology	pharmacology	NOUN
ajlm-1628	166	3	:	:	PUNCT
ajlm-1628	166	4	basic	basic	ADJ
ajlm-1628	166	5	principles	principle	NOUN
ajlm-1628	166	6	in	in	ADP
ajlm-1628	166	7	therapeutics	therapeutic	NOUN
ajlm-1628	166	8	.	.	PUNCT
ajlm-1628	167	1	new	new	PROPN
ajlm-1628	167	2	york	york	PROPN
ajlm-1628	167	3	,	,	PUNCT
ajlm-1628	167	4	ny	ny	PROPN
ajlm-1628	167	5	:	:	PUNCT
ajlm-1628	167	6	macmillan	macmillan	PROPN
ajlm-1628	167	7	;	;	PUNCT
ajlm-1628	167	8	1978	1978	NUM
ajlm-1628	167	9	,	,	PUNCT
ajlm-1628	167	10	p.	p.	NOUN
ajlm-1628	167	11	1978	1978	NUM
ajlm-1628	167	12	.	.	PUNCT
ajlm-1628	168	1	anderson	anderson	PROPN
ajlm-1628	168	2	gd	gd	PROPN
ajlm-1628	168	3	,	,	PUNCT
ajlm-1628	168	4	pak	pak	PROPN
ajlm-1628	168	5	c	c	PROPN
ajlm-1628	168	6	,	,	PUNCT
ajlm-1628	168	7	doane	doane	PROPN
ajlm-1628	168	8	kw	kw	PROPN
ajlm-1628	168	9	,	,	PUNCT
ajlm-1628	168	10	et	et	PROPN
ajlm-1628	168	11	al	al	PROPN
ajlm-1628	168	12	.	.	PROPN
ajlm-1628	168	13	revised	revise	VERB
ajlm-1628	168	14	winter	winter	NOUN
ajlm-1628	168	15	-	-	PUNCT
ajlm-1628	168	16	tozer	tozer	PROPN
ajlm-1628	168	17	equation	equation	NOUN
ajlm-1628	168	18	for	for	ADP
ajlm-1628	168	19	normalised	normalise	VERB
ajlm-1628	168	20	phenytoin	phenytoin	ADJ
ajlm-1628	168	21	concentrations	concentration	NOUN
ajlm-1628	168	22	in	in	ADP
ajlm-1628	168	23	trauma	trauma	NOUN
ajlm-1628	168	24	and	and	CCONJ
ajlm-1628	168	25	elderly	elderly	ADJ
ajlm-1628	168	26	patients	patient	NOUN
ajlm-1628	168	27	with	with	ADP
ajlm-1628	168	28	hypoalbuminemia	hypoalbuminemia	NOUN
ajlm-1628	168	29	.	.	PUNCT
ajlm-1628	169	1	ann	ann	PROPN
ajlm-1628	169	2	pharmacother	pharmacother	PROPN
ajlm-1628	169	3	.	.	PUNCT
ajlm-1628	170	1	1997;31(3):279–284	1997;31(3):279–284	NUM
ajlm-1628	170	2	.	.	PUNCT
ajlm-1628	171	1	https://doi.org/10.1177/106002809703100301	https://doi.org/10.1177/106002809703100301	PROPN
ajlm-1628	171	2	kane	kane	PROPN
ajlm-1628	171	3	sp	sp	PROPN
ajlm-1628	171	4	,	,	PUNCT
ajlm-1628	171	5	bress	bress	NOUN
ajlm-1628	171	6	ap	ap	PROPN
ajlm-1628	171	7	,	,	PUNCT
ajlm-1628	171	8	tesoro	tesoro	PROPN
ajlm-1628	171	9	ep	ep	PROPN
ajlm-1628	171	10	.	.	PUNCT
ajlm-1628	172	1	characterisation	characterisation	NOUN
ajlm-1628	172	2	of	of	ADP
ajlm-1628	172	3	unbound	unbound	ADJ
ajlm-1628	172	4	phenytoin	phenytoin	NOUN
ajlm-1628	172	5	concentrations	concentration	NOUN
ajlm-1628	172	6	in	in	ADP
ajlm-1628	172	7	neurointensive	neurointensive	ADJ
ajlm-1628	172	8	care	care	NOUN
ajlm-1628	172	9	unit	unit	NOUN
ajlm-1628	172	10	patients	patient	NOUN
ajlm-1628	172	11	using	use	VERB
ajlm-1628	172	12	a	a	DET
ajlm-1628	172	13	revised	revise	VERB
ajlm-1628	172	14	winter	winter	NOUN
ajlm-1628	172	15	-	-	PUNCT
ajlm-1628	172	16	tozer	tozer	PROPN
ajlm-1628	172	17	equation	equation	NOUN
ajlm-1628	172	18	.	.	PUNCT
ajlm-1628	173	1	ann	ann	PROPN
ajlm-1628	173	2	pharmacother	pharmacother	PROPN
ajlm-1628	173	3	.	.	PUNCT
ajlm-1628	174	1	2013;47(5):628–636	2013;47(5):628–636	X
ajlm-1628	174	2	.	.	PUNCT
ajlm-1628	175	1	https://doi.org/10.1345/aph.1r651	https://doi.org/10.1345/aph.1r651	ADP
ajlm-1628	175	2	noval	noval	NOUN
ajlm-1628	175	3	m	m	PROPN
ajlm-1628	175	4	,	,	PUNCT
ajlm-1628	175	5	seung	seung	PROPN
ajlm-1628	175	6	h	h	PROPN
ajlm-1628	175	7	,	,	PUNCT
ajlm-1628	175	8	armahizer	armahizer	NOUN
ajlm-1628	175	9	m.	m.	NOUN
ajlm-1628	175	10	evaluation	evaluation	NOUN
ajlm-1628	175	11	of	of	ADP
ajlm-1628	175	12	fosphenytoin	fosphenytoin	ADJ
ajlm-1628	175	13	therapeutic	therapeutic	ADJ
ajlm-1628	175	14	drug	drug	NOUN
ajlm-1628	175	15	monitoring	monitoring	NOUN
ajlm-1628	175	16	in	in	ADP
ajlm-1628	175	17	the	the	DET
ajlm-1628	175	18	neurocritical	neurocritical	ADJ
ajlm-1628	175	19	care	care	NOUN
ajlm-1628	175	20	unit	unit	NOUN
ajlm-1628	175	21	.	.	PUNCT
ajlm-1628	176	1	drugs	drug	NOUN
ajlm-1628	176	2	r	r	PROPN
ajlm-1628	176	3	d.	d.	PROPN
ajlm-1628	176	4	2020;20(1):17–22	2020;20(1):17–22	PROPN
ajlm-1628	176	5	.	.	PUNCT
ajlm-1628	177	1	https://doi.org/10.1007/s40268-019-00292-1	https://doi.org/10.1007/s40268-019-00292-1	PROPN
ajlm-1628	178	1	lagneau	lagneau	PROPN
ajlm-1628	179	1	f	f	PROPN
ajlm-1628	179	2	,	,	PUNCT
ajlm-1628	179	3	perbet	perbet	PROPN
ajlm-1628	179	4	s	s	PROPN
ajlm-1628	179	5	,	,	PUNCT
ajlm-1628	180	1	delefosse	delefosse	PROPN
ajlm-1628	180	2	d	d	NOUN
ajlm-1628	180	3	,	,	PUNCT
ajlm-1628	180	4	et	et	PROPN
ajlm-1628	180	5	al	al	PROPN
ajlm-1628	180	6	.	.	PUNCT
ajlm-1628	181	1	drugs	drug	NOUN
ajlm-1628	181	2	pharmacokinetics	pharmacokinetic	NOUN
ajlm-1628	181	3	in	in	ADP
ajlm-1628	181	4	icu	icu	PROPN
ajlm-1628	181	5	patients	patient	NOUN
ajlm-1628	181	6	:	:	PUNCT
ajlm-1628	181	7	consequences	consequence	NOUN
ajlm-1628	181	8	of	of	ADP
ajlm-1628	181	9	hypoalbuminemia	hypoalbuminemia	NOUN
ajlm-1628	181	10	upon	upon	SCONJ
ajlm-1628	181	11	drugs	drug	NOUN
ajlm-1628	181	12	monitoring	monitor	VERB
ajlm-1628	181	13	and	and	CCONJ
ajlm-1628	181	14	dosing	dose	VERB
ajlm-1628	181	15	scheme	scheme	NOUN
ajlm-1628	181	16	.	.	PUNCT
ajlm-1628	182	1	intensive	intensive	ADJ
ajlm-1628	182	2	care	care	NOUN
ajlm-1628	182	3	med	med	PROPN
ajlm-1628	182	4	2004;30:1247	2004;30:1247	NUM
ajlm-1628	182	5	.	.	PROPN
ajlm-1628	182	6	https://doi.org/10.1007/s00134-004-2313-6	https://doi.org/10.1007/s00134-004-2313-6	PROPN
ajlm-1628	183	1	smetana	smetana	PROPN
ajlm-1628	183	2	ks	ks	PROPN
ajlm-1628	183	3	,	,	PUNCT
ajlm-1628	183	4	cook	cook	NOUN
ajlm-1628	183	5	am	am	NOUN
ajlm-1628	183	6	,	,	PUNCT
ajlm-1628	183	7	thompson	thompson	PROPN
ajlm-1628	183	8	bastin	bastin	PROPN
ajlm-1628	183	9	ml	ml	PROPN
ajlm-1628	183	10	,	,	PUNCT
ajlm-1628	183	11	oyler	oyler	PROPN
ajlm-1628	183	12	dr	dr	PROPN
ajlm-1628	183	13	.	.	PROPN
ajlm-1628	183	14	antiepileptic	antiepileptic	PROPN
ajlm-1628	183	15	dosing	dose	VERB
ajlm-1628	183	16	for	for	ADP
ajlm-1628	183	17	critically	critically	ADV
ajlm-1628	183	18	ill	ill	ADJ
ajlm-1628	183	19	adult	adult	NOUN
ajlm-1628	183	20	patients	patient	NOUN
ajlm-1628	183	21	receiving	receive	VERB
ajlm-1628	183	22	renal	renal	ADJ
ajlm-1628	183	23	replacement	replacement	NOUN
ajlm-1628	183	24	therapy	therapy	NOUN
ajlm-1628	183	25	.	.	PUNCT
ajlm-1628	184	1	j	j	PROPN
ajlm-1628	184	2	crit	crit	PROPN
ajlm-1628	184	3	care	care	PROPN
ajlm-1628	184	4	.	.	PUNCT
ajlm-1628	185	1	2016;36:116–124	2016;36:116–124	X
ajlm-1628	185	2	.	.	PUNCT
ajlm-1628	186	1	https://doi.org/10.1016/j.jcrc.2016.06.023	https://doi.org/10.1016/j.jcrc.2016.06.023	NUM
ajlm-1628	186	2	wolf	wolf	PROPN
ajlm-1628	186	3	gh	gh	PROPN
ajlm-1628	186	4	,	,	PUNCT
ajlm-1628	186	5	mcclain	mcclain	PROPN
ajlm-1628	186	6	cd	cd	PROPN
ajlm-1628	186	7	,	,	PUNCT
ajlm-1628	186	8	zurakowski	zurakowski	PROPN
ajlm-1628	186	9	d	d	PROPN
ajlm-1628	186	10	,	,	PUNCT
ajlm-1628	186	11	dodson	dodson	PROPN
ajlm-1628	186	12	b	b	PROPN
ajlm-1628	186	13	,	,	PUNCT
ajlm-1628	186	14	mcmanus	mcmanus	PROPN
ajlm-1628	186	15	ml	ml	PROPN
ajlm-1628	186	16	.	.	PUNCT
ajlm-1628	186	17	total	total	ADJ
ajlm-1628	186	18	phenytoin	phenytoin	NOUN
ajlm-1628	186	19	concentrations	concentration	NOUN
ajlm-1628	186	20	do	do	AUX
ajlm-1628	186	21	not	not	PART
ajlm-1628	186	22	accurately	accurately	ADV
ajlm-1628	186	23	predict	predict	VERB
ajlm-1628	186	24	free	free	ADJ
ajlm-1628	186	25	phenytoin	phenytoin	ADJ
ajlm-1628	186	26	concentrations	concentration	NOUN
ajlm-1628	186	27	in	in	ADP
ajlm-1628	186	28	critically	critically	ADV
ajlm-1628	186	29	ill	ill	ADJ
ajlm-1628	186	30	children	child	NOUN
ajlm-1628	186	31	.	.	PUNCT
ajlm-1628	187	1	pediatr	pediatr	PROPN
ajlm-1628	187	2	crit	crit	PROPN
ajlm-1628	187	3	care	care	PROPN
ajlm-1628	187	4	med	me	VERB
ajlm-1628	187	5	.	.	PUNCT
ajlm-1628	188	1	2006;7(5):434–439	2006;7(5):434–439	X
ajlm-1628	188	2	.	.	PUNCT
ajlm-1628	188	3	https://doi.org/10.1097/01.pcc.0000235252.43921.de	https://doi.org/10.1097/01.pcc.0000235252.43921.de	PROPN
ajlm-1628	188	4	cheng	cheng	PROPN
ajlm-1628	188	5	w	w	PROPN
ajlm-1628	188	6	,	,	PUNCT
ajlm-1628	188	7	kiang	kiang	PROPN
ajlm-1628	188	8	tkl	tkl	PROPN
ajlm-1628	188	9	,	,	PUNCT
ajlm-1628	188	10	bring	bring	VERB
ajlm-1628	188	11	p	p	PRON
ajlm-1628	188	12	,	,	PUNCT
ajlm-1628	188	13	ensom	ensom	NOUN
ajlm-1628	188	14	mhh	mhh	PROPN
ajlm-1628	188	15	.	.	PUNCT
ajlm-1628	189	1	predictive	predictive	ADJ
ajlm-1628	189	2	performance	performance	NOUN
ajlm-1628	189	3	of	of	ADP
ajlm-1628	189	4	the	the	DET
ajlm-1628	189	5	winter	winter	NOUN
ajlm-1628	189	6	-	-	PUNCT
ajlm-1628	189	7	tozer	tozer	PROPN
ajlm-1628	189	8	and	and	CCONJ
ajlm-1628	189	9	derivative	derivative	ADJ
ajlm-1628	189	10	equations	equation	NOUN
ajlm-1628	189	11	for	for	ADP
ajlm-1628	189	12	estimating	estimate	VERB
ajlm-1628	189	13	free	free	ADJ
ajlm-1628	189	14	phenytoin	phenytoin	NOUN
ajlm-1628	189	15	concentration	concentration	NOUN
ajlm-1628	189	16	.	.	PUNCT
ajlm-1628	190	1	can	can	AUX
ajlm-1628	190	2	j	j	PROPN
ajlm-1628	190	3	hosp	hosp	PROPN
ajlm-1628	190	4	pharm	pharm	PROPN
ajlm-1628	190	5	.	.	PUNCT
ajlm-1628	191	1	2016;69(4):269–279	2016;69(4):269–279	NUM
ajlm-1628	191	2	.	.	PROPN
ajlm-1628	192	1	https://doi.org/10.4212/cjhp.v69i4.1573	https://doi.org/10.4212/cjhp.v69i4.1573	VERB
ajlm-1628	192	2	kiang	kiang	PROPN
ajlm-1628	192	3	tkl	tkl	PROPN
ajlm-1628	192	4	,	,	PUNCT
ajlm-1628	192	5	ensom	ensom	PROPN
ajlm-1628	192	6	mhh	mhh	PROPN
ajlm-1628	192	7	.	.	PUNCT
ajlm-1628	193	1	a	a	DET
ajlm-1628	193	2	comprehensive	comprehensive	ADJ
ajlm-1628	193	3	review	review	NOUN
ajlm-1628	193	4	of	of	ADP
ajlm-1628	193	5	the	the	DET
ajlm-1628	193	6	predictive	predictive	ADJ
ajlm-1628	193	7	performance	performance	NOUN
ajlm-1628	193	8	of	of	ADP
ajlm-1628	193	9	the	the	DET
ajlm-1628	193	10	sheiner	sheiner	NOUN
ajlm-1628	193	11	-	-	PUNCT
ajlm-1628	193	12	tozer	tozer	PROPN
ajlm-1628	193	13	and	and	CCONJ
ajlm-1628	193	14	derivative	derivative	ADJ
ajlm-1628	193	15	equations	equation	NOUN
ajlm-1628	193	16	for	for	ADP
ajlm-1628	193	17	the	the	DET
ajlm-1628	193	18	correction	correction	NOUN
ajlm-1628	193	19	of	of	ADP
ajlm-1628	193	20	phenytoin	phenytoin	ADJ
ajlm-1628	193	21	concentrations	concentration	NOUN
ajlm-1628	193	22	.	.	PUNCT
ajlm-1628	194	1	ann	ann	PROPN
ajlm-1628	194	2	pharmacother	pharmacother	PROPN
ajlm-1628	194	3	.	.	PUNCT
ajlm-1628	195	1	2016;50(4):311–325	2016;50(4):311–325	NUM
ajlm-1628	195	2	.	.	PUNCT
ajlm-1628	196	1	https://doi.org/10.1177/1060028016628166	https://doi.org/10.1177/1060028016628166	AUX
ajlm-1628	196	2	javadi	javadi	VERB
ajlm-1628	196	3	s	s	PROPN
ajlm-1628	196	4	-	-	PUNCT
ajlm-1628	196	5	s	s	NOUN
ajlm-1628	196	6	,	,	PUNCT
ajlm-1628	196	7	mahjub	mahjub	ADJ
ajlm-1628	196	8	r	r	NOUN
ajlm-1628	196	9	,	,	PUNCT
ajlm-1628	196	10	taher	taher	PROPN
ajlm-1628	196	11	a	a	PRON
ajlm-1628	196	12	,	,	PUNCT
ajlm-1628	196	13	mohammadi	mohammadi	PROPN
ajlm-1628	196	14	y	y	PROPN
ajlm-1628	196	15	,	,	PUNCT
ajlm-1628	196	16	mehrpooya	mehrpooya	PROPN
ajlm-1628	196	17	m.	m.	NOUN
ajlm-1628	196	18	correlation	correlation	NOUN
ajlm-1628	196	19	between	between	ADP
ajlm-1628	196	20	measured	measure	VERB
ajlm-1628	196	21	and	and	CCONJ
ajlm-1628	196	22	calculated	calculate	VERB
ajlm-1628	196	23	free	free	ADJ
ajlm-1628	196	24	phenytoin	phenytoin	NOUN
ajlm-1628	196	25	serum	serum	NOUN
ajlm-1628	196	26	concentration	concentration	NOUN
ajlm-1628	196	27	in	in	ADP
ajlm-1628	196	28	neurointensive	neurointensive	ADJ
ajlm-1628	196	29	care	care	NOUN
ajlm-1628	196	30	patients	patient	NOUN
ajlm-1628	196	31	with	with	ADP
ajlm-1628	196	32	hypoalbuminemia	hypoalbuminemia	NOUN
ajlm-1628	196	33	.	.	PUNCT
ajlm-1628	197	1	clin	clin	PROPN
ajlm-1628	197	2	pharmacol	pharmacol	PROPN
ajlm-1628	197	3	.	.	PUNCT
ajlm-1628	198	1	2018;10:183–190	2018;10:183–190	NOUN
ajlm-1628	198	2	.	.	PUNCT
ajlm-1628	199	1	https://doi.org/10.2147/cpaa.s186322	https://doi.org/10.2147/cpaa.s186322	PROPN
ajlm-1628	199	2	barra	barra	VERB
ajlm-1628	199	3	me	i	PRON
ajlm-1628	199	4	,	,	PUNCT
ajlm-1628	199	5	phillips	phillips	PROPN
ajlm-1628	199	6	km	km	PROPN
ajlm-1628	199	7	,	,	PUNCT
ajlm-1628	199	8	chung	chung	PROPN
ajlm-1628	199	9	dy	dy	PROPN
ajlm-1628	199	10	,	,	PUNCT
ajlm-1628	199	11	rosenthal	rosenthal	PROPN
ajlm-1628	199	12	es	es	PROPN
ajlm-1628	199	13	.	.	PUNCT
ajlm-1628	200	1	a	a	DET
ajlm-1628	200	2	novel	novel	ADJ
ajlm-1628	200	3	correction	correction	NOUN
ajlm-1628	200	4	equation	equation	NOUN
ajlm-1628	200	5	avoids	avoid	VERB
ajlm-1628	200	6	high	high	ADJ
ajlm-1628	200	7	-	-	PUNCT
ajlm-1628	200	8	magnitude	magnitude	NOUN
ajlm-1628	200	9	errors	error	NOUN
ajlm-1628	200	10	in	in	ADP
ajlm-1628	200	11	interpreting	interpret	VERB
ajlm-1628	200	12	therapeutic	therapeutic	ADJ
ajlm-1628	200	13	drug	drug	NOUN
ajlm-1628	200	14	monitoring	monitoring	NOUN
ajlm-1628	200	15	of	of	ADP
ajlm-1628	200	16	phenytoin	phenytoin	NOUN
ajlm-1628	200	17	in	in	ADP
ajlm-1628	200	18	critically	critically	ADV
ajlm-1628	200	19	ill	ill	ADJ
ajlm-1628	200	20	patients	patient	NOUN
ajlm-1628	200	21	.	.	PUNCT
ajlm-1628	201	1	ther	ther	PROPN
ajlm-1628	201	2	drug	drug	PROPN
ajlm-1628	201	3	monit	monit	PROPN
ajlm-1628	201	4	.	.	PUNCT
ajlm-1628	202	1	2020;42(4):6	2020;42(4):6	NUM
ajlm-1628	202	2	-	-	SYM
ajlm-1628	202	3	17–25	17–25	NUM
ajlm-1628	202	4	.	.	PUNCT
ajlm-1628	203	1	https://doi.org/10.1097/ftd.0000000000000739	https://doi.org/10.1097/ftd.0000000000000739	PROPN
ajlm-1628	203	2	tseng	tseng	PROPN
ajlm-1628	203	3	y	y	PROPN
ajlm-1628	203	4	-	-	PROPN
ajlm-1628	203	5	j	j	PROPN
ajlm-1628	203	6	,	,	PUNCT
ajlm-1628	203	7	huang	huang	PROPN
ajlm-1628	203	8	s	s	PROPN
ajlm-1628	203	9	-	-	PROPN
ajlm-1628	203	10	y	y	PROPN
ajlm-1628	203	11	,	,	PUNCT
ajlm-1628	203	12	kuo	kuo	PROPN
ajlm-1628	203	13	c	c	PROPN
ajlm-1628	203	14	-	-	PUNCT
ajlm-1628	203	15	h	h	PROPN
ajlm-1628	203	16	,	,	PUNCT
ajlm-1628	203	17	wang	wang	PROPN
ajlm-1628	203	18	c	c	PROPN
ajlm-1628	203	19	-	-	PUNCT
ajlm-1628	203	20	y	y	PROPN
ajlm-1628	203	21	,	,	PUNCT
ajlm-1628	203	22	wang	wang	PROPN
ajlm-1628	203	23	k	k	PROPN
ajlm-1628	203	24	-	-	PROPN
ajlm-1628	203	25	c	c	PROPN
ajlm-1628	203	26	,	,	PUNCT
ajlm-1628	203	27	wu	wu	PROPN
ajlm-1628	203	28	c	c	PROPN
ajlm-1628	203	29	-	-	PUNCT
ajlm-1628	203	30	c.	c.	PROPN
ajlm-1628	203	31	safety	safety	NOUN
ajlm-1628	203	32	range	range	NOUN
ajlm-1628	203	33	of	of	ADP
ajlm-1628	203	34	free	free	ADJ
ajlm-1628	203	35	valproic	valproic	ADJ
ajlm-1628	203	36	acid	acid	NOUN
ajlm-1628	203	37	serum	serum	NOUN
ajlm-1628	203	38	concentration	concentration	NOUN
ajlm-1628	203	39	in	in	ADP
ajlm-1628	203	40	adult	adult	NOUN
ajlm-1628	203	41	patients	patient	NOUN
ajlm-1628	203	42	.	.	PUNCT
ajlm-1628	204	1	plos	plos	PROPN
ajlm-1628	204	2	one	one	NUM
ajlm-1628	204	3	.	.	PUNCT
ajlm-1628	205	1	2020;15(9):e0238201	2020;15(9):e0238201	X
ajlm-1628	205	2	.	.	PUNCT
ajlm-1628	205	3	https://doi.org/10.1371/journal.pone.0238201	https://doi.org/10.1371/journal.pone.0238201	NOUN
ajlm-1628	205	4	.	.	PUNCT